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Parkinson’s disease is the second most common neurodegenerative disorder. There is 
currently no cure, and only symptomatic treatment is available. Homozygous 
mutations in PINK1 result in early onset Parkinson’s disease. Homozygous mutations 
in GBA1 lead to Gaucher’s disease, whilst heterozygous mutations in GBA1 are the 
most common risk factor for Parkinson’s disease. Research in both areas is hindered by 
a lack of suitable loss of function vertebrate models. The zebrafish has recently 
emerged as an effective model for disease.  
Hypothesis 
Loss of function zebrafish models in pink1/gba1 will suitably model the human disease, 
allowing the study of gene-gene interactions and identifying potential new drug 
targets.  
Results 
The glycolytic inhibitor tigarb, was found to be upregulated in pink1 -/- embryos; its 
inhibition completely preventing Th neuron reduction and mitochondrial dysfunction. 
Inhibition of the tumour suppressor vhl was also found to rescue Th neuron reduction 
in the pink1 -/- embryos, but this requires further validation.  
A gba1 orthologue in zebrafish was identified. Its expression was shown to be constant 
and not spatially restricted. Inhibition of gba1 at embryological stages showed no signs 
of Th neuron reduction. Stable mutants were successfully constructed and found to 
have marked phenotypes reminiscent of type II Gaucher’s disease, ultimately leading 
to death at 12 weeks of age. Some mild phenotypes were also identified in 
heterozygous gba1 mutant zebrafish 
Conclusions 
Zebrafish are an effective model for both pink1 and gba1 deficiency. Gene-gene 
interaction studies identified tigarb and vhl as a potential target for disease modifying 
therapy in Parkinson’s disease. Zebrafish are also an effective model for Gaucher’s 
disease, whilst heterozygous phenotypes may reveal mechanisms of gba1 linked 
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1.1  Parkinson’s disease; incidence, symptoms and treatments 
1.1.1 General introduction 
Parkinson’s disease (PD) is a common neurodegenerative movement disorder, 
affecting approximately 13.4 persons per 100,000 of the population.1  The pathological 
hallmark of the disease is the cell death of the dopaminergic (DA) neurons in the 
substantia nigra.2 Within the surviving neurons, protein inlusions, known as Lewy 
bodies are usually found, that are composed of alpha synuclein and ubiquitin, and are 
believed to be driving pathology.3 The DA neuron loss leads to a decrease of dopamine 
in the striatum and causes the classical parkinsonian symptoms of  bradykinesia, 
freezing, abnormal gait, and tremor.4 Non-motor symptoms (NMS) are often 
overlooked, and include, among others depression; dementia and apathy.5 These can 
be as disabling to the patient as the motor symptoms. No cure for PD currently exists, 
and only symptomatic treatment is available. Although initially effective, the benefit of 
the currently available medications, such as Levodopa, reduces over time. Patients can 
then exhibit side effects such as dyskinesias.6 
The cause of PD is mostly unknown, with the majority of cases being sporadic in 
nature.7 However, a small group of patients develop the disease due to monogenically 
inherited genetic defects.8  By studying these genetic subtypes, it is hoped that insight 
will be gained into the disease pathogenesis of the whole patient population. By using 
genetics or chemicals to model the disease, the disease process can be further 
elucidated, in turn hopefully leading to the development of disease-modifying 
treatments.  
1.1.1 Incidence of Parkinson’s disease 
Affecting 1% of the total population by the age of 65, rising to 6% of the total 
population by the age of 85, PD is the second most common form of neurodegeneration 
facing the western world after Alzheimer's disease.1, 9, 10 It is mostly a disease of the 





Figure 1 Incidence of PD by age. The Incidence of PD as a percentage of the total population, per age 
range.  Incidence is approximately 0.1% of the general population, at the 50-54 age group, rising to 2% at 
the 80-84 age group. PD clearly rises with age, making age the biggest risk factor in disease development. 
Adapted from Kowal et al, with permission.10 
Patients developing the disease before the age of 50 have been arbitrarily defined as 
early onset cases, although this can also be defined as an age of onset <40 years of age. 
11, 12 These make up a minority of patients, for example, in UK studies focusing on 
idiopathic PD, out of a total of 156 patients, 20 were below 50 years of age, making up 
12% of the patient population.13 Similar findings have also been shown in other 
countries such as Japan, with an early onset PD (EOPD) population comprising 10% of 
the total disease group.11 Early onset cases are more likely to have an underlying 
genetic cause to their illness, such as mutations in PINK1 or PARK2/PARKIN.8, 9, 14, 15 
This has become a feature of other common diseases with, as yet, mostly unknown 
cause, where some early onset cases can be explained by single gene mutations, such as 
BRCA1 in early onset breast cancer, and APP in familial Alzheimer’s disease.16, 17 This is 
exemplified in studies where PARK2 mutations were analysed in early and late onset 
patients.  In a study focusing purely on early onset cases, of 253 patients, 18 (7.1%) 
were homozygous/compound heterozygous for PARK2 mutations, with the mutation 
frequency decreasing with age of onset. Two studies focusing on late onset PD with a 
combined total of 250 patients, did not detect homozygous PARK2 mutations in any of 
the individuals.18-20 
Familial PD, defined as having a patient with a first degree relative also positive for 
PD, makes up a significant component of the patient population, however the majority 
of patients (approximately 90%) have no identifiable cause of the disease, and are 
hence “sporadic” in nature.9 21 Both sexes are affected by the disease, although for 



























Incidence by race has been analysed in many studies, but typically the data is either 
conflicting or not significant. 1 With the majority of PD cases defined as sporadic, the 
only major factor predicative of disease risk is age.1, 9, 23 As we live in an aging society, 
the cases of PD, like other diseases of the elderly, will continue to rise relative to the 
rest of the population. Estimates have been made which projects patient numbers 
doubling by 2030.24 This puts increasing strain on primary care givers. This burden is 
not only physical and emotional for patients and carers, but also causes considerable 
financial cost to the patient and to their healthcare systems (see Figure 2 for projected 
PD related healthcare costs for the USA). Studies have shown that patients cost about 
$14,000 per annum, but this cost is tripled when taking into account patients suffering 
from additional dementia.10, 25 
 
Figure 2. The projected cost of PD treatment and care in the USA. From 2010-2050, due to higher 
incidence rates, PD care costs rises substantially, from $7 billion, to $20 by 2050. Figure adapted from 
Kowal et al., with permission.10 
1.1.2 Diagnosis 
PD can be difficult to diagnose clinically. Not only can other diseases present with 
“parkinsonian” symptoms, but diagnosis of bona fide PD is complicated by 
heterogeneous symptoms at clinical presentation.26, 27 Traditionally, diagnosis was 
made upon the exhibition of two of the cardinal motor symptoms, such as 
bradykinesia, resting tremor and rigidity; however, this can cause misdiagnosis of 
other parkinsonian diseases such as multiple system atrophy, and progressive 
supranuclear palsy.28 The addition of other criteria, such as response to Levodopa (L-
Dopa), has helped to improve diagnosis. These additions have provided the 
framework for unified criteria such as the UK Parkinson’s Disease Society Brain Bank 




















1.1.3 Motor symptoms 
Among the clinical features of PD, motor symptoms are the most striking at clinical 
presentation. The cardinal signs are considered to be tremor, bradykinesia, rigidity and 
postural instability.4 Bradykinesia describes a slowness of movement, which can cause 
difficulty in daily life, especially when undertaking tasks in which precise motor 
control is required. Spontaneous movement such as blinking and swallowing is also 
effected.29-31 Tremor, more specifically resting tremor, is the most recognisable 
symptom of PD. It presents typically in an asymmetrical fashion at onset. However, it 
is noted that the tremor typically disappears during action, or with sleep.32, 33 Postural 
instability, generally occurring in late stage PD, is due to an impairment of postural 
reflexes. This is an important cause of the typical falls by patients (often leading to hip 
fractures) in PD.4, 34 Approximately 50% of PD patients develop freezing, which 
typically occurs during walking; the freezing episode manifests as a sudden inability to 
move.35, 36 
1.1.4 Non-Motor Symptoms (NMS) 
Although considered a movement disorder, PD also manifests with a large set of NMS. 
These lead not only to disability, but also to a decrease in the quality of life and a 
shortened lifespan. These symptoms classically manifest as difficulties with sleep, 
autonomic dysfunction, pain, neuropsychiatric issues and dementia.4, 37 Of note, many 
of these symptoms manifest early in the course of the disease, and can precede motor 
symptoms by decades. 38-40 
Issues affecting sleep are extremely common in patients and present in several 
different forms. Nearly all patients exhibit disturbed sleep, the cause being 
multifactorial in nature.41 These include REM sleep behaviour disorder, which causes 
patients to physically act out their own dreams, sometimes resulting in kicking and 
screaming whilst still asleep.42 Patients can also develop excessive daytime sleepiness, 
characterised by a lack of energy, regardless of the quality or the length of the previous 
night time sleep. Studies have demonstrated that patients can go from a wakeful state 
to one of sleep extremely quickly (approximately 2 seconds), in a similar way to 
narcoleptic patients.43 Neuropsychiatric symptoms can manifest with depression, 
anxiety, apathy, psychosis and hallucinations. All of these are clearly disabling to the 




that of their caregiver. Psychosis, in particular, is the most common cause of nursing 
home administration for patients, and therefore one of the most costly.44-46  
Approximately 40% of PD patients develop dementia, which worsens with age.47 
Attention and memory are mostly affected, and in addition, a change of personality 
can occur.48 Dementia also has substantial economic impact on carers and the health 
care system. Demented PD patients cost 3.3 times more ($42,000) than PD patients 
without dementia. The majority of costs (67%) are due to institutional cases.25 
Autonomic dysfunction, another key NMS, is an umbrella term for many difficulties 
experienced by patients, including drooling, sweating, swallowing and constipation.49 
Of these, constipation is one of the most common, but also the most frequently 
reported NMS. Occurring in approximately 70% of patients (depending on the study), 
this causes a decrease in bowel movement frequency, which may then worsen with the 
severity of disease.50, 51 
Pain is another unexpectedly common, yet often overlooked, PD NMS, with substantial 
pain being present in over 40% of patients. Partly exacerbated by motor symptoms; the 
pain sensation felt by patients is varied and can be experienced as musculoskeletal 
pain, neuropathic pain, dystonia-related pain, primary pain and akathitic dysfunction. 
The most severe pain sensations are due to the sustained muscle contractions caused 
by dystonia. Some forms of pain in PD can be alleviated with PD medication, others 
treated by physical therapy.52, 53  
Olfactory dysfunction, a loss of sense of smell, is also very common in PD patients 
(90%) but often not appreciated by the patient until tested. This particular symptom is 
so prevalent in patients, it has been suggested olfactory tests could be more robust at 
identifying PD than motor tests.54, 55 Olfaction presents as defects in odour detection 
and identification, but can also result in a decrease in effective odor discrimination. 
Defects in olfaction may additionally correlate with disease severity, but this requires 
further investigation. 56 
1.1.5 Parkinson’s disease treatments 
There is no current cure for PD, but there are effective symptomatic treatments, not 
only for motor symptoms, but also for at least some of the non-motor symptoms. L-3,4-
Dihydroxyphenylalanine (L-Dopa) is the precursor to a group of neurotransmitters, the 




Dopa (also known as Levodopa) has been the main treatment option for dopamine 
replacement therapy for the last 40 years. It is so effective at reversing the motor 
symptoms, and the patient response is so robust, that it can aid the diagnosis.57-59 
Unfortunately, over time, patients can develop a new set of motor complications as a 
direct result of the L-Dopa therapy, particularly at higher doses. Known as dyskinesias, 
these are involuntary movements made by the patient, and can become equally as 
disabling as the original motor symptoms.58, 60 After 5 years of L-Dopa treatment, it has 
been estimated that approximately 50% of patients experience these motor 
complications. 61 
Alternatives to L-Dopa are dopamine agonists, such as apomorphine and Pramipexole, 
which activate dopamine receptors directly. Although effective in treating motor 
symptoms, they are less efficacious than L-Dopa. They also eventually result in 
dyskinesias and other side effects seen in L-Dopa therapy.62  
To enhance L-Dopa therapy efficacy, it can be utilised in conjunction with catechol-O-
methyl transferase inhibitors, such as Entacapone. These act by delaying L-Dopa 
metabolism, increasing its half-life within the brain. Double blind placebo controlled 
trials have shown it to effectively enhance motor function in conjunction with L-Dopa. 
63 
For patients that don’t respond to pharmacological agents, or experience too many side 
effects, surgical techniques can be utilised in the form of deep brain stimulation. These 
are now seen as an effective method of treating motor symptoms in advanced PD 
patients. Classically, an electrical lead is utilised to target the sub-thalamic nucleus or 
globus pallidus pars interna, emitting high frequency electrical impulses to the brain. 
64-66 
Although the described treatments are very efficient at relieving symptoms, they are 
not neuroprotective. Consequently, future therapies must prevent, or at least slow DA 





1.2 Causes of Parkinson’s disease 
1.2.1 Monogenically-inherited, Mendelian forms of Parkinson’s disease  
Previously, in order to determine the genetic component of disease, twin studies were 
utilised, measuring concordance between monozygotic and dizygotic twins. 
Monozygotic twins have virtually identical genetic material. Genetic causes are 
inferred if concordances are higher in monozygotic twins than in dizygotic twins, as 
the latter only share 50% of their genetic material. 68  A large 2011 study in the Swedish 
population, found concordance of monozygotic twins for sporadic PD was 11%, whilst 
only 4% for dizygotic twins, implying a genetic contribution to PD development.  In a  
separate study, early onset PD was analysed for concordance in twin pairs, 
concordance was 100% in monozygotic and 17% in dizygotic twins, demonstrating a 
very strong genetic factor, but only in PD patients with age of onset <50. 69, 70 
Studies such as these have difficulty in identifying the causes of complex traits, due to 
incomplete penetrance and genetic heterogeneity, especially for late onset PD. In terms 
of sporadic PD, studies suggest that up to 30% of patients have a family history of the 
disease, with  first degree relatives having a 2-7 increase relative risk.71  Studies such as 
these have been varied due to methodological issues, but strong correlations have been 
reported for early onset PD compared to late, in a similar manner to twin studies. A 
meta-analysis of 29 familial studies of patients having a first degree relative also 
having PD had a relative risk of 2.9, whilst relative risk was 4.4 for pairs of siblings. 
When relative risk was split between late onset and early onset, the risk was 2.7 and 4.7 
respectively. 21, 23 
As the human genome became more annotated and understood, linkage analysis was 
utilised to locate highly penetrant, rare disease causing mutations. Requiring very large 
family pedigrees, the disease causing mutation is tracked in the genome by co-
segregation with genetic markers, such as restriction fragment length polymorphisms 
and microsatellites. Once a small enough region has been identified which co- 
segregates with the disease, all genes within that region can be sequenced in patients to 
identify potential pathogenic mutations. Missense mutations that effect conserved 
residues, or nonsense mutations, insertions and deletions, would aid in the 
identification of the disease gene. These are further screened in healthy controls (such 
as unaffected family members) to identify which mutations lead to the specific disease. 




recessive manner, or autosomal dominant manner, and are generally highly penetrant 
with an early age of onset. For example, Huntington’s disease (autosomal dominant) 
and cystic fibrosis (autosomal recessive) were both discovered in this manner by 
linkage analysis.72-74 
The first PD gene to be discovered was a point mutation in alpha synuclein (SNCA), in 
3 large Greek/Italian pedigrees, leading to amino acid change of Ala53Thr.  The point 
mutation caused early onset PD in an autosomal dominant manner, suggesting a toxic 
gain of function of the mutation, with onset being between 30-50 years of age in all 
cases.75 Duplications and triplications of the SNCA locus have also been reported in 
large PD families which are also inherited in an autosomal dominant fashion. The age 
of onset being either late or early respectively. With the existence of WT SNCA 
duplication causing late onset PD and triplication leading to early onset, these data 
show the effect gene dosage has on the disease course and progression in familial PD.76, 
77 But, highly penetrant disease causing SNCA mutations are rare.78 The function of the 
alpha synuclein protein is still unknown but is believed to be involved in snare 
complex formation at synaptic terminals, required for long term neuronal health.79 The 
pathogenic mechanism leading to PD is still uncertain, however; due to the apparent 
dosage effects, and furthermore, due to its presence in Lewy bodies, it is believed to be 
caused by alpha synuclein protein aggregation, which overwhelms the proteosomal 
and autophagy pathways, ultimately leading to DA neuronal death. 
Linkage analysis has also been utilised to discover mutations in the genes for PINK1, 
PARK2 and DJ-1. All lead to early onset forms of PD that are inherited in an autosomal 
recessive fashion. Large deletions, insertions and exonic rearrangements have all been 
recorded for each of these genes, as well as missense and nonsense point mutations, all 
leading to loss of function.8, 15, 80, 81  
Homozygous/compound heterozygous mutations in the PARK2 gene that codes for 
the E3 ubiquitin ligase PARKIN are some of the most common genetic causes of early 
onset PD.14 Patients present with typical PD but generally at a very early age (<45 
years); however not all patients show signs of Lewy body pathology at autopsy. 
Symptoms progress very slowly, and respond very well to standard L-Dopa 
treatments, but these patients can then also develop dyskinesias. 80, 82 80, 83 Although 




link between PARK2 heterozygous mutations or single nucleotide polymorphisms 
(SNPs) and sporadic PD, although this remains controversial.84 
Homozygous mutations in PARK7 coding for DJ1, also cause EOPD, but are very rare; 
estimates of PARK7 mutation frequency from several studies have suggested they are 
responsible for only 1% of EOPD.81, 85 The function of DJ1 is still unknown, but it is 
believed to be an onco-protein that is involved in the response to oxidative stress, and 
may have a role in mitochondrial health.86, 87  
The PINK1 gene is another early onset PD gene, and as the focus of this study, will be 
addressed later in this thesis in greater detail. 
Mutations in LRRK2 (leucine rich repeat kinase 2) are one of the more frequent causes 
of familial PD.  They were also discovered through linkage studies and sequencing.  To 
date, only missense mutations have been reported, the disease manifesting in an 
autosomal dominant fashion with incomplete penetrance. Unlike the disease genes 
previously discussed, LRRK2-linked PD is a cause of late onset PD, likely to be caused 
from toxic gain of function mutations. Clinical presentation resembles that of sporadic 
PD, with at least some patients developing Lewy bodies. LRRK2 mutations, especially 
the G2019S mutation, are very common.  Its occurrence varies greatly between 
populations, with a frequency 1-3% in sporadic PD, and can be as high as 40% in 
familial PD.88-90 The LRRK2 gene, possessing 51 exons, encodes a very large protein, 
2527 amino acids in length. Its function is still not completely understood, but is 
known to be part of the ROCO protein family. This possesses ROC and COR domains, 
as well as GTPase and kinase functions.91 
Another important gene in PD genetics is glucocerebrosidase 1 (GBA1).  Homozygous 
mutations in this gene present as Gaucher’s disease (GD), whilst heterozygosity for 
GBA1  mutations remains the most common risk factor for PD. Clinically almost 
identical to idiopathic PD, several multicentre analyses have compiled the odds ratio  
(OR) of GBA1 mutations for PD risk as being 5.0-7.0.92-94 This gene is also one of the 
focuses of this study, so shall be addressed later in the thesis in greater detail. 
As sequencing technologies have become more advanced in the post genomics era, 
whole exome sequencing has been utilised to find highly penetrant rare PD genes. 
Recently, this has allowed the identification of the pAsp620Asn mutation in the VPS35 




autosomal dominant form, but with incomplete penetrance.95 Subsequent screening 
studies have identified these mutations as a rare cause of LOPD.96 The VPS35 protein, 
part of the retromer complex,  is involved in vesicle transport,  shuttling vesicles 
between organelles such as the mitochondria and peroximsomes.97  Proteomic studies 
have also demonstrated its presence in cortical Lewy bodies.98 
1.2.2 Common genetic variants identified by GWAS 
Although linkage analysis and whole genome sequencing are powerful tools in finding 
rare genetic causes of PD with large effects, genome wide association studies (GWAS) 
must be employed to identify common genetic defects that have a small and 
potentially additive effect in disease development. GWAS, using single nucleotide 
polymorphism (SNP) genotyping arrays, that sequences a specific set of SNPs that can 
be considered representative for large genomic blocks, due to linkage disequilibrium.  
These are compared between cases and controls, to identify SNPs that occur in cases at 
a different frequency from the controls. These specific SNPs are markers for genomic 
regions associated with disease, as opposed to identifying specific genes that are causal 
or protective.99  
The genomic regions co segregating with the SNP implicated in disease will only ever 
have a small effect toward disease risk, with an average OR of 1.33, and will only 
explain a small proportion of genetic variability within a population.  The SNPs only 
mark a genomic region as associated with disease, and may not be identifying the 
pathogenic variant. Extensive sequencing for the region would then be required to 
fully identify the actual pathogenic mutations, as well as identifying the rarer variants 
that may affect disease at that specific locus. 99 
The arrays are limited as they will only detect common SNPs that are present in the 
population with a frequency of >5%. Consequently, although they can identify 
common variants with low genetic contribution to disease, and linkage analysis can 
identify rare variants that have high penetrance, both techniques cannot identify 
variants that are of intermediate frequency <5% and are of intermediate penetrance. 
For example, GBA1 variants which are causal for PD, and TREM2 variants that are 
causal for Alzheimer’s disease.93, 99, 100 
Initial GWAS were hampered by underpowered studies, but now many have been 




comprehensive meta-analysis of PD GWAS and candidate gene analysis, Lill et al., 
combined data from several different studies to analyse SNPs from 16,432 PD cases 
and 48,810 controls. This work identified variants at 12 different genomic loci, 
including ITGA8, a gene that had previously not been identified in preceding PD 
GWAS studies due to low power. Loci of particular interest included MAPT, a gene 
encoding tau, a key protein in Alzheimer’s disease pathology, but also in PD, due to its 
presence in Lewy bodies.102-104 
Other loci of interest included those for SNCA, LRRK2 and GBA1, as not being rare 
genes with high penetrance, but have been identified as causal for PD. Yet, those 
variants identified by the meta GWAS are common variants with high odds ratios. The 
GBA1 SNP for allele N370S had an OR of 3.51, unusually high for common variants; 
the OR for the majority of variants from the meta-analysis was 1.10-1.35.  It must be 
noted though that this SNP was identified from meta-analysis of candidate gene 
studies, as standard SNP arrays do not detect N370S SNP as its frequency at 1% is too 
low in the general population. For a table summarising the main PD genes identified 
see Table 1 (highly penetrant genes) and Table 2 (GWAS identified genes). 
Although their overall contribution to the disease is small, the variants are likely to 
have an additive, synergistic or complex effect with each other and the environment. 
These also exclude structural variants that will be elucidated by whole genome 
sequencing once the technology has become cost effective. Extensive deep sequencing 
of each variant must be undertaken, as well as confirmatory in vivo studies to elucidate 
the disease causing mechanism of the variant.102  
  
 
Table 1. A summary of PD linked genes. A list of all recorded PD linked genes with high penetrance listing 






Table 2. A Summary of GWAS identified genes implicated in PD. A list gene loci  identified as causal for 
PD from the PD GWAS Meta-analysis with accompanying odds ratios and samples sizes. Table adapted 
with permission from Lill et el.102 
1.2.3 Environmental causes of Parkinson’s disease and protective factors 
Environmental factors have additionally been implicated in the causality of PD, and 
exposure is likely to increase risk development, especially in conjunction with genetic 
risk factors. Thus far, exposure to pesticides, insecticides and herbicides have been 
implicated with disease development, with coffee drinking, and smoking having the 
opposite effect.23 Many studies have investigated generalised exposure to pesticides, 
including meta-analyses, producing conflicting data, some studies suggest a high odds 
ratios of 1.3-3.7. However this is controversial as some studies have not identified any 
correlation, or any correlation that is statistically significant.106-110 The most studied 
chemicals are rotenone and paraquat, both commonly utilised in agriculture. The 
former is a pesticide capable of acting as a mitochondrial Complex I inhibitor, and the 
latter, a herbicide that produces reactive oxygen species (ROS). Both have been shown 
to cause selective degeneration of DA neurons in numerous studies in rats and mice.111, 
112 Drinking well water and rural living have also been implicated in increased 
prevalence of PD, but these are perhaps compounded by additional exposure to 
pesticides.23, 113, 114  
In contrast, smoking and coffee drinking have been found to be neuroprotective 
against PD. Coffee intake and PD prevalence has been studied extensively. A meta-
analysis pooling data from 5 cohort and 8 case control studies identified a relative risk 
















of developing PD of 0.69 compared to non-coffee drinkers. Several meta- analyses have 
been conducted investigating the neuroprotective capacity of smoking. A study from 
Hernan et al., pooling data from 44, studies found the relative risk of PD development 
to be 0.8 for past smokers, and 0.39 for current smokers. 115 
1.3 Models of Parkinson’s disease 
1.3.1 Toxin induced Models of Parkinson’s disease 
Initially in PD research, toxin induced models were utilised to study the disease 
process and assay new pharmacological therapies. The classical PD toxin is MPTP (1-
methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) which causes the selective loss of DA 
neurons. It was discovered as a result of drug addicts attempting to manufacture 
synthetic heroin. MPTP was created as a by-product, and once injected, the users 
developed symptoms identical to idiopathic PD.116  
Biochemically, MPTP is rapidly metabolised to MPP+, where it selectively enters the 
DA cells through the action of DAT (Dopamine Transporter).117 Once intracellular, 
MPP+ can accumulate in mitochondria and inhibit mitochondrial Complex I of the 
electron transport chain, impairing respiration.118, 119 It has become the toxin of choice 
to induce PD symptoms and DA neuronal cell loss in a variety of model organisms 
including fish, mice and primates.120-122  
The second classical chemical utilised for toxin-induced models of PD is 6-
hydroxydopamine, an analogue of dopamine in its hydroxylated form. This can lead to 
neuronal cell death by oxidative stress and Complex I inhibition.123, 124 It is fairly 
specific for DA neurons due to preferential uptake by DAT. However, unlike MPTP, it 
cannot cross the blood brain barrier and must be directly injected into the brain, 
requiring surgery.123 It effectively destroys 60% of the Tyrosine Hydroxylase (TH) 
neurons in the brains of mice and rats, leading to motor defects. An advantage of its 
use is that unilateral injections allow for the uninjected half of the brain to be utilised as 
an internal control.125  
Although chemical and toxin induced models are effective in producing symptoms 
such as DA cell death and some motor symptoms, they fail to fully recapitulate the 
disease features, such as Lewy body formation. DA neuronal death in these models is 




toxin models are useful at modelling the end stage PD, they fail to accurately model the 
pre-symptomatic and early stages of the disease.126 
1.3.2 Genetic models of Parkinson’s disease 
Using reverse genetic and transgenic strategies, molecular tools such as the Cre LOX 
system have been utilised to generate knockout (KO), conditional KO and knockin 
animals for many of the PD related genes thus far discovered. 127-129 
1.3.2.1 Models of Parkin Deficiency 
parkin KO drosophila (whose entire parkin coding sequence had been deleted), were 
generated using a transposon mutagenesis screen. Homozygous mutants, although 
develop normally, accumulate marked phenotypes with age, ultimately leading to 
decreased lifespan. This is coupled with male sterility due to a defective mitochondrial 
compartment in the maturing spermatids. Mutants developed abnormal wing posture, 
accompanied by a decrease in flight ability, due to apoptotic flight muscles. The flight 
muscles were revealed to have large, swollen, disintegrating mitochondria. Structural 
alterations were recorded in the TH neurons, although no specific Th neuron reduction 
itself was detected. This study demonstrated the importance of parkin for 
mitochondrial homeostasis, due to the cell death of mitochondrial rich tissues such as 
muscle and sperm. 130  
Several different Parkin KO mice have been generated through homologous 
recombination with embryonic stem cells. All demonstrate a distinct lack of 
neurodegeneration of TH neurons. The first KO described by Itier et al., did not present 
any cell loss in TH or DAT neurons up to 24 months, although a decrease in DAT 
protein was observed. Defects in cognition and neurotransmission were also recorded. 
At the biochemical level, homozygous mutants additionally showed mitochondrial 
dysfunction, yet in the absence of any gross mitochondrial morphological 
abnormalities.131, 132 Separate studies using different Parkin KO alleles confirmed the 
lack of TH cell loss, but could not replicate the defects in cognition and 
neurotransmission.133 
1.3.2.2 Models of DJ1 deficiency 
Dj1 loss of function studies have also been conducted in Drosophila and mice. 
Drosophila possess 2 orthologues of the human DJ1 with high homology (50-70%).  In 




similar viability and morphology to WT. This is accompanied by an absence of 
neurodegeneration; implying dj1 status does not affect neuronal homeostasis. 
However, dj1 mutants were found to have a marked increase in sensitivity to oxidative 
stress, such as H2O2 (10 fold greater sensitivity), confirming dj1’s function as a 
oxidative stress responsive protein.134 Dj1 KO mice have similar phenotypes to KO 
flies. Homozygous mutants develop normally without an effect on viability. There is a 
complete absence of neurodegeneration, but an increased sensitivity to oxidative 
stress.135, 136 
1.3.2.3 Knock –In and Knock – Out LRRK2 models 
As LRRK2 mutations are thought to be pathogenic, either predominantly or exclusively 
due to a toxic gain of function, transgenic knockin methods have been employed to 
investigate these LRRK2 mutations in flies and mice. In addition, KO strategies have 
also been employed to investigate the biological function of LRRK2 in vivo. In 
Drosophila, KO study reports have been conflicting. Some studies report no overt 
phenotype or TH neuron loss, while others report extreme phenotypes reminiscent of 
parkin KO flies.137, 138 KO mice also develop normally with a lack of neurodegeneration 
and a sensitivity to MPTP, suggesting Lrrk2 is dispensable for normal neuronal 
homeostasis, at least in vertebrates. SNCA pathology was reported, not in the brain, 
but in the kidney, of one Lrrk2 KO line.139  
Transgenic approaches have been equally inconsistent, transgenic flies overexpressing 
mutant lrrk2 have been described as either asymptomatic, or as developing 
parkinsonian like phenotypes with TH neuron loss.137, 140 Similar findings have been 
reported in Lrrk2 transgenic mice as either asymptomatic or developing late onset TH 
neuron loss. But this may be dependent on the type of Lrrk2 mutation being over 
expressed, and the level of expression achieved.141, 142 
1.4 The zebrafish as a model for disease 
1.4.1 The zebrafish as a model organism 
Over the past 15 years the zebrafish (Danio rerio) has been firmly established as a model 
for biomedical research. Zebrafish are vertebrates, and have greater genetic homology 
to humans than flies. Maintenance costs are a fraction of those for keeping mice. Their 




organisms, such as Xenopus, they possess a diploid genome and a similar complement 
of genes to humans. At least 70% of human genes have an obvious zebrafish 
orthologue.143  
Zebrafish were initially utilised as a model species for development, due to rapid 
embryogenesis and transparency. Zebrafish embryos develop from a single cell to a 
whole organism, with its entire body plan and major organs established, within 24 
hours. The majority of development is completed by 5 days post fertilisation and 
sexual maturity is reached by 2.5 months of age. Consequently, generation time is 
comparatively small. As they develop ex vivo and in great numbers, this allows the 
study of mutations that may be embryonic lethal. Their small size makes them cost 
effective, with a single female being capable of producing hundreds of eggs per week.  
Breeding is controlled by a simple light cycle (14 hours light, 10 hours dark) allowing 
manipulation of embryo production, as breeding takes place when the lights are 
turned on. 144 Their transparency allows in vivo imaging in real time, especially when 
using transgenic reporter lines.145  
Zebrafish are also a suitable model for phenotypic drug screening. Embryos can fit into 
96-well plates and be utilised to screen compound libraries for their biological effect. 
Drugs can be dispensed and absorbed directly into the raising media.146 Since whole 
animals are utilised in these screens, the assay simultaneously evaluates bioavailability, 
toxicity and teratogenicity. This allows the identification of small molecules that 
suppress disease, or induce phenotypes.146, 147  Focusing on ameliorating a specific 
phenotype, zebrafish chemical screens make no assumption on the molecular target, 
allowing identification of unknown rescue mechanisms. For example, a chemical 
screen undertaken in a classic study by Yu et al,. resulted in the discovery of the first 
bone morphogenetic protein (BMP) antagonists.148 BMP is required for correct dorso-
ventral patterning, and by using a simple developmental readout, it was possible to 
screen a library of compounds for chemicals that effect developmental patterning. A 
lead compound was discovered, known as dysomorphin, and was found to inhibit the 
BMP type 1 receptor, but not the highly homologous TGF-β-receptor. Since its 
discovery, dysomorphin has been successfully tested in mouse models of BMP 
dysregulation, such as fibrodysplasia ossificans progressive.148, 149 See Figure 3 for a 
flow chart illustrating the sequential steps of phenotypic drug discovery in zebrafish 





Figure 3. Phenotypic drug discovery using zebrafish. A flow diagram illustrating the sequential steps of 
phenotypic drug discovery using zebrafish, compared to traditional high throughput drug discovery hit to 
lead process. As zebrafish screening simultaneously assays for bioavailability, toxicity and efficacy, the 
time to reach the clinic is considerably reduced. Adapted with permission from Bowman et al.150 
1.4.2 Zebrafish genetic tools 
Different genomic tools for targeted genome modification and RNA interference 
strategies are in use to study the consequences of loss of function mutations in 
zebrafish. RNA interference strategies include the use of Morpholinos, a knockdown 
(KD) technology ideal for fast genetic inhibition studies. Stable mutants can be 
generated by large-scale N-ethyl-N-nitrosourea (ENU) mutagenesis screens, which 
create point mutations at random. For precise genome editing, technologies such as 
zinc-finger nucleases (ZFNs), transcription activator-like effector nuclease (TALEN) 
systems and the clustered-regularly-interspaced-short-palindromic-repeats 
(CRISPR)/CRISPR associated protein 9 (Cas9) systems can be utilised.127, 151, 152 Due to 




zebrafish mutation project (ZMP), which aims to create a loss of function mutation for 
every zebrafish gene.153  
Morpholinos have emerged as a powerful efficient RNA inference technology for KD 
studies in zebrafish. Morpholinos are 25-mer modified oligonucleotides, containing a 
morpholine instead of deoxyribose rings that effectively bind to RNA nucleotides 
through RNase H independent mechanisms. They can either be targeted to bind to the 
5’ untranslated region of the mature RNA species, blocking translation, or can be 
targeted to the exon junctions of the pre-mRNA complex, interfering with splicing and 
leading to exon skip or intron inclusion in the mature mRNA species. Morpholinos are 
micro-injected into the zebrafish embryos at the single cell stage. Effective KD is 
assessed by either western blot (translation blocking) or RT-PCR (splice blocker), and 
typically lasts for 3-5 days. They are cost effective, 300nmols costing $400, and can be 
kept at room temperature for up to 5 years.  They allow for fast and effective loss of 
function studies in zebrafish embryos.152, 154, 155 
However, Morpholino KD has its draw backs, as a significant proportion of 
Morpholinos produce off target effects. These classically cause a delay in development, 
heart oedema, neural apoptosis and craniofacial defects. These non-specific off-target 
effects are often p53-mediated. Consequently, co-knockdown of p53 with the 
Morpholino targeting the gene of interest has been utilised to ameliorate at least some 
of the off target effects. It has been estimated that 15-20% of Morpholinos produce off 
target effects in zebrafish embryos. However, in the author’s experience, this figure is 
likely to be closer to 40% in practice, and is dependent on the target gene. 
Consequently, unless a stable loss of function mutant can validate the Morpholino 
phenotypes, Morpholino data should be interpreted with caution, especially when 
investigating cell death. Morpholino KD, although fast at inhibiting gene function at 
the embryonic stages, their effects are only transient and wear off 3-5dpf. Consequently 
they cannot be used for loss of function genetic studies in adult Zebrafish.156 
Morpholino KD is fast and cost effective but is transient in nature and may produce off 
target effects; consequently it is preferable to work with stable mutant lines to 
investigate loss of function genetic studies. Generating stable mutants through ENU 
screens are not targeted and induce point mutations at random.  Consequently directed 
genome editing is now the preferred method to generate loss of function mutants. 




bind specific sequences of DNA (9bp each) are constructed and fused to a FOK1 
endonuclease. Once bound to the specific DNA sequences, the FOK1 subunits 
dimerise, creating the stranded DNA breaks which can induce small insertions and 
deletions into the DNA sequence due to error-prone non homologous end joining.157 
The main drawbacks of this technique were difficulty in construction for in-house 
methods and the rarity of potential binding sites. Commercially available ZFNs were 
not cost effective at $20,000 each.158 
Targeted genome editing became much more technically simple with the invention of 
the TALEN system. Similar to ZFNs, TALENs function in pairs, to create small indels 
and are composed of a specific DNA binding element fused to a FOK1 endonuclease. 
The DNA binding element is a transcription activator-like effector from the plant 
pathogen Xanthomonas. Target specificity is determined by approximately 15 ‘repeat di 
variable’ residues (RVDs), each binding to a specific DNA nucleotide. By engineering 
the composition of the RVDs, they can be designed to bind to specific DNA sequences. 
Although still context dependent, TALENs are much more versatile, with binding sites 
appearing on average every 35bp. Due to the availability of TALEN construction in kit 
form and their fast assembly (approximately 1 week), TALEN mutagenesis is rapid, 
cost effective and user friendly.159 
The CRISPR cas9 technology has recently been introduced as a further genome editing 
technology. It exploits the CAS systems within prokaryotic organisms that provide 
them with adaptive antiviral activity. The cas9 protein complexes with the CrRNA 
(CRISPR RNA), and the trans-activating crRNA (tracrRNA). It then becomes an 
endonuclease, binding to specific foreign DNA and cleaving it in two. The RNA 
molecules can be fused together to form a single RNA species, the guide RNA (gRNA). 
By altering the binding sequence it can be engineered to bind to specific DNA 
sequences, without the need for changing the cas9 protein complement, allowing 
targeted binding and cleaving of specific genomic sequences. Its only requirement is a 
20bp DNA sequence with a proto-spacer adjacent motif (PAM) site, consisting of 5’-
NGG-3’.160, 161 CRISPRs have the advantage over TALENs that the protocol is even 
faster and user friendly, the requirement after site selection is to generate an ultramer 
for the gRNA template and transcribe the appropriate RNA species. It has a generation 
time of a single day. Although still context-dependent, PAM sites are a frequent feature 
of all genomes. So where a site is not suitable for TALEN mutagenesis, it will likely 




that, as they bind a shorter sequence of DNA, they produce far more off target effects 
than TALENs. In the context of zebrafish mutations, this is not necessarily a major 
problem, but any identified allele would need to be outcrossed several times to a WT 
background.162 See Figure 4, for an illustration demonstrating TALEN and CRISPR 
function. 
 
Figure 4. TALEN and CRISPR/CAS9 activity. TALEN cutting (Figure 4A) occurs between the pairs of 
TALENs in the spacer region. CAS9 (Figure 4B) cuts the DNA helix directly upstream from the PAM site. 
As TALENs require a larger binding region of 30 bases, they produce less off target background mutations 
compared to the CAS9 system that only binds to 20 bases. Figures reproduced with permission from 
Cermak et al. and Ran et al.159, 163 
TALENs and CRISPRs have the additional advantage (over ENU screens) of not just 
causing insertions and deletions, but can also generate targeted point mutations to the 






molecules (ssDNA), once the target has been cleaved, the ssDNA can act as a template 
for homology directed repair. This has been utilised in zebrafish to change single bases, 
effectively inserting loxP sites and restriction sites into genomic DNA. In the context of 
modelling PD, this could in theory be utilised to generate toxic gain of function 
mutations, as seen in human patients, such as the LRRK2 G2019S mutations, without 
the need for the generation of transgenic lines.161 
1.4.3 Zebrafish as a vertebrate model of human neurodegenerative diseases 
Zebrafish have been utilised as a model organism for many neurodegenerative 
diseases, including PD. There are some notable differences between the brains of 
humans and zebrafish, but the functional organisation remains very similar. The DA 
neurons that project to the ventral telencephalon in zebrafish are found in the posterior 
tuberculum of the ventral diencephalon, making these neurons analogous to those seen 
in the mammalian nigrostriatal system.164 In zebrafish embryos, the DA neuronal 
system is established very early, with the first TH-positive neurons emerging 18 hours 
post fertilisation (hpf). By 3 days post fertilisation (dpf), the DA system is extremely 
well established and has been well characterised, with comprehensive maps of all TH 
neuron clusters within the central nervous system (CNS) of both embryos and adults. 
The small number of neurons and transparency of the embryos allows for simple 
quantification of the DA system, using markers for TH or DAT. 165 MPP+ studies on 
embryos and adult zebrafish have induced parkinsonian like phenotypes, including 
TH neuron loss and movement deficits, further implicating these neuronal clusters as 
the zebrafish equivalent of the substantia nigra in rodents and humans.120, 166 Toxin 
exposure, such as those just described in zebrafish, have the additional advantage that 
drugs can be simply administered to embryo E3 media, not requiring invasive 
procedures for administration. The generation of transgenic GFP reporter lines for DA 
neuronal system, such as DAT, allow for the analysis of DA neuronal death in real 
time.167 
Specifically in terms of modelling PD, loss of function studies have been performed 
using Morpholino KD. Several have been conducted on monogenically inherited PD 
genes, such as the autosomal recessive inherited genes parkin, pink1 and dj1, but also to 
study the functional consequences of lrrk2 deficiency. Zebrafish do not possess an 




parkin loss of function has been investigated in a study by Flinn et al., who 
demonstrated that Morpholino KD of parkin led to a 25% reduction in TH neurons, and 
a decrease in mitochondrial Complex I activity at 3dpf, as well as an increased 
susceptibility to MPP+. Analysis of HuC expression (a pan neuronal marker of post-
mitotic neurons) and islet1 (a motor neuron marker) showed no change between 
morphants and uninjected controls, demonstrating that the effects of parkin KD were 
specific for DA neurons. Swimming behaviour was also unaltered, but this was likely 
to be due to the comparatively mild TH neuron loss. PD patients only develop motor 
symptoms after a reduction of at least 50% of their DA neurons. As Parkin KO mice do 
not exhibit neurodegeneration, the parkin KD zebrafish represented the first parkin 
deficient vertebrate model of Th neuron reduction.168 
However, a similar study by Fett et al., found no reduction in TH neurons at the same 
time point. This discrepancy could be due to different KD efficiencies. 169 PARK2-
mediated PD is due to loss of function of the protein. Flinn et al’s Morpholinos 
achieved a KD of approximately 90%, whilst those utilised by Fett et al., only reduced 
expression by 50%. Consequently, Fett et al., only induced a representative 
heterozygous state, which may not be enough loss of parkin to induce Th neuron 
reduction.168, 169 
dj1 KD in zebrafish resulted in phenotypes similar to KO mice and Drosophila. dj1 KD 
did not result in loss of TH neurons, but led to an increased sensitivity to oxidative 
stress after H2O2 exposure and proteosome inhibition after treatment with MG132. Dj1 
KD also resulted in a large upregulation of p53. Inhibition of the protein (p53) with 
phifithrin alpha completely rescued the Th neuron reduction caused in dj1 morphants 
by MG132.134, 135, 170 
Several studies have focused on KD of lrrk2, but have presented conflicting data, even 
when using identical reagents. Sheng et al., originally utilised a start site Morpholino to 
completely block translation of lrrk2, and found morphants to be lethal by 3dpf. The 
embryos showed signs of developmental delay, small head size and heart oedema, 
compared to uninjected controls. Sheng et al., also utilised a splice site Morpholino to 
KD the WD40 domain, in order to produce a weaker phenotype. Morphants developed 
normally, but showed a decrease in DA neurons and an increase in apoptosis. 
Morphants additionally had a movement defect that could be rescued by L-Dopa. In 




change in DAT neuron count or TH neuron count between morphants and uninjected 
controls. 171, 172  
pink1 loss of function studies have been investigated by three independent groups with 
a Morpholino strategy, all reporting different phenotypes. KD with start site 
Morpholinos by Anichtchik et al., exhibited phenotypes of developmental delay, small 
heads, and gross deformity accompanied by apoptosis. The majority of morphants did 
not survive past 3dpf. The TH neurons were reduced in number by 30%, compared to 
uninjected controls, but this may have been due to developmental retardation as 
opposed to cell death per se.173    
A KD study by Xi et al., also using start sites Morpholinos, only reported minor 
deformities in morphants, and a Th neuron reduction of 8% as opposed to 30%. 
However, the TH neurons showed disorganisation and mispatterning. The KD was 
also embryonic lethal, with most morphants not surviving to 10 dpf. 174 
Sallinen et al., have also reported pink1 phenotypes, but using splice site Morpholinos. 
In sharp contrast to previous findings, the morphants displayed no overt deformity or 
decrease in TH neuron count. Although morphants did display an increased sensitivity 
to sub effective doses of MPTP.175 
The discrepancies between phenotypes in each study are most likely explained by 
classical p53 mediated off target effects, especially in the study by Anichtchik et al., 
whose KD features all the main deformities described as off target by Robu et al.  When 
one considers the phenotypes of loss of function Drosophila and mice, one would expect 
possibly an intermediate phenotype when using a zebrafish model. Even though 
Drosophila pink1 KO have an marked phenotype with reduced lifespan, they still 
successfully complete development and maturation, unlike the morphants described 
by Anichtchik and Xi, that are both deformed and are embryonic lethal.176 Other likely 
explanations are the use of different Morpholinos, and KD efficacies, each group using 
different Morpholino sequences. The lack of a significant phenotype in Sallinens et al., 
study was possibly due to lack of efficacy, many of their TH neuron counts were 
recorded at 5dpf as the Morpholino was losing effect. Although their study was very 
thorough in demonstrating that their Morpholinos were non-toxic. The lack of 
agreement in Th neuron reduction by all groups, may also be due to method of TH 
neuron counting, Anichtchik counting all TH positive neurons within the brain, Xi et 




mispatterning studies) and Sallinen et al., counting only individual TH groups 
described by Rink et al.165 173-175  See Figure 5 for an illustration of the location of the TH 
positive groups in Zebrafish larvae counted by Sallinen et al., which are the same as 
those counted as part of this thesis. 
 
Figure 5. TH positive neuronal groups in 5dpf Zebrafish. TH neuronal groups counted in this thesis as 
defined by Rink and Wulliman are located in the diencephalon of the zebrafish larva. Only groups I, II, IV 
and V believed to be analogous to the substantia nigra in humans and thus are only counted during TH 
experiments in this thesis. Figure reproduced from Rink and Wulliman 2002. 
 
Apart from PD, zebrafish have also been utilised to model Huntington’s disease and 
motor neuron disease. The zebrafish Huntington’s model offers many insights, as 




genetics stance, although demonstrating the importance of Htt in vertebrate 
gastrulation, mouse Htt loss of function mutants are impractical to study due to the 
nature of their in vivo development. This is not an issue for zebrafish that are 
transparent and develop ex vivo.177 KD of htt in zebrafish resulted in defects in iron 
homeostasis and iron deficiency.178, 179Additional KD studies have shown an aggressive 
phenotype of a small head, CNS apoptosis, enlarged brain ventricles and a sharp 
decrease in Bdnf levels (60% decrease). Application of Bdnf protein to morphants 
ameliorated many of the phenotypes caused by KD of htt, demonstrating Bdnf levels 
strongly influence the htt KO phenotype.180 
As HD mutations are toxic gain of function in nature, Morpholino studies, although 
useful for understanding protein function, do not model the natural history of the 
disease seen in human patients. Consequently, over expression studies in zebrafish 
embryos expressing the poly-glutamine expansions (seen in human patients) are more 
appropriate. One such study over expressed the N-terminal of Htt containing 102 Q 
repeats, modelling the Htt expansion seen in HD with the GFP construct, allowing for 
imaging of polyQ aggregates by fluorescent microscopy in real time. Large cytoplasmic 
inclusions were detected just after 24hpf which grew larger over time by absorbing 
soluble Q102-GFP. The model was utilised to test known inhibitors of PolyQ 
aggregation as a proof of principle, then successfully tested experimental compounds 
for efficacy.181  
Zebrafish have also been utilised to model familial forms of SOD1 linked motor neuron 
disease, in both loss of function and overexpression models. In the former, a stable T70I 
mutant was generated from an ENU mutagenesis screen. Homozygous mutants 
possess decreased Sod1 activity, are sensitive to oxidative stress during development 
and possess altered neuromuscular junction morphology. Adult mutants develop a 
50% reduction in large motor neurons and spend more time moving slower. These fish 
also spent 20% more time swimming on the bottom of the tank, suggesting an anxiety 
like phenotype.182, 183  
In an over expression model developed by McGown and Ramesh et al., a transgenic 
line over expressing human mutant SOD1 was constructed adjacent to a Dsred element 
under the control of an HSP70 promoter, independent of mutant SOD1. Consequently 
Dsred is only transcribed in the presence of heat shock or cellular stress. In the absence 




specifically in their CNS, implying neuronal stress. Dsred expression was not detected 
in lines overexpressing WT SOD1. This mutant SOD1 over expressing line model was 
found to have a decrease in glycinergic currents occurring in spinal motor neurons, 
changes in neuromuscular junctions and movement defects.184 Riluzole, a compound 
utilised to treat motor neuron disease, decreased Dsred fluorescence in lines 
overexpressing mutant SOD1, implying it was decreasing neuronal stress, as a proof of 
principle. Both models are now being extensively utilised for small molecule chemical 
screens for motor neuron disease.182, 184, 185 
1.4.4 Medaka as a model for Parkinson’s disease 
The Japanese fresh water fish, Medaka (Oryzias latipes) extensively utilised in the field 
of developmental biology, has also been utilised to model PD loss of function 
mutations.  They additionally produce parkinsonian-like phenotypes in response to 
traditional PD chemical toxins, such as MPTP and MG132. In contrast to zebrafish, only 
stable mutations have been studied in Medaka in the context of PD. Loss of function 
alleles have been generated for pink1, parkin and dj1. pink1 -/- and parkin  -/- Medaka 
have mild phenotypes similar to KO mice. Loss of function pink1 and parkin Medaka 
develop normally; segregating in a Mendelian ratio, but have a decrease in mass 
compared to WT at 12 months of age. Both showed a decrease in spontaneous 
movement in the absence of neurodegeneration. Double mutants also developed 
normally, reaching adulthood, but showed a decrease in TH neurons of 30%, TH 
protein levels and a decrease in dopamine in their brains. Their brain tissue also had 
accompanying mitochondrial dysfunction, with a specific decrease in mitochondrial 
Complex I and II activity; the organelles were grossly enlarged with fragmented 
cristae. This data challenges the concept of pink1 and parkin acting in a linear pathway 
in vertebrates. A dj1 null Medaka has been generated, but has yet to be 
characterised.186-190 
1.5 PINK1 
1.5.1 PINK1 function 
The initial focus of this thesis was to characterise and investigate gene-gene 
interactions in a stable loss of function zebrafish pink1 mutant. Loss of function 




a similar manner to PARK2 linked PD, both having  an early onset of 18-50 years, a 
long disease duration (~20 years) and an excellent response to L-Dopa. Symptoms are 
indistinguishable from idiopathic PD.191 Genetically, the disease segregates in an 
autosomal recessive manner, coupled with a large variety of extreme deleterious 
mutations (exon deletions, nonsense mutations), these mutations are considered to be 
pathogenic due to a loss of function effect. PINK1 heterozygous mutations are over 
represented in sporadic PD cases compared to healthy controls, suggesting they may 
contribute to disease progression, although this is controversial. 192 
PINK1 linked PD, unlike PARK2 linked PD, is not a common cause of EOPD, making 
up between 1-4% of early onset patients, depending on the population; however PINK1 
mutations are still more common than DJ-1 mutations.193, 194  
PINK1 is a serine/threonine kinase, additionally possessing a mitochondrial 
localisation signal, further linking mitochondrial dysfunction to PD pathogenesis.15 
PINK1 is expressed ubiquitously, with higher expression in organs with a large energy 
demand; namely the heart, muscle and the brain, within which expression is highest in 
the substantia nigra.195 Functional studies have demonstrated its role in the mitophagy 
pathway, among others.196, 197 PINK1 is believed to function in the same pathway as 
another PD related protein, the E3 ubiquitin ligase PARKIN, at least in Drosophila. 
However, whether this pathway is linear in vertebrates has been called into 
question.190, 198 PINK1 deficiency results in mitochondrial dysfunction with a decrease 
in mitochondrial membrane potential, a decrease in ATP levels and a decrease in 
mitochondrial Complex I and IV activites.199-201 
PINK1 protein is constantly expressed, trans-locating to the mitochondria where it is 
processed into two forms; firstly cleaved by a matrix processing peptidase to remove 
the mitochondrial targeting signal to form 60kDa  -MTS –PINK1. The 60kDa form is 
then cleaved again by PARL (presenilin associated rhomboid like protein) to a 52kDa 
form in the inner mitochondrial membrane, and finally is completely degraded by the 
proteosome.202 Some of the 52kDa PINK1 isoform escapes to the cytoplasm, where it 
physically binds to, and inhibits PARKIN recruitment to the mitochondria.203 Cleavage 
by PARL is believed to be dependant on the mitochondrial membrane potential. 204 
When the membrane potential is substantially decreased, full length 60kDa PINK1 is 
not cleaved and accumulates on the outer mitochondrial membrane (OMM) where it 




marking the mitochondrion for recycling by mitophagy.203, 205 Potential protein 
ubiquitination targets of PARKIN have been identified on the OMM, including p62, 
VDAC1, MFN1, MFN2.206-209 Once ubiquitinated, the mitochondria migrate to the 
perinuclear area and are degraded by autophagy.206 
TRAP1, a mitochondrial heat shock protein, has been shown to be a substrate of 
PINK1. TRAP1 exerts a neuroprotective effect by preventing cytochrome c release in 
the mitochondria. Overexpression of WT TRAP1 rescues pink1 -/- defects in Drosophila 
and in cell culture models.210, 211  
PINK1 appears to have additional functions in maintenance of the mitochondrial 
network and its dynamics, although data is conflicting depending on the model. pink1 -
/- Drosophila and PINK1 deficient rat DA neuronal cultures both have elongated 
mitochondria.212, 213 Conversely, KD in other cell lines such as HELA and SH-SY5Y, 
produce fragmented mitochondria.214, 215 Even with these discrepancies, and given its 
interactions both genetically and physically with many proteins involved in fission and 
fusion of the mitochondria, namely, DRP1, MFN1, MFN2 and OPA, PINK1 clearly 
influences mitochondrial dynamics 213, 216, 217. 
To analyse the involvement of PINK1 and PARKIN in the mitophagy pathway at the 
cellular level, many studies rely on toxins such as CCCP that completely depolarise the 
mitochondrial membrane. This induces irreversible damage and the subsequent 
destruction of the whole organelle. If damage is only mild, such as in the case of 
oxidative stress, then the loss of the whole organelle is potentially costly to the cell.206, 
207 An alternative strategy is to remove only the damaged part of the organelle. The 
damaged section of organelle is identified by PINK1 and PARKIN, through currently 
unknown mechanisms, and a mitochondrial derived vesicle is generated around the 
damaged area. This vesicle then directly fuses with lysosomes without the addition of 





Figure 6.  Models of the PINK1 and PARKIN mitophagy pathway. Flow diagram 1 (left) is the classic 
mitophagy model, severe mitochondrial damage, dissipates the mitochondrial membrane potential 
stabilising PINK1 on its surface and recruiting PARKIN. Post recruitment, PARKIN then ubiquitinates 
substrates for destruction, leading to phagophore formation around the damaged organelle (by LC3) and 
subsequent degradation by the lysosome. Flow diagram 2 (right), a model proposed by Mclelland et al., 
demonstrates PINK1 PARKIN involvement in response to mild stress. Mild localised stress does not 
depolarise the mitochondrial membrane. PINK1 somehow localises around the damaged area only, 
recruiting and activating PARKIN. This somehow leads to the excision of the damaged material only in 
mitochondrial derived vesicles and subsequent degradation by the lysosomal. Figure reproduced with 
permission from Shlevkov 2014.219 
New evidence suggests PINK1 has an active role in the heart and its development. 
PINK1 is highly expressed in the heart, as well as the brain, most likely due to its high 




end stage heart failure, cardiac tissue has been shown to have a large decrease in 
PINK1 protein levels (however not transcript levels). The decrease is so large that 
PINK1 protein was nearly undetectable in some heart failure patients, compared to 
healthy controls. With age, Pink1 KO mice begin to develop cardiac hypertrophy, with 
an average increase in heart to body ratio of 18% by 8 months.  Individual 
cardiomyocytes increased in size by 50%, compared to WT controls, with an absence of 
an increase in cell number.220 Mitochondrial analyses in Pink1 KO mice showed 
classical mitochondrial dysfunction, such as an increase susceptibility to oxidative 
stress, a decrease in ATP levels and a decrease in mitochondrial membrane potential. 
PINK1 function is clearly required for mitochondrial health in cardiac tissue, and not 
only purely for neuronal health.220, 221 
1.5.2 Models of PINK1 deficiency 
A variety of genetic models were constructed to gain a better understanding of PINK1 
function through a reverse genetic approach. Loss-of-function pink1 flies developed 
severe and robust phenotypes. These were most obvious in the morphology where 
mutants have the so-called downward turning wing phenotype and a degenerating 
thorax. The mutants can walk normally, however, have a decrease in flight ability and 
slower climbing speeds. Muscle fibres were disorganised and undergo degeneration. 
Analysis of mitochondria showed swollen organelles with a decrease in ATP levels.  
Sperm development was also found to be defective (again due to mitochondrial 
abnormalities) causing male sterility. Phenotypes become worse over time, leading to 
increase in susceptibility to oxidative stress and also a decrease in lifespan.  A modest 
decrease in TH neurons was reported by two studies, implying neurodegeneration, 
however were found un-changed in another.176, 222, 223 
These phenotypes were reminiscent of parkin KO Drosophila described by Greene et al. 
Overexpressing WT parkin on the pink1 null background partially ameliorated thorax 
and wing morphological defects. Mitochondrial dysfunction in muscle was also 
restored with a complete reduction in muscle and TH cell degeneration. Conversely, 
overexpressing WT pink1 on a parkin null background could not alter any phenotypes.  
Yang et al., also overexpressed WT dj1 on a pink1 null background to also find it did not 
rescue any phenotypes. 176, 222, 223 
Flies carrying homozygous mutations for both parkin and pink1 do not show a 




single mutants. These genetic studies suggest not only pink1 and parkin to be in the 
same linear pathway, but that also parkin acts downstream of pink1. In contrast, recent 
studies undertaken in vertebrates have challenged this concept.176, 190, 222, 223 
Pink1 KO mice only develop very mild phenotypes compared to pink1 KO Drosophila.  
Homozygous mutant mice generated by homologous recombination developed a 20% 
decrease in mass at 1 year. By 1.5 years they exhibited a decrease in spontaneous 
movement. Measurements of strength and anxiety remained unchanged compared to 
WT. Complex behaviours such as the acoustic startle-response was also identical 
between the mutant and WT.199  
Although a significant decrease in dopamine was recorded in aged PINK1 deficient 
mice, there was a complete absence of TH cell loss. Although neuronal cell loss could 
not be detected, mitochondrial dysfunction was present, with decreases in ATP levels 
and reduced mitochondrial Complex activities.129, 199, 224   Due to the lack of TH cell loss 
in single Pink1, Parkin and Dj1 KO mice, a triple KO was made to explore any genetic 
interactions. Triple KO mice also displayed no gross deformity and exhibited no 
neurodegeration.129 These data imply that PINK1 may confer a protective mechanism 
as opposed to it being required for maintenance of neuronal health, at least in mice.129, 
199  
pink1 deficient Medaka fish, containing a premature stop codon, have also been 
characterised. The stop codon results in a decrease in pink1 transcript, most likely due 
to nonsense mediated decay, demonstrating loss of function. In keeping with mice, 
pink1 KO Medaka develop normally, showing no gross morphological changes and 
exhibit a reduction in mass compared to WT at late stages (12/18 months). Unlike 
Drosophila, no defects in sperm, muscle or mitochondria could be identified. Similar to 
KO mice, pink1 mutant Medaka show altered dopamine metabolism and a decrease in 
spontaneous movement, however in the absence of neurodegeneration. Medaka 
double mutants (KO for pink1 and parkin) synergistically display a decrease in DA 
neurons, this conclusion arguing against pink1 and parkin functioning in a linear 
pathway, at least in vertebrates. 188, 190  
1.5.3 p53-Inducible Regulator of Glycolysis and Apoptosis (TIGAR) 
The initial focus of this study was the further characterisation of a loss of function pink1 




interest for further study in the model was tigarb, an orthologue of the human gene 
TIGAR (p53-Inducible Regulator of Glycolysis and Apoptosis). Tigarb was identified 
through an unbiased genome wide expression study as it was shown to be significantly 
upregulated in pink1 -/- 5dpf larvae compared to their WT siblings.201  
The p53 protein, a highly researched protein in cancerous mechanisms, possesses a 
broad range of functions that ultimately allow it to prevent tumour progression by 
reducing cellular stress.225, 226 In a further study to understand p53 responsive genes, a 
microarray analysis following p53 induction identified several of these elements. One 
of these, uncharacterised at the time, was TIGAR.227 The genomic structure of TIGAR is 
highly conserved across all vertebrates (mammals, birds, fish, amphibians etc), and is 
noticeably absent from invertebrates and other forms of complex life. The TIGAR 
sequence contains two separate p53 binding sites in humans, although only one is 
conserved in mammals, and codes for a protein of 30kDa. Its expression is rapidly 
induced, in a variety of difference cell lines following p53 induction by Adriamycin 
treatment. This p53 induction is believed to be only in response to mild repairable 
cellular damage, as chronic induction with high cellular stress leads to constant p53 
upregulation. This will induced TIGAR upregulation. However after initial 
upregulation, TIGAR expression falls rapidly, whilst p53 induction remains constant. 
This implies TIGAR may be part of a molecular switch for p53 controlling its complex 
functions in response to different forms of stress.228 TIGAR additionally possesses p53 
independent induction, as cells lines not expressing p53, will still express TIGAR at 
basal levels.228 
TIGAR function was elucidated due to its homology to the glycolytic enzyme 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2).228 PFK-
2/FBPase-2 has the dual function of both kinase and bisphosphate activity, with the 
TIGAR protein only sharing homology to the bisphosphatase domain. Bensaad et al., 
demonstrated that the function of TIGAR is to degrade fructose-2,6-bisphosphate to 
fructose-6-phosphate.228 The former is a potent effector of 6-phosphfructo 1-kinase, a 
glycolytic stimulator. Fructose-2,6-bisphosphate additionally functions as an inhibitor 
of fructose-1,6-bisphosphatase, a gluconeogenic regulator.229 By reducing levels of 
fructose-2,6-bisphosphate, degrading it to fructose-6-phosphate, TIGAR functions to 





Figure 7. The metabolic pathways affected by enzymatic TIGAR function. Fructose-2.6-bisphosphate is 
converted to Fructose-6-phosphate, preventing allosteric activation of PFK-1.This in turn, diverting 
metabolism towards the pentose phosphate pathway and Hexosamine pathway. This not only lowers 
oxidative stress, but also provides materials for DNA repair. Reproduced with permission from Lee 
2014.230 
 
This inhibition leads to a diversion of metabolism towards the pentose phosphate 
pathway, causing not only a decrease in oxidative stress, but also a decrease in 
apoptosis.228 Although TIGAR substrate specificity has recently been challenged by 
Gerin et al., who demonstrated TIGAR has a far greater affinity for 2,3 bi-
phosphoglycerate (23BPG), than for fructose-2,6-bisphosphate, the concept of TIGAR 
thus acting as a 23BPG phosphatase would actually increase glycolytic intermediates as 
opposed to inhibiting them. This new function of TIGAR calls into question its primary 
mode of action as a glycolytic inhibitor, or at least suggests its functions are more 
complex than first perceived. 228, 231 
Overexpressing TIGAR has been discovered to lower levels of ROS in response to 
chemical stress, metabolic, stress or starvation, as well as basal levels of ROS. The KD 
of TIGAR will increase levels of ROS under all previously described conditions. 
However, as basal levels of ROS represent important cellular signalling, processes such 
as autophagy can also be affected by TIGAR manipulation.232, 233 Indeed, TIGAR KD 
was shown to robustly induce autophagy, not only in unstressed cells, but also those 




to reduce autophagy. Additionally, TIGAR KD stimulates autophagy even in p53 null 
cell lines, indicating p53 is not required for modulation of autophagy by TIGAR.232 
DRAM, also a p53 responsive gene, functions in promoting autophagy. The increase in 
autophagy after TIGAR KD was found not to be effected by DRAM status, showing 
that both p53 responsive genes do not work in concert to manipulate autophagy 
pathway. TIGAR modulation of autophagy was demonstrated to be mTOR 
independent, as KD did not lead to a change in the down-stream targets of mTOR.228 
The function of TIGAR to limit ROS has been demonstrated in cancer cell lines; when 
under hypoxic stress, a proportion of TIGAR relocates to the outer mitochondrial 
membrane. Stabilisation of Hypoxia-inducible factor 1-alpha (HIF1 ) by small 
molecules such as DMOG also relocated TIGAR to the outer mitochondrial membrane. 
TIGAR’s translocation was dependant on glucose and Hexokinase 2 (HK2), as 
depletion of both removed the re-localisation. TIGAR was found to bind exclusively to 
HK2 but not HK1, which can also bind to the OMM. TIGAR physically binding to HK2 
enhances its activity (without altering TIGAR expression). The binding is retained by 
TIGAR, even in mutants without an FBPase-2 domain.234 Mitochondrial localisation 
and HK2 binding is dependent only on 4 amino acids (human residues 258-261), and 
that co-localisation under hypoxia was shown to be HIF1  dependant, as inhibition of 
HIF  prevents relocation of TIGAR.234 Furthermore, enhancing HK2 activity lowers 
ROS and cell death.234 HK2 KD prevented TIGAR over expression to reduce ROS 
formation, mostly likely as it is required to maintain the mitochondrial membrane 
potential.234, 235 This action appears to be cell type dependent as in cardiomyocytes; 
hypoxia causes a p53 dependant increase in TIGAR expression. Over expression of 
TIGAR increased apoptosis after hypoxia induction. Conversely KD of TIGAR was 
found to rescue the mitochondrial membrane potential and prevent apoptosis after 
hypoxic induction.236  
Three KO mouse models have been constructed to understand the function of Tigar in 
vivo. In a similar manner to p53 KO mice, Tigar KO mice develop normally and do not 
exhibit morphological defects. Homozygous mutants are viable, live to adulthood, 
with genotypes segregating in a Mendelian fashion.237, 238 
As expected, Tigar KO shows an increased level of Fructose-2,6-bisphosphate in 
keeping with human cells. Expression in vivo showed Tigar to be highly expressed in 




genotypes, following toxin ablation, Tigar KO showed a decrease in size and number of 
regeneration within their crypts. Analysis of WT tissue showed a marked upregulation 
of Tigar 24-72 hours after toxin exposure, indicating that Tigar is required for 
proliferation of tissue during regeneration, likely due to its capacity to generate 
nucleotides and antioxidants required for growth.237 
Conversely, Tigar deficient mice have been shown to be more protected in a model of 
ischemic injury. Tigar KO mice develop an increase in autophagy markers at sites of 
ischemic injury, phenocopying p53 null mice. Both KO mice showed a reduction in 
build-up of defective mitochondria. Although, PARKIN was found to not translocate 
to the mitochondria during metabolic stress, in P53/Tigar KO animals there was a 
marked activation of BNIP3 that initiates autophagy as well as mitophagy during 
hypoxia. Consequently TIGAR may inhibit BNIP3 and indirectly inhibit mitophagy if 
over expressed.232, 238 
1.5.4 Von Hippel-Lindau and hypoxia 
The second phase of the pink1 project involved the investigation of gene-gene 
interactions between pink1 and vhl (Von Hippel-Lindau), loss of function mutations 
which lead to specific cancers.  
As described above, pink1 -/- zebrafish exhibit an upregulation of tigarb, an inhibitor of 
glycolysis, implying a reduced glycolytic flux. In contrast, vhl -/- zebrafish exhibit an 
upregulation of glycolytic genes implying an enhanced glycolytic flux, common in 
many cancers. It was hypothesised that crossing these lines together, generating 
zebrafish homozygous for both pink1 and vhl mutations, would normalise their 
glycolytic pathways and may lead to a rescue of phenotypes seen in pink1 and vhl      -
/- larvae. 
VHL disease is an autosomal dominant inherited disorder, caused by mutations in the 
VHL tumour suppressor gene. Patients carry heterozygous mutations and only 
develop tumours when the WT allele is mutated by exogenous mechanisms. Once both 
alleles have been mutated causing loss of function that leads to upregulation of many 
pathways involved in hypoxic signalling.  The most commonly associated tumours 
with VHL disease are haemangioblastomas of the retinal and central nervous system, 
renal cell carcinomas and pancreatic islet tumours. Renal cysts can also develop, 




The VHL gene codes for a 231 amino acid protein (pVHL30) and a smaller pVHL19 
which is missing amino acids 1-53. A large variety of disease causing mutations have 
been described, however the majority (40%) consist of large deletions due to alu 
mediated recombination.240 VHL is an E3 ubiquitin ligase and tumour suppresser with 
multiple complex functions; its main role appears to be in hypoxic signalling. Under 
normoxia, VHL constantly binds to the alpha subunits of HIF1a and HIF2a, marking 
them for degradation.  Oxygen is required for the modification of HIF1 and HIF2 by 
PHD (prolyl hydroxylase) enzymes, which allows VHL to bind them. Under hypoxic 
conditions, as oxygen is unavailable for this reaction, HIF1 and HIF2 remain un- 
modified, and so VHL is unable to bind to them, allowing for their stabilisation. Once 
stabilised, they are able to act freely as transcription factors, leading to the transcription 
of a vast array of hypoxic responsive elements, promoting angiogenesis.239, 241 In the 
absence of viable VHL, HIF1a is continually stabilised allowing for the transcription of 
its target genes, and hence dysregulation of hypoxic signalling occurs, making the cell 
act as if it is hypoxic even when it has the full requirement of oxygen.241  See Figure 8. 
 
Figure 8. VHL and hypoxic signalling. The activity of VHL in response to oxygen levels within the cell. 
Under normoxia VHL continually binds to HIF1α marking it for degradation. During hypoxia, VHL is 
unable to bind to HIF1α HIF1α can then bind to HIF1β, and acts as a transcription factor for hypoxia 
responsive genes. Figure reproduced with permission from Maher 2010.239 
Vhl homozygous mutations are embryonic lethal in mice. Consequently, as it develops 
ex vivo, the zebrafish has successfully been utilised to model VHL deficiency in vivo, 
through development. Microarray studies on the vhl -/- mutants demonstrate an 
upregulation of many genes involved in anaerobic metabolism (such as the glycolytic 




hypoxic response. Functionally, this leads to an increase in VEGF signalling leading to 
polycythaemia, increased blood flow and disorganised branched blood vessels in the 
vascular network. The vessels become leaky, which in the eye, where the vascular 
network is vastly increased, leads to retinal lesions and in some cases, retinal 
detachment from the neuronal layers. This is very suggestive of macular oedema 
which can also be observed in human patients with VHL disease. The vhl –/- zebrafish 
eventually begin to hyperventilate and although mature through the stages of 
development, die at 10dpf due to oedema.242, 243 
1.6 Glucocerebrosidase 1 
1.6.1 Gaucher’s disease 
The third part of this thesis concentrated on establishing loss of function models of 
zebrafish for Glucocerebrosidase (gba1) using KD/KO strategies and to assess if the 
zebrafish is a suitable model of gba1 deficiency.  
GBA1 is a lysosomal enzyme required for the conversion of Glucocerebroside 
(otherwise known as Glucosylceramide) to ceramide and glucose (see Figure 9), 
mutations in its gene present with Gaucher’s disease (GD), a lysosomal storage 
disorder. 
 
Figure 9. The GBA1 catalysed chemical reaction. GBA1 catalyses the conversion of Glucocerebroside 
(Glucosylceramide) to Ceramide and Glucose. 
The GBA1 gene is located in a highly gene-rich region within the human genome 
comprised of 7 genes and 2 pseudo genes within an 85 kb region located on human 
chromosome 1. Due to a duplication event, (present before the diversion of humans 
and primates) both GBA1 and the nearby mitochondrial import gene Metaxin have very 




GBA1, but contains a 55bp deletion within exon 9, that can be utilised for diagnostic 
purposes.244 The gene has two in frame ATG start sites producing polypeptides of 
different lengths which are both post-translationally processed to yield a 497 residue 
mature enzyme. GBA1 is expressed ubiquitously in all tissues in a similar fashion to a 
housekeeper; however GBA1 enzyme activity rarely correlates with transcript levels.244, 
245 
So far, over 300 GBA1 mutations have been reported, the majority being missense 
mutations (80%), but also nonsense mutations, splice site mutations and small indels 
producing frameshifts. The majority of GBA1 mutations are found in exons 8 and 9, but 
they  have also been observed in all other GBA1 exons.244  The presence of the 
pseudogene and its 55bp deletion, are also the cause of both reciprocal and non-
reciprocal recombination events, termed complex alleles representing a distinct and 
significant portion of GD mutations. Despite the severity of certain mutations, there is 
a poor correlation between genotype and clinical presentation with the exception of the 
N370S and L444P mutations that more commonly give rise to types I and II GD 
respectively. The L444P and N370S mutations are the most prevalent, making up 
around 70% of cases either in a homozygous or compound heterozygous state.244, 246  
Bi-allelic mutations in GBA1 lead to GD, the most common lysosomal storage disorder 
with a prevalence of approximately 1/100,000.247 The disorder presents with 
heterogeneous symptoms, giving rise to three  subtypes, although this is increasingly 
viewed as a continuous spectrum.92 Type 1 GD is based on the absence of neurological 
symptoms, making up 90% of all GD cases. It presents with highly variable symptoms, 
many patients can go undiagnosed for years as they appear almost asymptomatic. 
Common features in type I include anaemia, thrombocytopia, organomegaly and 
osteoporosis. Patients are also at a higher risk of certain cancers such as non-Hodgkin’s 
lymphoma.92, 93, 248, 249 
 Type II GD, also known as neuropathic GD, leads to early death, approximately 9 
months after birth due to neurological decline which is rapid and patients may also 
present with seizures and hypertonia. Progressive hepatosplenomegaly and other 
symptoms such as apnoea, cachexia and growth arrest also occur. A subset of patients 
(known as collodian babies), are born with congenital ichthyosis, with death occurring 
shortly after birth. Type III GD, also neuropathic in nature, is a chronic progressive 




neurological decline with seizures, horizontal supranuclear palsy, and hydrocephalus 
to mild hepatosplenomegaly and cardiac valvular involvement.92, 250-252 
Although type I GD has always been categorized as a non-neuropathic form of the 
disease, this has been brought into question with many type I patients presenting with 
PD in later life.253 
Effective treatment is available. Enzyme replacement therapy (recombinant GBA1) is 
extremely effective at treating the majority of symptoms. However, enzyme 
replacement therapy is not a suitable treatment for type II or type III GD, as 
recombinant GBA1 does not cross the blood-brain barrier.254, 255 
Glucocerebroside is a key component of sphingolipid metabolism in the salvage 
pathway which provides up to 80% of the cells ceramide requiements.256 All GBA1 
mutations lead to partial if not complete loss of enzyme activity, leading to substrate 
accumulation of glucocerebroside and glucosylsphingosine within lysosomes. Due to 
the large lysosomal content of macrophages, the cells become engorged, the lysosomes 
pushing their nuclease to the side of the cell membrane. Within the cell the cytoplasm 
appears to possess many crinkles and striations. This has classically been described as a 
“wrinkled tissue paper” appearance. The swollen cells, known as “Gaucher cells” are 
highly activated macrophages, and congregate in particular organs leading to 
hepatosplenomegaly. Any cell of a mononuclear phagocyte lineage may be affected in 
this fashion, including kupffer cells (present in the liver), osteoclasts (present in bone) 
and microglial cells (present in the CNS). The latter microglial cells although don’t 
directly cause disease; increase severity judging from conditional mouse models.128, 257 
Gaucher cells secrete many chemokines, such as Interleukin-1β, that are elevated in the 
plasma of GD patients. Chitotriosidase, a human chitinase, a marker of activated 
macrophages, is markedly upregulated in its activity in GD patients’ plasma.  Indeed, 
it is utilised as a GD biomarker for evaluating efficacy of enzyme replacement 
therapy.258, 259 
1.6.2 Models of GBA1 deficiency 
Drosophila possess two orthologues of GBA1 too close to each other to create a 
chromosome with mutations in both genes with standard techniques.  By simple 
molecular manipulation, animals with heterozygous mutations in both genes have 




and demonstrate activation of the unfolded protein response. Survival from larvae to 
adult is reduced by 50% compared to WT. Transgenic flies expressing either human 
WT GBA1, N370S or L444P mutations show further activation of unfolded protein 
response (UPR) compared to WT. Both mutant transgenic and double het flies show a 
decrease in flight capacity, with large reductions in climbing activity of up to 80% by 
22dpf.260 
The first Gba1 KO mouse models constructed, possessed a neomycin resistance cassette 
inserted between exons 9 and 10. GBA1 activity in homozygous mutants was reduced 
to 4% of WT. All homozygous mutants were underweight, exhibited abnormal 
respiration and died within 24 hours of birth. Gaucher like cells were detected in the 
liver, spleen and brain, the phenotypes strikingly similar to type II GD collodian 
babies.261 
As most human patients still retain some residual GBA1 activity, in order to more 
faithfully model the disease, mouse models were generated that possessed mutations 
seen in humans (L444P and RecNcil). The L444P mutation is one of the most common 
found in patients, whilst RecNcil is an example of a complex recombination allele 
genotyped using the NciI restriction enzyme. L444P mice retained 20% residual GBA1 
activity, whilst RecNcil only had 4%. Both homozygous mutants all died 24-48 hours 
after birth. They would not feed and possessed very red dry skin. Glucocerebroside 
accumulation was detected in the skin of both mutants, however substrate 
accumulation  in the brain could only be detected in the RecNcil mutant.262 
Mice carrying Gba1 point mutations seen in human patients have also been generated, 
including N370S, D409H, D409V and V394L. N370S homozygotes died during the 
neonatal period. All other mutants retained only 25% enzyme activity compared to 
WT, but did not model the disease, as all were viable and did not accumulate 
glycolipids in the brain. 263 
As KO mice develop such severe phenotypes that make study impractical, conditional 
KO were generated to analyse Gba1 loss of function in particular organs. Enquist et al., 
generated a conditional KO mouse that was a KO in all organs apart from the skin, the 
K14-lnl/lnl. K14 mice had a reduction in GBA1 activity by 95% and accumulated 
glucocerebroside in the brain, liver and spleen. Unlike complete KO mice, K14 mice are 
viable during the first week of life, however, after a symptom free period of ten days, 




motor dysfunction and seizures. K14 mice all had to be culled at 2 weeks of age due to 
excessive seizures leading to end stage paralysis.128  
K14 brains contained a large reduction in neuronal cells as well as cellular density. 
Large neurons were surrounded by microglial like cells, many containing large 
vacuoles most likely due to substrate accumulation.  K14 brains had increased caspase 
3 and TUNEL staining, showing neuronal cell loss due to cell death, as well as 
microglial activation and astrogliosis. Conditional KO mice that retained GBA1 activity 
in skin and microglia (Nestin mice), develop phenotypes identical to the K14 mice, 
however, symptoms only start to appear a week after K14. Suggesting Gba1 status in 
microglia effects disease duration as opposed to driving the primary pathology. From 
these mouse models it is clear that GBA1 activity is critical for neuronal survival.128 
Other conditional mouse models have been constructed for other organs excluding 
neuronal tissue. Mistry et al., constructed a conditional mouse KO that is Gba1 null in 
all tissues of hematopoietic and mesenchymal lineages, reducing GBA1 activity in 
these tissues to 5% of WT activity. Although these mice were viable, they developed 
marked substrate accumulation of glycolipids in their liver and spleen (approximately 
30 fold), similar to human disease. The Gba1 -/- mice display classic gibbus formation, 
hepatosplenomegaly and anaemia. Spleen size rising to 8 fold that of WT. Mutant mice 
go on to develop Gaucher cells, invading organs such as the bone leading to severe 
osteopenia.264 
1.6.3 Glucocerebrosidase and Parkinson’s disease 
Interest in GBA1 mutations has significantly increased in the biomedical field since the 
discovery that heterozygote GBA1 mutations are a risk factor for PD and dementia 
with Lewy bodies. 8, 93, 265 
The association was first detected when it was noted that there was an over 
representation of PD in  patients with type I GD, previously considered to be the non-
neuropathic form of GD.253 Type I GD is not 100% penetrant when assessing patients 
on traditional symptoms such as organomegaly. To assess for an association between 
GD type I and PD, sporadic PD patients were screened for GBA1 mutations in 
Ashkenazi Jewish populations, as this population has unusually high incidence rates of 
both diseases. Of 99 patients screened, 30% carried a GBA1 mutation, compared to only 




for the common GBA1 mutations implying that heterozygosity on its own may be a 
risk factor for PD.266 Large scale screening studies have confirmed this association, 
making GBA1 mutations the most common risk factor for PD. GBA1 mutations have 
also be found to additionally be the most common risk factor for dementia with Lewy 
bodies.102  
However, it has also been suggested that these mutations may in fact not be a risk 
factor, but actually a cause of autosomal dominant PD with lower penetrance.267 The 
OR for gene mutations is approximate 5-15 depending on the population, meta- 
analysis have deduced OR of 3.51.102  This OR is likely to be higher in reality as, due to 
practicalities, the majority of studies only screen for common GBA1 mutations of 
N370S and L444P, which make up 70% of cases. This therefore will not identify the 30% 
of patients carrying one of the 300 recorded GBA1 mutations.93, 244 
Few functional studies have yet to be carried out on how GBA1 mutations could lead to 
PD, reports mainly implicating SNCA interactions as a driver of pathology, however 
GBA1 deficiency may be even more key to PD than originally thought, due to the 
discovery that even PD patients without GBA1 mutations display a decrease in GBA1 
activity in brain tissue.268 
1.6.4 GBA1 pathology due to loss of function mutations 
The role of GBA1 in the development of synucleinopathies is poorly understood, with 
many questions remaining. Models have been put forward for both toxic gain of 
function, loss of function or a synergy of the two.269 
Although a variety of GBA1 mutations have been catalogued, thus far, no GD patients 
have been recorded that possess large deletions and exonic rearrangements,  that are 
present in classic loss of function autosomal recessive inherited forms of disease such 
as PINK1 and PARK2 disease. The exceptions to these are patients containing complex 
alleles due to recombination with the pseudo gene. These have only been found in 
homozygous form in patients that are stillborn neonates. Complex alleles have been 
found in compound heterozygosity with other more common GD alleles, however, 
these also tend to present perinatal-lethal GD. As common GBA1 mutations have been 
shown to cause a partial decrease in enzyme activity, this and KO mice would imply 




remaining disease genes could potentially be viewed as hypo-morphs or partial loss of 
function.270, 271 
KO Mouse models of Gba1 lead to rapid neurodegeneration, however, the effect of 
Gba1 heterozygous mutations on neuronal health have yet to be investigated in vivo. In 
neuronal cell culture, complete loss of GBA1 activity by CBE (conduritol b epoxide , a 
specific GBA1 inhibitor) inhibition had no effect on cell viability, and did not affect 
basal levels of ATP, mitochondrial membrane potential or mitochondrial Complex 
activity; however GBA1 inhibition did lead to SNCA accumulation. This was 
complemented by inhibition of GBA1 by a KD.272  A separate study by Manning-Bog et 
al., also confirmed CBE inhibition of GBA1 to be sufficient to lead to SNCA 
accumulation in the absence of a change in SNCA transcript levels.273 
The latter study assessed complete loss of function as seen in GD and not partial loss of 
function as seen in GBA1 heterozygous mutations linked to PD. A study by Mazzulli 
utilised a KD approach to assess partial loss of GBA1 function on SNCA levels. GBA1 
protein levels were reduced by 50%, leading to accumulation of glucocerebroside in the 
absence of neurotoxicity although lysosomal dysfunction was evident. Notably, this 
decrease in GBA1 protein led to an accumulation of SNCA in the absence of a change 
in transcript levels, suggesting protein aggregation.  This data was confirmed using iPS 
neurons derived from GD patients fibroblasts, which also accumulated SNCA.274  
The indirect consequences of GBA1 deficiency were also analysed with respect to 
SNCA accumulation. GBA1 substrates which accumulate upon GBA1 loss of function 
were found to increase SNCA aggregation in vitro. The same study also demonstrated 
that overexpression of WT SNCA prevented proper folding and transport of GBA1 in 
the endoplasmic reticulum. This reduced GBA1 protein levels and therefore GBA1 
activity even further. Consequently, this suggests SNCA and GBA1 work in a bi 
directional feedback loop. Loss of GBA1 activity increasing SNCA levels in vivo, due to 
glucocerebroside induced aggregation. SNCA in turn preventing correct GBA1 folding 
and maturation in the lysosome, decreasing activity further. This demonstrates how 
loss of GBA1 activity may be a unifying pathogenic mechanism in PD. In patients 
without GBA1 mutations there is SNCA accumulation in the form of Lewy body 
pathology. This could interfere with correct GBA1 processing leading to a decrease in 





This was demonstrated in a study by Gegg et al., where brain tissue of patients with 
sporadic PD was analysed for GBA1 activity. Patients who did not possess GBA1 
mutations still had a decrease in GBA1 activity in different parts of their brain, 
especially the substantia nigra.  This was accompanied by a decrease in GBA1 protein 
levels but not of the mRNA transcript levels, demonstrating that a decrease in GBA1 
activity was a post transcriptional effect and not simply a downregulation of GBA1. 
268The study confirmed findings from Mazzulli et al., that overexpression of SNCA 
reduces GBA1 protein levels but not transcript levels. 268 
Lowered mitochondrial Complex I activity is an important pathogenic mechanism 
observed in both sporadic PD and familial subtypes. Of note, decreased Complex I 
activity also reduces GBA1 activity. KD of PINK1 produces mitochondrial dysfunction 
and oxidative stress in a neuronal cell culture system.  Gegg et al., also demonstrated it 
to decrease GBA1 protein levels and subsequent activity in these PINK1 deficient cells.  
SCNA accumulation following GBA1 deficiency has been recently challenged by 
Dermentzaki et al. Using CBE a at a range of concentrations, they could not detect 
SCNA aggregation and dysfunction of lysosomal or autophagy pathways.275 
1.6.5 Toxic gain of function 
Evidence for toxic gain of function has been highlighted through overexpression of 
different mutant GBA1 constructs leading to accumulation of SNCA compared to WT 
in several different cell lines. Cullen et al., analysed SNCA levels after overexpression 
of WT GBA1, GD associated GBA1 mutations and loss of function GBA1 mutations 
within neuronal cell culture systems. WT overexpression had no effect on the levels of 
SNCA, whilst overexpression of GD associated alleles N370S, D409V, L444P and 
D409H all increased the levels of SNCA. L444P and D409H, producing the most robust 
increase, with SNCA levels rising to 170% and 248% respectively to that of WT, notably 
without the activation of the unfolded protein response.276 
Transgenic approaches using Drosophila overexpressed the human GBA1 and the GD 
mutant allele RecNciI under the promoter of specific GAL 4 lines which expressed the 
transgenic protein in the eye cells of the Drosophila, including certain photoreceptor 
neurons and pigment cells. WT GBA1 developed minor phenotypes, slightly affecting 
eye morphology. Overexpression of the mutant GD allele RecNciI led to severe rough 




flies compared to controls. Mutant transgenic flies also show up regulation of markers 
indicative of ER stress.277 
Analysis of mice heterozygous for either Gba1 KO allele compared to point mutation 
mice, D409V demonstrated that GBA1 mutations linked to PD may be toxic gain of 
function as at 6 months of age since Gba1 -/+ D409V mice develop ubiquitinated SNCA 
deposits within their brains. Mice  -/+ for Gba1 null alleles do not develop any such 
pathology at the same time point, regardless of the fact that both alleles possess the 
same amount of residual GBA1 activity.278 
 In animal models, it has been demonstrated that overexpression of complex GBA1 
mutation alleles (RecNcil) in Drosophila lead to neurodevelopmental defects and 
endoplasmic reticulum stress (ER) compared to overexpression of WT GBA1 alone. 
1.6.6 GBA1 unfolded protein response and mitochondrial dysfunction 
Secondary explanations of pathogenicity revolve around the unfolded protein response 
(UPR). To prevent misfolded proteins damaging cell homeostasis, they are recycled via 
endoplasmic reticulum associated degradation (ERAD). This occurs through 
ubiquitination, followed by degradation by the proteosome.279 Under normal 
conditions GBA1 assembles in the ER and is then shuttled to the lysosome. Mutant 
GBA1 fails to fold properly and is ubiquitinated for degradation. Several E3 ubiquitin 
ligases have been identified that recognise mutant GBA1, namely PARKIN and ITCH, 
although the involvement of PARKIN has recently been questioned.260, 280, 281 GBA1, 
being constitutively expressed, will cause mutant GBA1 to be constantly turned over 
activating the UPR, potentially overwhelming E3 ubiquitin ligases. This results in the 
neglect of their other substrates, leading to ER stress. Clearly UPR activation and ER 
stress would impact on SNCA turnover, likely leading to its cellular accumulation. 
Indeed, UPR activation has been detected in GD and GBA1 mutation carrying 
fibroblasts, as well as in fly models.260, 280, 282 Conversely, UPR activation has not been 
seen in other models, such as brain tissue from neuropathic mouse models, and 
neuronal cultures treated with CBE.128, 283 Clearly, the relationship between SNCA and 
UPR in the context of GD and Parkinson’s related GBA1 mutations requires further 
evaluation. 
Mitochondrial dysfunction has also been suggested to explain how GBA1 mutations 




ROS levels, a decrease in mitochondrial membrane potential,  a decrease in ATP levels 
and fragmented mitochondrial network. The mitochondrial dysfunction observed in 
GBA1 deficient fibroblasts is therefore very similar to those seen in PARK2 mutant 
fibroblasts.272, 284 Using primary neuronal cultures from the previously established 
neuropathic conditional Gba1 KO mouse, Osellame et al. demonstrated defective 
autophagy and UPS breakdown, resulting in ubiquitinated aggregates and SNCA 
accumulation. Mitochondrial Complex 1 defects, increased ROS and fragmented 
mitochondria were also observed, similar to Cleeter et al. The dysfunction was revealed 





1.7 AIMS AND OBJECTIVES 
Ultimately both projects were to establish whether the zebrafish could firstly model the 
human disease pathology and to identify benefits they would have over existing 
models of PD and GD. If the specific mutant suitably modelled the disease course in 
humans, the model in question could be used for further scientific analysis. Specifically 
genetic interactions and rescue experiments to identify new drug targets for both 
diseases and potential new protein functions.  
Objectives for each project were as follows, 
pink1 
1. Further analyse mutant phenotypes in greater depth.  
Identifying movement defects that are similar to PD motor symptoms exhibited by 
human patients.  Evaluate the cause of the decrease in TH neurons in the pink1 -/- 
larvae. 
2. Identify genetic interactions in pink1 -/- larvae. 
 To identify potential rescue mechanisms, up-regulated transcripts in pink1 -/- will be 
inhibited and pink1 -/- phenotype reassessed. 
 
gba1 
1. Generate gba1 mutant zebrafish.  
Loss of function models will be generated in a transient manner for pilot studies, 
following which, stable mutants will be generated. Loss of function will be assessed in 
both models of gba1 deficiency. 
2. Phenotype gba1 mutant zebrafish.  
Symptoms presented by GD patients in the clinic will be evaluated for similarity in the 
mutant gba1 zebrafish. Phenotypes will be assessed biochemically, behaviourally and 
histologically. Once the model has been validated, pathology will be assessed in 











2.1 Chemicals and other reagents 
All chemicals were purchased from Sigma Aldrich unless otherwise stated. All 
restriction enzymes and buffers were purchased from New England Biolabs. 
2.2 Zebrafish husbandry  
All adult and larval zebrafish were housed at the University of Sheffield; experimental 
procedures being in accordance with UK Home Office Animals (Scientific Procedures) 
Act 1986 (Project license PPL40/3402, held by Dr Oliver Bandmann, Personal license 
PIL 40/1009, held by Marcus Keatinge).  
Fish were housed at a density of 40 per tank, whilst on a cycle of 14 hours of light, ten 
hours of dark. Adults and larvae were kept at constant temperature of 28ºC. 
2.3 Fin clipping 
For genotyping, adult fish were anesthetised in a solution of tricaine (80ug/ml) and a 
small portion of the caudal fin was removed with sterile surgical scissors. The clipped 
fish was then moved to an individual tank, until the genotype was established. 
2.4 DNA extraction 
Genomic DNA, suitable for use in genotyping by polymerase chain reaction (PCR) was 
obtained using the REDExtract-N-Amp™ Tissue PCR Kit (Sigma). 
A zebrafish fin clip, was placed in the well of a PCR tube, homogenised with a solution 
of 25 µl extraction solution and 6.25 µl tissue preparation solution. The sample was 
vortexed for ten seconds, incubated at room temperature for 15 minutes, vortexed 
again, then finally incubated for three minutes at 95 ºC. Once the sample had cooled, 25 




2.5 Polymerase Chain Reaction 
PCR was utilised to amplify both genomic and cDNA for analysis.  Each PCR reaction 
was composed of 10 µl Biomix Red TM (Bioline), 2 µl forward primer (10 µM), 2 µl 
reverse primer (10 µM), 4 µl H2O and 2 µl of DNA. The reaction was heated to 95 ºC for 
three minutes then went through the following cycle for a total of 34 cycles. Each cycle 
consisted of incubation at 95 ºC for 30 seconds, 60 ºC for 30 seconds, and 72 ºC for 1 
minute. This was followed by final 5 minutes incubation at 72 ºC. The reaction was 
heated using a BIORAD DNA Engine gradient thermo cycler (BIORAD). Primers were 
designed using Primer3 software (v. 0.4.0) supplied by INTEGRATED DNA 
TECHNOLOGIES Ltd. For PCR, both the forward and reverse primers were used at 10 
µM. For a list of all the primers used see Table 3 below. For qPCR reactions, primers 
were optimised for annealing temperature, concentration and efficiency. SYBR green 
master mix (Agilent) was utilised for the enzyme reaction, reaction incubated and 
analysed by Stratagene MxPro 3000p (Stratagene). ef1 alpha was used as a reference 




PRIMER Sequence (5'-3') Description 
PINK1 Genotyping R AGCTTCACCACCAGCTGAAC PINK1 line genotyping 
PINK1 Genotyping F AAAGCAGATGTGTGGGCTGT PINK1 line genotyping 
GBA 178 G>A R GGGAAAGTTCCCTCAAAAATG GBA sanger line genotyping 
GBA 178 G>A F AGTACCGTTTCGTGAGAGTGC GBA sanger line genotyping 
MWO1 #4 R ATGTCATGGGCGTAGTCCTC GBA TALEN genotyping, all alleles 
MWO1 #4 F AAAGCAGCACGATATGTCCA GBA TALEN genotyping, all alleles 
M13 R CAGGAAACAGCTATGAC Colony PCR for TOPO Ta cloning 
M13 F GTAAAACGACGGCCAG Colony PCR for TOPO Ta cloning 
VHL Genotyping R CGAGTTAAACGCGTAGATAG VHL line genotyping 
VHL Genotyping F TAAGGGCTTAGCGCATGTTC VHL line genotyping 
PINK1 NMD R CTGATGACGTTCAGCTGGTG PINK1 qPCR 
PINK1 NMD L CCACAGACTGATGTGCAGGA PINK1 qPCR 
TigarB qPCR R TCAGCATTTCTTTTATTGCATGA TigarB qPCR 
TigarB qPCR L TGTGAGCTGGCTGAACGTAA TigarB qPCR 
Hdac9B qPCR R CCTACAAGAGCTTTGAGAGTTGTG Hdac9B qPCR 
Hdac9B qPCR L GAATTTAGCCGACAGAGTCTTTT Hdac9B qPCR 
Apex1 qPCR R ACTTCCCATGGCAGTGTTTC Apex1 qPCR 
Apex1 qPCR L TTTCGGGAGCTCTATCCAGA Apex1 qPCR 
TigarA qPCR R TCAGGGATGGACAAACTTGG TigarA qPCR 
TigarA qPCR L ATAGGACCAGCCCTTTCACC TigarA qPCR 
TigarB WISH R TCAGCCAGCTCACAAAACTG TigarB WISH probe 
TIgarB WISH L CTGCTGCAAGGTCAGGGTAT TigarB WISH probe 
TigarA WISH R ATAGGACCAGCCCTTTCACC TigarA WISH probe 
TigarA WISH L CATAGCTGAGGGAGGTCGAG TIgarA WISH probe 
EF1a qPCR R TGACTCCAACGATCAGCTGT qPCR House Keeper 
EF1a qPCR L TGGTACTTCTCAGGCTGACT qPCR House Keeper 
OTPa WISH R ACTCTGCTGGCTGGAGGACTGGGTG OTPa WISH PROBE 
OTPa WISH L GGAAAAGCATTTCGCCCTGGAGCG OTPa WISH PROBE 
TBMO2 RT PCR R GACAGAGGTGTGTCAATACCCTGAC TBMO2 efficacy detection 
TBMO2 RT PCR L TCAGTGACGTCATTTATCTGCAAC TBMO2 efficacy detection 
TBMO3 RT PCR R TCTCAGCTGTCTGTATAGCTCTTTG TBMO3 efficacy detection 
TBMO3 RT PCR L CTGCAAGGTCAGGGTATTGA TBMO3 efficacy detection 
PINK4 MO DEC R TCTGCTAGACAGCAGCCAAA PINK4 ie and ei efficacy detection 
PINK4 MO DEC L AACATTGGGGCTGGTTCAT PINK4 ie and ei efficacy detection 
PINK5 MO DEC R TCAGGTGCCATTAGACAGGA PINK5 MO efficacy detection 
PINK5 MO DEC L CTGACTTTGAACGGGCACTT PINK5 MO efficacy detection 
GBA MO 8 DEC R TCCTCTTCAGACCTGTTTAGAATG GBA MO 8 efficacy detection 
GBA MO 8 DEC L CAGGACCTGAATAATTATGTGACC GBA MO 8 efficacy detection 
GBA MO 9 DEC R CCAGGACCTGAATAATTATGTGACC GBA MO 9 efficacy detection 




PRIMER Sequence (5'-3') Description 
GBA MO 7 DEC R GGTCCAGCCGGTCACATAAT GBA MO 7 efficacy detection 
GBA MO 7 DEC L GATGACAACCGCCTTATGCT GBA MO 7 efficacy detection 
GBA NMD #3 R GGGTGAAGTTCTGGAGATCG GBA NMD qPCR 
GBA NMD #3 L AGTACCGTTTCGTGAGAGTGC GBA NMD qPCR 
GBA NMD #5 R CACCGTTTGATCCCAGACTT GBA NMD qPCR 
GBA NMD #5 L CACTTCAGCAAGTTCCTGTG GBA NMD qPCR 
 
Table 3. Primer list. A table listing all primers utilised in this study. 
2.6 DNA gel electrophoresis 
DNA gel electrophoresis was used to visualise PCR products. A 2% agarose gel was 
constructed from 2 grams of agarose powder heated in 100 ml of TAE buffer (40 mM 
Tris, 20 mM acetic acid, 1 mM EDTA) until fully dissolved. The solution was allowed 
to cool, and then poured into a gel tank with a comb to produce sample wells. Once the 
gel had set it was then moved to an electrophoresis tank and covered in fresh TAE(x1) 
buffer. Hyper ladder IV, 2 µl (Bioline) was pipetted into the first available well on 
every gel for sample size reference and concentration analysis. Samples were pipetted 
in the wells after this at 2 µl unless otherwise stated. Samples were electrophoresed at 
150 volts for 15-30 minutes. DNA products were visualised under UV light in a 
GENi™ (SYNGENE). 
2.7 Zebrafish Genotyping 
Primers required for genotyping for each mutant line can be found in the primer list 
(Table 3). The primers were used to amplify the region containing the mutation using 
gDNA, and genotyped by direct sequencing at the University of Sheffield Core 
Genomics Facility using the Reverse primer. Sequencing data were analysed using 
FINCH TV, Version 1.4.0 (Geospiza Inc). All pink1 sequences were reverse 
complemented and the lead up sequence, 5’GCGATCGCTTA was located. 
5’GCGATCGCTTAT was WT 
5’GCGATCGCTTAN was heterozygous for the pink1 Y431* stop mutation 




The gba1 sa1621 line was genotyped using the primer pair GBA 178 G>A. The primers 
were used to amplify the region containing the mutation, then genotyped by direct 
sequencing using the forward primer. The lead up sequence was 5’CACATGAAG 
located and used to genotype the allele. 
5’CACATGAAGG was WT 
5’CACATGAAGN was heterozygous for the sa1621 mutation 
5’CACATGAAGA was homozygous for the sa1621 mutation 
The gba1 23bp deletion was genotyped using the primer pair MWO1 #4. The primers 
were used to amplify the region containing the deletion, and then electrophoresed on 
2% agarose gel for 25 minutes. Genotyping was performed directly from the 
photograph of the gel.  
A product of size 203 was WT 
A product of size 180 was a homozygous mutant for 23bp deletion. 
2 products of both these sizes were heterozygous.  





Figure 10. gba1 23bp del genotyping. Genomic PCR illustrating gba1 23bp del allele primers situated 
around the TALEN-targeted MwoI site of gba1. WT individuals produce a product of 203bp (Lane 1), 23bp 
del gba1 -/- of 180bp (Lane 3) and 23bp del gba1 -/+ individuals produce products of both sizes (Lane 2).   
The 8bp and 7bp deletion TALEN lines were genotyped with MWO1 #4 primers and 
the PCR product digested with 1µl of MwoI restriction enzyme (NEB) and incubated at 
60ºC for 4 hours. 2µl of digested PCR product was electrophoresed on a 2% gel for 30 
minutes. 
A single product at size 225 was a homozygous mutant 
A single product at 110 was WT 
A product at 225 and 110 was heterozygous. 
The vhl line was genotyped using primer pair VHL genotyping. The primers were used 
to amplify the region containing the vhl mutation, and then electrophoresed on a 2% 
agarose gel for ten minutes to check PCR was successful, genotype was determined by 
digest. Briefly 5 µl of PCR product was digested in a mixture of 1.8 µl buffer 4 (NEB), 
13 µl H2O and 0.2 µl Bci IV enzyme. The mixture was incubated for 4 hours at 37ºC 
then electrophoresed a 2% gel for 30 minutes. 












A single product of size 400 was a homozygous mutant 
A product at 200 and 400 was heterozygous 
2.8  Basic Local Alignment Search Tool 
To identify orthologues of human genes in zebrafish, the human protein sequence was 
located in ENSEMBL and pasted into the Basic Local Alignment Search Tool (BLAST) 
function of ENSEMBL. The species selected was ‘Danio Rerio’ and the database selected 
was ‘protein’. The sensitivity was selected at no optimisation. The sample was then 
run. The hit with the greatest homology was selected. This was repeated with the 
human cDNA and all settings remained the same, except that the database selected 
was DNA database (cDNA library specifically). Once the top hit was duplicated in 
these BLAST searches, the top cDNA and protein match (both these were coded for by 
the same gene) was compared to the orthologue assigned to Human gene by 
ENSEMBL itself to validate the match. Both genes had the basic genetic architecture 
compared (exon number for example) then genomic regions were compared. The area 
used for gene synteny comparison was 1.0 mega bases, by using the ‘compare region’ 
function in ENSEMBL. 
2.9 RNA extraction 
To extract RNA required for cDNA generation; 20 larvae / brain tissue (12 wpf), were 
placed in a microcentrifuge tube and all E3 media was removed. 250 µl of TRIzol® 
(Life Technologies) was added and the larvae homogenised with a 23 gauge needle, 
followed by incubation at room temperature for 5 minutes. 50 µl of Chloroform was 
then added; the tube was inverted 8 times, then left to incubate for a further 5 minutes 
at room temperature. The sample was then centrifuged in a microcentrifuge for 15 
minutes at 13,000 rpm at 4 ºC. 100 µl of the supernatant was removed and placed into a 
new sterile microcentrifuge tube. 100 µl of isopropanol was added, the tube was 
inverted to mix, then incubated at room temperature for ten minutes. The sample was 
then centrifuged again at the same settings. All supernatant was discarded and the 
RNA pellet washed with 70% ethanol and centrifuged for 5 minutes at 7,000 rpm, at 




minutes, followed by re-suspension in 20 µl DEPC treated H2O. RNA extraction from 
brain tissue was identical, with two brains used per sample. 
2.10 DNase Treatment 
To remove DNA from purified RNA, the DNA-Free KIT ™ was utilised (Invitrogen™) 
10 µl buffer and 1µl DNase 1 were added to the RNA, then incubated for 30 minutes at 
37 ºC. 2 µl DNAse inactivation solution was added, mixed and incubated at room 
temperature for 2 minutes. The contents were then centrifuged at 10,000g for 2 
minutes. The RNA supernatant was then transferred to a fresh tube. 
2.11 Reverse transcription 
Purified RNA was firstly quantified by using a Nanodrop (Thermo scientific). 1000 ng 
RNA was made up to 10 µl with DEPC H2O. The Verso cDNA synthesis kit (Thermo 
Scientific) was utilised for the reverse transcription reaction. 4µl 5X cDNA synthesis 
buffer, 2 µl dNTP MIX, 1 µl RNA primer and 1 µl Verso enzyme mix, was added to the 
10 µl RNA. The mixture was incubated for 30 minutes at 42 ºC then for 2 minutes at 95 
ºC. 
2.12 PCR purification 
PCR product was purified using QIAquick PCR purification KIT (Qiagen) as follows: 5 
volumes of PB buffer was added to 1 volume of the PCR reaction and mixed. The 
mixture was placed in a QIAquick column and centrifuged for 60 seconds in a micro-
centrifuge. The flow-through was discarded and 750 µl PE buffer added to the column 
and centrifuged again. The flow-through was again discarded and the column 
centrifuged for a further minute. The flow-through was again discarded and the 
column transferred to a fresh microcentrifuge tube. 30 µl EB was added to the centre of 
the column and incubated at room temperature for 1 minute. The column was then 




2.13 Plasmid purification 
The QIAprep mini-prep kit (Qiagen) was used to isolate plasmid DNA from bacterial 
cultures. Firstly 1-6ml of bacterial culture was centrifuged down with a micro-
centrifuge and the supernatant discarded. The bacterial pellet was re-suspended with 
250 µl Buffer P1 by vortexing. 250 µl of Buffer P2 was added and the microcentrifuge 
tube inverted 6 times to mix until the solution became clear. 350 µl of Buffer N3 was 
then added; the tube was then inverted 6 more times and afterwards centrifuged at 
13,000 rpm for 10 minutes in a micro-centrifuge. The supernatant was then applied to a 
QIAprep spin column and centrifuged again for 1 minute. The flow-through was 
discarded and 750 µl Buffer PE added. The column was centrifuged for a further 
minute and the flow-through discarded. The column was centrifuged for a further 
minute to get rid of any residual buffer in the column. The spin column was then 
transferred to a fresh tube and 30 µl EB buffer added to the centre of the column. The 
column was incubated for 1 minute at room temperature then centrifuged for 1 minute 
to elute the plasmid DNA.  
2.14 RNA purification 
The RNeasy® Mini Kit (Qiagen) was used to purify RNA for TALEN injection. Firstly 
the sample volume was adjusted to 100 µl with RNase free water followed by the 
addition of 250 µl ethanol (100%). The sample was then transferred to an RNeasy Mini 
spin column placed in a 2ml collection tube and centrifuged for 15 seconds at 8000g. 
The flow-through was discarded and 500 µl Buffer RPE added to the RNeasy spin 
column and centrifuged again for 15 seconds. The flow-through was again discarded, 
and again 500 µl Buffer RPE was added to the column but then centrifuged for 2 
minutes at 8000g. The column was then placed in a new tube and 30 µl RNase free 
water added to the centre. The tube was centrifuged for 1 minute to at 8000 g to elute 
the DNA. 
2.15 Large scale Plasmid purification 
The Nucleobond® Xtra Midi plasmid purification kit was used to purify plasmids at 
high concentrations from bacterial cell culture.  Bacterial culture was firstly harvested 




bacterial pellet re-suspended with 8ml re-suspension buffer RES. The cells were then 
lysed with 8 ml Lysis buffer LYS and the mixture inverted 5 times to mix. The mixture 
was then incubated at room temperature for 5 minutes. During the incubation, a 
Nucleobond® Xtra column with inserted filter was equilibrated with 12 ml 
Equilibration buffer EQU. Post incubation, the mixture was neutralised with 8 ml 
Neutralisation buffer NEU, then inverted 10 times to mix. Once a homogenous lysate 
was achieved, the mixture was poured into the Xtra column and allowed to flow 
through by gravity. The column was washed with 5 ml Equilibration buffer EQU and 
the filter was then discarded. The column was then directly washed with 8 ml buffer 
wash. The plasmid DNA was eluted and collected by applying 5 ml Elution buffer ELU 
to the column. The elute was then treated with 3.5 ml of room temperature isopropanol 
and centrifuged for 15 minutes at 5,000g to precipitate the plasmid DNA. The 
supernatant was discarded and the DNA pellet washed with 2 ml 70% ethanol by 
spinning again at 5,000g for 5 minutes. The supernatant was discarded and the pellet 
air dried for 5 minutes followed by dissolving it in 1 ml TE buffer. 
2.16 Ligation independent Cloning and transformation 
Molecular Cloning was achieved using the TOPO TA cloning® kit (Invitrogen, Life 
technologies). A PCR product was amplified and purified using a QIAquick PCR 
purification KIT (Qiagen). 4 µl of purified DNA, 1 µl TOPO vector, 1 µl salt solution 
(1:4 dilution with H2O) were mixed together and incubated at room temperature for 30 
minutes. Meanwhile chemically competent DH5β (NEB) cells were defrosted on ice for 
30 minutes. The Cloning reaction was then added to the cells on ice and incubated for 
30 minutes. The cells were then heat shocked at 42 ºC for 30 seconds and returned to ice 
for a further 5 minutes. 900 µl of SOC media (Sigma) was added, and then incubated 
for 1 hour on a shaker at 37°C. During the incubation phase, agar plates containing 
ampicillin at a concentration of 0.1 mg/ml were also incubated at 37 ºC to dry them. In 
close proximity to a Bunsen flame, 100 µl of the transformation was plated onto the 
agar plates and distributed evenly using a cell scraper. The plate was then incubated 




2.17 Colony PCR 
To determine if TOPO TA cloning was successful, colony PCR was performed. After 
overnight incubation of the transformation plate, colonies were picked for analysis. A 
PCR master mix was made up as previously described, using M13 primers. For the 
DNA portion of the reaction, a single colony was picked using a sterile p10 pipette tip 
and dabbed into the PCR reaction. All reactions were amplified as standard and 
electrophoresed on a 2% agarose gel. Reactions positive for PCR cassette were sent for 
sequencing with M13 primers. 
2.18 RIBO probe manufacture and design 
To generate RNA probes, for whole mount in situ hybridisation (WISH), primer 3 
(http://bioinfo.ut.ee/primer3-0.4.0/) was used to design primers that would amplify a 
region 700-1000 bp in length of cDNA. This sequence was searched against the cDNA 
database to determine the specificity of the probe. The PCR product was amplified and 
sub cloned into a TOPO TA, colonies positive for the cassette were sent off for 
sequencing and the orientation was determined. To generate the probe, the plasmid 
was cut at the opposite end of the cassette to transcription using a restriction enzyme. 
The cassette was also checked not to have a restriction site at the same site as the 
digesting enzyme by analysing the sequence with NEBcutter V2.0 (New England 
Biolabs) (http://tools.neb.com/NEBcutter2/). The restriction digest was constructed of 
10 µg of plasmid DNA, 5 µl restriction enzyme and 10 µl appropriate buffer. The 
reaction was made up to 100 µl H2O and incubated at the optimum temperature for the 
enzyme for 4 hours. 2 µl uncut plasmid and 5 µl of cut plasmid were electrophoresed 
on a 2% gel to determine if linearization was complete. The cut plasmid was purified 
using QIAquick PCR purification KIT (Qiagen). To generate the riboprobe , 1000ng cut 
plasmid, 2 µl transcription buffer, 2 µl DIG labelling mix, 2 µl of transcription enzyme 
(either T7, T3 or Sp6) and 1 µl RNAase were made up to 20 µl with H2O, then 
incubated for 2 hours at 37 ºC. All transcription reagents were purchased from Roche. 
Following incubation, 2 µl DNAse was added and the mixture incubated for a further 
15 minutes.  2 µl of probe reaction was electrophoresed on a 2% gel to check for probe 
transcription and complete DNA digestion. 10 µl 7.5 M NH4C2H3O2 (Ammonium 
Acetate) and 60 µl Ethanol (both ice cold) was added to the transcription reaction and 




ºC, and 15 minutes). The supernatant was discarded and the pellet washed with 100 µl 
ethanol (70%) and centrifuged again for 5 minutes. The supernatant was again 
discarded, the pellet air dried for 3 minutes and re-suspended in a 100 µl mixture of 
formamide and H2O (70:30 respectively) then stored at -80 ºC. 
2.19 Embryo fixation 
To preserve zebrafish larvae for whole mount in situ hybridisation (WISH), larvae 
were fixed. Zebrafish larvae were de-chorionated and put into 1.5 ml microcentrifuge 
tubes in groups of 20. All E3 media was removed and 500 µl 4% PFA 
(paraformaldehyde) solution (made up with sterile PBS) was added. The larvae were 
incubated on a rocker at room temperature for 2 hours. PFA was removed and 
replaced with 500µl 100% methanol, incubated at room temperature for 15 minutes and 
then stored at -20 ºC. 
2.20 Whole mount in in-situ hybridisation  
WISH was utilised to investigate the expression of specific mRNA transcripts. Fixed 
larvae were rehydrated in a series of 500 µl 5 minute washes of 75% methanol: 25% 
PBT, 50% methanol: 50% PBT, 25% methanol: 75% PBT, and finally 4 washes with 100% 
PBT. Larvae were then digested at room temperature with 500 µl 10 µg/ml proteinase 
K for the following time, depending on the age of larvae: 8 minutes for 24 hpf, 14 
minutes for 48 hpf, 30 minutes for 72 hpf, 40 minutes for 96 hpf and 45 minutes for 120 
hpf larvae. Proteinase K was then removed and replaced with 500 µl 4% PFA and 
incubated for 20 minutes at room temperature. Samples were then washed with 500 µl 
of PBT for 5 minutes, 5 times each. The PBT was removed and replaced with 500 µl 
Hyb A buffer (50% formamide, 5XSSC solution, 0.5 mg/ml tRNA, 0.1% tween 20, 50 
ug/ml Heparin, pH was adjusted to 6.0 with 1M citric acid) and incubated at 70 ºC for 5 
hours. Hyb A solution was then replaced with a solution of Hyb A 2% riboprobe and 
incubated overnight at 70 ºC. Each tube then had a brief wash with 70 ºC 100% Hyb B 
solution (Hyb A without tRNA and Heparin) then sequential 500 µl washes at 70 ºC for 
15 minutes each with 75% HybB: 25% 2xSSC, 50% HybB: 50% 2xSSC, 25%Hyb B: 75% 
2XSSC then 100% 2XSSC. Each sample was then washed twice with 0.2XSSC for 30 
minutes at 70ºC.  Each sample then went through sequential washes of decreasing 




for ten minutes, then 50% 0.2XSSC: 50% PBT for ten minutes, then 25% 0.2XSSC: 75% 
PBT for ten minutes followed by a final 10 minutes PBT wash. Each sample was then 
incubated in 500 µl blocking buffer (2mg/ml Bovine serum albumin (BSA), 2% sheep 
serum, all dissolved in PBT) for 3 hours. Each sample was them incubated in 500 µl 
Blocking buffer with a 1:5000 dilution of anti-dig antibody (Roche) and protected from 
light at 4 ºC overnight.  
The following morning each sample went through 6 washes of PBT for 15 minutes 
each. This was followed by 3, 5 minutes washes with 500 µl NTMT buffer (0.1M 
TrisHCl pH 9.5, 50 mM MgCl2, 0.1M NaCl, 0.1% Tween 20). The Buffer was then 
exchanged with 500 µl staining solution (3.5 µl and 4.5 µl, BCIP and NBT respectively, 
per ml of NTMT). Samples were inspected every 15 minutes for stain development 
(appearance of purple stain). When the stain had developed satisfactorily, the samples 
were washed 3 times with PBT. 
To remove any background, each sample was washed with 500 µl 50% methanol then 
incubated in 100% methanol, until all background had been cleared. Each sample was 
then washed again with 50% methanol, then twice with PBT.  4% PFA was then used to 
re-fix larvae for 20 minutes at room temperature. Each sample was washed 3 times 
with PBT, then placed into 75% glycerol and stored at 4 ºC. 
2.21 Tyrosine Hydroxylase Neuron Counting 
When assessing the number of DA neurons, 3 dpf larvae were always used, unless 
otherwise stated. The neurons were stained by WISH for Tyrosine Hydroxylase (TH) 
as a marker of DA neurons, unless otherwise stated. Zebrafish larva heads were 
mounted in glycerol for correct orientation and TH positive neurons counted by eye 
using axioplan 2 (Zeiss) compound microscope at X20 magnification. TH neuron count 
was assessed by counting DA subgroups 1, 2, 4 and 5 in the diencephalon. Groups 
were defined according to the descriptions of Rink and Wulliman.165 For Each embryo 
TH neuron count, each experiment contained n of ten individuals (unless otherwise 
stated) in all groups. Each experiment was performed in triplicate (unless otherwise 
stated). The mean count of control groups in each experiment was set as 100%, and all 




2.22 Tyrosine Hydroxylase Neuron staining and counting in 12 wpf 
zebrafish 
In order to quantify TH neurons in 12 wpf zebrafish, IHC was employed to stain the 
neurons. This experiment was jointly undertaken between the author and Dr Yu-Chia 
Chen. Brain dissection and fixing was performed by the author. TH neuron staining 
and count was performed by Dr Yu-Chia Chen. 
12 wpf were culled and brains removed then fixed as previously described in PFA, and 
dehydrated in 100% methanol. To stain, whole brains were rehydrated in a series of 
PBST/methanol, for 60 minutes each, at concentrations of 25%, 50%, 75% and 100%. 
Samples were then digested with proteinase K (10 µg/ml) in PBST at room 
temperature for 3 minutes. Samples were then refixed in 4%PFA at room temperature 
for 30 minutes. Each sample was then incubated in PBST twice for a single hour at 
room temperature. All samples were incubated in blocking buffer composed of 4% 
normal goat serum +1 % DMSO in PBST at 4°C for 24 hours. 
For the next four following days, each sample was incubated with a anti Tyrosine 
Hydroxylase antibody diluted in blocking buffer (Mouse monoclonal anti-TH, 
DiaSorin Inc), at 4°C. Following incubation, each sample was washed twice with PBST 
for one hour at room temperature, then incubated overnight at 4°C in PBST. 
Each sample was then incubated with an Alexa Fluor® 488 goat anti-mouse IgG 
diluted in blocking buffer as a concentration of 1/1000, for 24 hours at 4°C. Following 
incubation, each sample was washed twice with PBST for one hour at room 
temperature, and then incubated overnight at 4°C in PBST. 
Each sample was incubated in a 50% glycerol/PBS solution, overnight at 4°C. Samples 
were then incubated in an 80% glycerol/PBS solution for 2 days at 4°C. Each sample 
was then mounted and imaged. TH neurons were counted according to Sallinens 
dfinition.120  
2.23 Morpholino design and optimisation 
The preferred exons junctions targeted for binding had their exon-intron boundary 
sequences sent to Gene-Tools for Morpholino design (http://www.gene-tools.com/). 




SNPs in the sequence would lead to rejection of the designed Morpholino. 
Morpholinos were ordered from Gene-Tools and re-suspended at 2 mM with H2O and 
stored at room temperature with protection from light. A list of all Morpholino used in 
the experiments are listed in the Morpholino Table 4. 
Morpholino Sequence 5'-3' Optimised concentration 
TigarB i5e6 ACCTGGAGAGACAAAAGCAGGATCT N/A -TOXIC 
TigarB e2i2 TAGAGTGTTTATCTACCTTGCAGCA 0.9mM 
TigarB i2e3 CCCTGACCTTCACATCAGATAAAAA N/A low efficacy 
GBA1 i8e9 TTGCTGTTAGTAAGGTACAAAGGCA N/A low efficacy 
GBA1 e8i8 GTGCTTTGAACGAGTCTGACCTGAA 0.9mM 
GBA1 i6e7 GTCACTTAGAACCTATAGCCGAAAA  N/A toxic 
VHL e1i1 GCATAATTTCACGAACCCACAAAAG 0.2mM 
PINK1 e5i5 AGAGTCTCTGAGCTCTTACTGTTGT 0.9mM 
PINK1 e4i4 GTGTTTTCATGTTTCCTCACTTCTT N/A TOXIC 
PINK1 i3e4 AGTGCCTGCAAAAATAGCAAAGCCA N/A low efficacy 
Table 4. Morpholino list 
To inject zebrafish embryos, working concentration (0.9 mM, 0.5 mM or 0.25 mM) 
Morpholino was loaded into a glass needle (borosilicate glass capillary, by WPI) pulled 
using a Model P97 micro-pipette puller, by Shutter Instruments. The full needle was 
hooked to a Pv 820 Pneumatic Pico-pump (WPI) for injections. Injection speed was 
calibrated by injecting the Morpholino solution into a drop of mineral oil placed on top 
of a 100x0.1=10mm graticule (Pyser-SGI), in order to correctly set the speed and 
pressure to inject 0.5nl with each burst. To optimise Morpholinos, WT 1 cell stage 
zebrafish embryos were injected with 0.9 mM, 0.5 mM and 0.25 mM Morpholino. 
Phenol red (0.00011mg/ml) was used to colour the Morpholino solution, to ensure 
correct injection. Embryos were injected with 1 nl each and inspected on days 1, 2 and 
3 post fertilisation, for mortality and deformity. Morpholino efficacy was determined 
by RT-PCR on days 1 and 3 post fertilisation compared to un-injected controls. 
Morpholinos were rejected if they lacked efficacy or were deemed toxic, definitions by 




2.24 TALEN design and construction 
A TALEN pairs to make targeted germ line mutations in ZF embryos were designed 
and manufactured as follows. The cDNA sequence for gba1 (ENSDART00000113093) 
was inputted into the TALEN TARGETTER 
https://boglab.plp.iastate.edu/node/add/talen. The targeter was set to allow spacers 
of 16bp as a minimum and 21bp as a maximum. Minimum repeat array was set at 15 
and maximum at 21. A pair of TALENs, including a region with a wide large 
restriction enzyme site was chosen. In the case of the TALENs targeting, gba1, a 
position in exon 7 was chosen with an MwoI restriction enzyme present that could be 
used to assay TALEN efficacy. A pair of TALENs binding 
5’TCTGTACCCTGATTACTT (RIGHT TAL) and 5’ATGCGCTGGGTGGAGTCCA 
(LEFT TAL) were chosen by the TALEN Targeter with plasmid codes of HD NG NN 
NG NI HD HD HD NG NN NI NG NG NI HD NG NG and NN NN NI HD NG HD 
HD NI HD HD HD NI NN HD NN HD NI NG respectively. 
Self-ligating plasmids were purchased from Addgene 
(http://www.addgene.org/TALeffector/goldengate/voytas/Plate1/). Each TALEN 
was made in two parts and joined at the end. Part A was assembled into the F5 
plasmid (pFusA) with the initial ten RVDS. The latter RVD plasmids would be 
assembled into pFUSBN, N=TOTAL RVD-11. For the initial assembly, 2 tubes were 
made up as follows: 
For each A part – 1 µl of each RVA plasmid (100ng/µl), 1 µl pFusA (100ng/µl) 4 µl 
H2O, 2µl T4 ligase buffer (NEB), 2 µl T4 ligase (NEB) and 1µl BSA1 (NEB). For each part 
B – 1 µl each RVD plasmid (150ng/µl), 1 µl pFusB (150ng/µl), 2 µl T4 DNA ligase 
buffer (NEB), 2 µl T4 DNA ligase (NEB), 1 µl Bsa1 (NEB), with the reaction made up to 
20 µl with H2O. Each reaction was then incubated in the following cycle for ten cycles: 
37 ºC for 5 minutes then 16 ºC for ten minutes. This was followed by a 5 minute 
incubation at 50 ºC, then at 80 ºC. 0.3 µl 25mM rATP and 1µl plasmid safe nuclease were 
added to each reaction then incubated for 1 hour at 37 ºC.  
Each reaction was then transformed (as previously described) into DH10Beta cells 
(NEB) which were then spread onto LB agar plates (50 ug/ml Spectinomycin, 0.1 mM 
IPTG and  XGal 40 µg/ml) and incubated overnight at 37 ºC. The following day, 3 




ug/ml Spectinomycin) and shaken overnight at 37 ºC. The following morning, all 
samples were centrifuged down and plasmids isolated with a Qiagen mini-prep kit. 
The second assembly stage took place to combine parts A and B of each TALEN as 
follows: 5 µl H2O, 4 µl mini-prep A, 4 µl mini-prep B, 1 µl 150ng/µl plasmid E4, 1 µl 75 
ng/µl pCAGT7TALEN, 2 µl T4 DNA ligase buffer (NEB), 2 µl T4 DNA ligase (NEB) 
and 1 µl Esp4I. The reaction was then incubated as follows for ten cycles: 37 ºC for 5 
minutes then 16 ºC for ten minutes. Followed by a 5 minute incubation at 50 ºC, then at 
80 ºC. 
Each reaction was then again transformed into DH10Beta cells (NEB), and streaked 
onto LB agar plates with carbenecillin selection (50 ug/mL carbenecillin and 0.1 mM 
IPTG and XGal 40 µg/ml) and incubated over night at 37 ºC. The following morning, 1 
colony was picked from each subunit and used to inoculate 100 ml LB (50 ug/mL 
carbenecillin) in a baffled flask, and shaken overnight at 37 ºC. The following morning 
each culture was purified using a Nucleo-bond midi-prep as previously described and 
the plasmid pellet re-suspended in 30 µl H2O.  
To generate TALEN mRNA, the final plasmids were linearized with a NotI digest as 
follows: - 6 µg DNA of each of the right and left constructs, 30 µl NEB3 buffer, 3µl 10 
mg/ml BSA and 10 µl NotI, then H2O up to 300 µl in a PCR tube. The reaction was 
incubated at 37ºC for 1 hour. RNA was synthesised using an Epicentre T7 MessageMax 
ARCA kit (CAMBIO) as follows. 3 µl DNA (400 ng/µl), 4 µl NTP CAP mix, 1µl buffer, 
1 µl 100 mM DTT and 1 µl enzyme mix was incubated for 30 minutes at 37ºC, then 1µl 
DNAse was added, followed by a further incubation for 15 minutes. RNA was purified 
using Qiagen MinElute system™. RNA was stored at -80ºC. To mutagenize zebrafish 
embryos, 1 nl of RNA solution (3.5 µl RNA and 0.5 µl Phenol RED) was injected into 1 
cell stage WT embryos and grown up to adulthood to create mosaic F0. 
2.25 Movement analysis of adult zebrafish 
Adult locomotion was quantified using Viewpoint analysis software version 3, 22, 3, 9 
and filmed on a CCTV LENS 2.8-12mm F1.4 camera (both Viewpoint). For filming 3 
year old PINK1 line, fish were filmed individually for a period of 4 hours (1 hour 
acclimation and 3 hours analysed) between the hours of 3pm and 7pm. For the gba1 




Low speed movements were defined as less than <5 cm/s. Medium speed movements 
were defined as 5<X<7cm/s. High speed movements were defined as movements over 
7cm/s. 
2.26 Bicinchoninic acid assay (BCA) protein assay 
The BCA assay was utilised to determine protein concentration of zebrafish brain 
homogenates. 
Adult zebrafish brains were homogenised as a 5% solution with a 100 µl glass on glass 
homogeniser (Decon instruments). Samples were kept on ice for the protein 
concentration to be measured. Two dilutions of 2.5 µl and 5 µl brain homogenates were 
made up to 50 µl with distilled H2O. Each volume for each sample was measured in 
duplicate. 1 ml bicinchoninic acid was added to each sample and mixed, then 
incubated at 37ºC for ten minutes. 20 µl of 4% copper sulphate solution was then added 
to each sample, mixed, then incubated for 20 minutes at 37ºC. The absorbance was read 
at 562nm and protein concentration calculated from a standard curve established from 
a set of dilutions of bovine serum albumin. 
2.27 Gba activity assay 
Gba1 and 2 activities were determined as follows: Whole zebrafish brain was 
homogenised (in distilled water) and diluted to 2 mg/ml. For total Gba activity 
(TOTAL) of the homogenate, 10 µl homogenate was mixed with 90 µl H2O. For basal 
Gba1 activity (Gba1), 10 µl homogenate was mixed with 80 µl H2O and 10 µl NBDNJ 
(50 µM, N-Butyldeoxynojirimycin, a specific GBA2 inhibitor).  For activated Gba1, 10 
µl homogenate was mixed with 50 µl H2O and 40 µl NAT (sodium taurocholate, GBA1 
activator/GBA2 inhibitor) (40mg/ml). Each mixture was incubated on ice for 1 hour. 
100µl substrate solution was added to each mixture (1.69mg/ml of 4-
methylumbelliferyl-beta-D-glucopyranoside dissolved in McIlvaine citrate phosphate 
pH 5.4), and incubated for 1 hour at 28ºC. The reaction was stopped with the addition 
of 1 ml of 1 M glycine NaOH buffer pH 10.4 and vortexed. Samples were read 
alongside a 1 nm 4-methylumbelliferone standard, with excitation 365 nm, emission 
450 nm. A blank was set up for all inhibitor conditions containing all reagents except 




Gba1 activity was also measured using CBE as an inhibitor as part of a collaboration 
between the author and Dr Matthew Gegg. Dr Matthew Gegg performed the assay and 
analysis, the author performed the genotyping, brain removal and processing. The 
assay was conducted as follows. 
Brains were homogenised in 75 µl RIPA buffer (150 mM NaCl, 1.0% (v/v) NP-40, 1% 
(w/v) sodium deoxycholate, 0.1% (w/v) SDS, 50 mM Tris, pH 7.4). Gba activity 
determined in samples (10 µg protein) by hydrolysis of 5 mM 4-methylumbelliferyl-β-
D-glucopyransoside in McIIvaine citrate phosphate buffer (pH 5.4) in the presence of 
22 mM sodium taurocholate at 37 °C for 1 hour. For CBE sensitive rate, duplicate 
samples were incubated in the presence of 5 mM CBE (15 minute pretreatment at 37 
°C, plus present during assay). The reaction was stopped by addition of 0.25M glycine 
(pH 10.4) and 4-methylumbelliferone fluorescence measured at excitation 360 nm, 
emission 460 nm. 
 
2.28 Total β Hexosaminidase activity assay 
Total zebrafish brain was homogenised as previously described, and diluted to 1 
mg/ml. 5 µl of this solution was diluted with 495 µl of McIlvaine citrate–phosphate 
buffer pH 4.5. 100µl of this further dilution was placed into a new 1.5 ml tube and 
warmed for 2 minutes at 37ºC. 100 µl of substrate solution (1.1 mg/ml of 4-
methylumbelliferyl-2-acetamido-2-deoxy-beta-d-gluco-pyranoside in McIlvaine 
citrate–phosphate buffer pH 4.5) was then added to each sample, mixed and incubated 
for ten minutes at 37ºC. The reaction was stopped with 1 ml of 1 M glycine NaOH 
buffer pH 10.4 and vortexed. Samples were read along with a 1nm 4-
methylumbelliferone standard, with excitation 365 nm, emission 450 nm. A blank was 
set up for containing all reagents except for the brain lysate.   
2.29 Chitotriosidase activity assay 
Zebrafish brains were homogenised as described and diluted to 2 mg/ml. To measure 
Chitotriosidase level 10 µl of brain homogenate was combined with 100 µl substrate 
solution (1.73mg/ml of 4-methylumberiferyl-beta-d-N, N’, N’’, -triacetychitotriose in 




The reaction was stopped with 1 ml 1 M glycine NaOH buffer pH 10.4 and vortexed. 
Samples were read along with a 1nm 4-methylumbelliferone standard, with excitation 
365 nm, emission 450 nm. A blank was set up for all conditions containing all reagents 
except for the brain lysate. 
2.30 β Galactosidase activity assay 
Zebrafish brains were homogenised as described and diluted to 2 mg/ml.  To measure 
β-Galactosidase activity, 10µl brain homogenate was mixed with 40 µl of McIlvaine 
citrate–phosphate buffer pH 4.1. This was combined with 150 µl substrate solution 
(1mM 4-methylumbelliferyl-D-galactopyranoside dissolved in 4.1 buffer). The reaction 
was incubated for 15 minutes at 28 ºC. The reaction was stopped with 1ml 1 M glycine 
NaOH buffer pH 10.4 and vortexed. Samples were read along with a 1nm 4-
methylumbelliferone standard, with excitation 365 nm, emission 450 nm. A blank was 
set up for all conditions containing all reagents except for the brain lysate. 
2.31 Haematoxylin and Eosin (H&E)/ Periodic acid–Schiff (PAS) 
staining 
For histological analysis of 12 wpf zebrafish, sections were stained with either H&E or 
PAS. This experiment was jointly undertaken between the author and Dr Aswin 
Menke. Genotyping and fixation of samples was performed by the author, sectioning, 
staining and analysis was performed by Dr Aswin Menke. 
Adult zebrafish were genotyped and fixed in Bouins fixative.  Each sample was 
embedded in paraffin and subsequently cut into, 4 µm transversal or saggital sections 
were made and stained with haematoxylin and eosin. The slides were analysed on a 
Axioskop 2 plus microscope by a board-certified pathologist. 
2.32 Microglial/Macrophage analysis 
For analysis of the macrophages and microglial in gba genotypes, a GFP reporter and 
confocal imaging was utilised. This experiment was jointly undertaken, between the 
author and Dr Felix Ellett. Imaging and analysis performed by Dr Felix Ellett, 




gba1 23bp del -/+ were crossed to Tg(mpeg1:EGFP-CAAX) described by Ellett et al.286 
Embryos were selected for GFP fluorescence, genotyped at 3 months. All subsequent 
embryo work was generated from an incross of gba1 23bp del -/+; Tg(mpeg1:EGFP-
CAAX) and imaged at 4 dpf using UltraVIEWVoX spinning-disk confocal microscope 
(PerkinElmer Life and Analytical Sciences). 2µm optical sections were taken for three 
fields of view for each embryo, principally: the caudal haematopoietic tissue; trunk, 
and head region anterior to the yolk. Volocity 5 (Improvision; PerkinElmer Life and 
Analytical Sciences) was used for imaging analysis of GFP positive cell shape and 
volume, with cell boundaries defined using fluorescence intensity. All analysis was 
performed blinded to embryo genotype. 
2.33 Mitochondrial Complex assays 
Mitochondrial Complex assays were utilised to measure the activity of each 
mitochondrial Complex in the electron transport chain. These experiments were jointly 
undertaken between the author, Dr Marc DaCosta and Dr Heather Mortiboys. The 
author performed Morpholino injections, genotyped and extracted brains then 
processed all samples. Dr Marc Da Costa performed the Complex assays on brain 
material; Dr Heather Mortiboys performed the Complex assays on larvae. Assays were 
performed as previously decribed.168  
2.34 Mass Spectrometry 
Mass spectrometry methods where conducted as previously described.287 Mass 
spectrometry experiments were jointly undertaken between the author and Dr Hai Bui. 
12 wpf brains were extracted and flash frozen by the author. Mass spectrometry 
analysis of the samples was conducted by Dr Hai Bui. 
2.35 Nomenclature 
All human genes and proteins are referred to in uppercase, with genes and transcripts 
italicised. All mouse proteins are referred to in uppercase with genes in lowercase with 
the exception of the first letter. All mouse genes are in italics. All zebrafish genes and 




case with the exception the first letter that is written in uppercase. See below for 
examples. The only exception to this stated nomenclature is tyrosine hydroxylase that 
is referred to as TH through the entire thesis. 
species / gene / protein 
zebrafish /pink1/ Pink1 
human / PINK1 / PINK1 
mouse / Pink1 / PINK1 
2.36 Statistical tests and analysis 
All statistical tests were performed using Graphpad prism V.5 software (Graphpad). N 
numbers for all experiments donated by the prefix n and all errors bars shown denote 
the mean ± Standard error of the mean. All experiments performed in triplicate unless 
different n number stated or the data described as pilot data. All data analysed with 
either T test, one way ANOVA or two-way ANOVA unless otherwise stated. 
Significance values denoted as follows. 
Non-significant (ns): p>0.05  














3.1 Characterisation of the pink1 Y431* zebrafish 
3.1.1 pink1 introduction 
Prior to commencement of this study, no previous vertebrate model of PINK1 
deficiency faithfully modelled the disease seen in humans, with no model 
demonstrating spontaneous DA cell loss.129, 188  It was hypothesised that zebrafish 
would be a more suitable model for pink1 deficiency, with the wider aim of using pink1 
mutant zebrafish for phenotypic drug discovery. Consequently a pink1 mutant 
zebrafish allele was generated from an ENU mutagenesis screen conducted by Dr 
Sandrine Bretaud that identified a pink1 allele with a nonsense mutation Y431*. The 
mutation leads to a premature stop codon appearing within the kinase domain of 
Pink1. The mutation was confirmed to be loss of function in kinase assays, and led to 
mitochondrial dysfunction in larvae and adult pink1 -/- (Experiments conducted by Ms 
Helen Woodroof and Dr Heather Mortiboys). The mitochondria appeared swollen and 
less electron dense, with pink1 -/- exhibiting a decrease in mitochondrial Complex 
activity, specifically in Complex I and III. This defect was present in 5dpf larvae and in 
adult fish in a manner that was not progressive in nature.  Unlike Pink1 KO mice and 
Medaka, pink1 -/- loss of function zebrafish exhibited a loss of TH neurons in 
development by 5dpf of approximately 20% (experiments conducted by Dr Laura 
Flinn). This decrease increased to 50% at the age of 18 months. This was the first 
vertebrate model of pink1 deficiency that demonstrated a loss of DA neurons. Not only 
does the loss appear very early in development, it also persisted through to 
adulthood.200 As part of this thesis, further validation, and functional studies of this 
zebrafish model of pink1 deficiency were carried out. The aim was to assess, firstly, 
whether zebrafish is a useful model species for studying pink1 deficiency, and secondly 
whether there are any genetic interactions that can modify the phenotypes, identifying 
possible new drug targets for PD. 
3.1.2 Zebrafish possess a single PINK1 orthologue (ENSDARG00000001929)  
Many studies have identified Zebrafish to have single orthologue of human PINK1, 
which possesses approximately 60% protein and DNA identity to the human gene, see 





Figure 11. Clustal alignment of human GBA1 and Zebrafish Gba1.The human protein sequence 
(ENSP00000314508) aligned via clustal to its zebrafish orthologue (ENSDARP0000098103). Both sequences 
have considerable homology of approximately 60% over 100% coverage. 
 
However, conserved synteny in the genomic loci of human and Zebrafish genes has yet 
to be illustrated, a further marker of true conservation between orthologues.   
A 500kb stretch of genomic locus of each gene was compared in both species, revealing 
there was indeed a conserved gene synteny between them both. Upstream of the 
PINK1 gene, four genes present in the human locus were also found, not only in same 
zebrafish locus, they also appear in the same sequential order. Specifically, these were 
CAMK2N1, MUL1, FAM43b and CDA at the human locus, their zebrafish orthologues 
being camk2n1b, mul1b, fam43b and cda respectively. All of which were found within 




conserved, with no genes located in both species within 200kb. See Figure 12 for a 
graphical representation outlining the similarities and differences of both loci. 
 
Figure 12. The genomic loci of the PINK1 in human and zebrafish. Both zebrafish and humans share 
conserved gene synteny surrounding the PINK1 gene, with four different genes (CAMK2N1, MUL1, 
FAM43B and CDA all upstream of the PINK1 sequence), in the same order in both species. Demonstrating 
that pink1 zebrafish is a true orthologue of human PINK1.  Synteny down- stream of the PINK1 does not 
appear to be conserved, with no genes in common in either species within the 300kb radius. 
3.1.3 pink1 Y431* transcript undergoes nonsense mediated decay 
The Y431* allele, a nonsense mutation, codes for a premature stop codon within the 
kinase domain of pink1.  Although this prevents the last 30% of the WT mRNA species 
from being translated into protein and one could hypothesise that the protein would 
not be able to fold properly or alternatively be kinase dead, further evidence was 
required to demonstrate loss of function. In parallel to the kinase assays that 
demonstrated the allele to be enzymatically non-functional, the experiment 
investigated possible activation of nonsense mediated decay (NMD) on the pink1 
transcript itself in pink1 -/-.  Subsequently, to further investigate whether the Y431* 
mutation results in decreased pink1 mRNA levels, pink1 qPCR was carried out in pink1 
-/- and WT. pink1 -/-had an approximately 65% reduction in pink1 transcript compared 


























Human PINK1 locus chromosome 1 




pink1 -/- fish  and further supports the assumption that the Y431* mutation results in 
Pink1 loss of function.201, 288 
 
Figure 13. The pink1 transcript expression in pink1 - /- compared to WT. The pink1 -/- larvae have a 
marked reduction in pink1 transcript levels (approximately 65%) compared to the WT (P<0.001 Unpaired T 
test). ef1a was use as a reference gene. 
3.1.4 Aged pink1 -/- zebrafish display a parkinsonian-like movement defect 
To evaluate for parkinsonian like movement defects in aged fish, 3 year old fish were 
filmed and their total displacement analysed. Each fish (n of ten per genotype) was 
filmed for a total of 4 hours. Habituation time of 1 hour was deemed appropriate for 
each genotype and total displacement calculated over the next 3 hour period.  3 year 
old pink1 -/- zebrafish covered 30% less distance over time than WT controls (P <0.05, 
unpaired T test) (see Figure 14). This demonstrated that pink1 -/- may move less often, 
at slower speeds or both. Behaviour such as this is indicative of bradykinesia and 





Figure 14. Total displacement of 3 year old pink1 -/- and WT controls. The pink1 -/- fish exhibited a 
decrease in total displacement (approximately 30% P<0.05 unpaired T Test, n=10 for both groups) over 
time, indicating slower and less frequent movements as seen in PD patients. 
3.1.5 pink1 -/- larvae do not exhibit defects in neuronal development 
Dr Laura Flinn had previously established that pink1 -/- larvae have a 25% reduction of 
TH neurons at 5dpf. This had been confirmed using DAT as a secondary marker, 
which also demonstrated a 25% reduction. 201 The nature of this reduction could either 
be due to cell death of the TH positive neurons, or a developmental phenotype. As 
zebrafish develop ex vivo, they present the perfect model to examine any possible 
neuro-developmental defects that may lead to the recorded TH neuron reduction. To 
investigate this, a series of neurodevelopmental markers were analysed in pink1 -/- 
and their WT controls.  The markers stained by WISH included shh, emx1, otpa, otpb, 
krox20, and pax2.1.  This experiment was jointly undertaken between the author and 
Ms Elena de Felice. Markers for shh, emx1, otpb, krox20, and pax2.1, were stained and 
analysed by Ms Elena de Felice. The marker otpa was stained and analysed by the 
author. Both genotypes were analysed throughout development at 1-5 days post 
fertilisation.  No differences in change of expression of any gene were seen in either 
genotype qualitatively or quantitatively (see Figure 15), suggesting that Th neuron 
reduction in pink1 -/- larvae is not due to a developmental defect after 24hpf. This does 





Figure 15. Developmental markers in pink1 -/- larvae. A series of neuronal developmental markers were 
analysed in pink1 -/- and WT from 1-5dpf (only 1dpf shown). These were emx1, shh, pax2.1, krox20, otpa 
and otpb. only 1dpf shown. No difference was observed in WISH staining in either group at any marker 
arguing against Th neuron reduction being due to a development defect at 24hpf and after.  
3.1.6 pink1 -/- microarray re-annotation 
Previous to the commencement of this thesis, microarray-based gene expression 
analysis had been conducted between pink1 -/- and WT controls at 5dpf to identify gene 
expression changes that may be leading to the reported Th neuron reduction. The 
original microarray had been annotated using ENSEMBL data of the Zebrafish genome 
during its 5th version. The zebrafish genome is now in its 9th assembly and 
considerably more detailed and annotated.  Approximately 80% of the probe changes 
in the original microarray were to unannotated zebrafish genes. To re-annotate the 
microarray using the 9th version of the zebrafish genome, each probe was searched for 
via BLAST in the zebrafish cDNA database with multiple stringencies. When the 
zebrafish transcript was identified, the zebrafish transcript was search for using BLAST 




automatically identified it as an orthologue of a human gene,. All probe hits that 
required re-annotation are highlighted in blue. See Table 5 for a re-annotated list of 
upregulated transcripts in the pink1 -/- 5dpf larvae and Table 6 for the down regulated 
transcripts. 
FCAbsolute GeneSymbol GeneName 
16.423103 hdac9b histone deacetylase 9b 
14.817871 tigarb tp53-induced glycolysis and apoptosis regulator b 
10.187797 cfh Complement factor H 
9.761307 CU463157.1 Similar to Complement factor H  
9.706486 N/A BLAST SEARCH GAVE NO HITS 
7.7182097 N/A Multiple HITS 
7.0322556 ALPP alkaline phosphatase, placental   
5.9192815  rpl13a ribosomal protein L13a 
5.836889 myl6 myosin, light chain 6, alkali 
5.437794 ccbl1 cysteine conjugate-beta lyase; cytoplasmic  
5.365619 N/A BLAST SEARCH GAVE NO HITS 
5.274791 N/A BLAST SEARCH GAVE NO HITS 
5.229535 tom1l2 target of myb1-like 2 (chicken) 
5.0453973 xkr9 XK, Kell blood group complex subunit-related family 
4.987913 fbxo16 F-box protein 16 
4.905778 apex1 APEX nuclease  1 
4.9030137 si:dkey-238c7.13 A non -protein coding transcript 
4.847179 uvrag UV radiation resistance associated gene  
4.8395343 zgc:101572 Protein kinase-like protein SgK196 
4.778119 ccbl1 cysteine conjugate-beta lyase; cytoplasmic  
4.6681256 crebl2 cAMP responsive element binding protein-like 2  
4.5243216 N/A BLAST SEARCH GAVE NO HITS 
4.2470703 N/A BLAST SEARCH GAVE NO HITS 
4.1389275 CCDC137 coiled-coil domain containing 137  
3.9723723 N/A Multiple HITS 
3.878004 capn8 calpain 8 
3.8745248 N/A BLAST SEARCH GAVE NO HITS 
3.7615082 capn8 calpain 8  
3.6562207 N/A Multiple HITS 
3.5966234 N/A processed transcript si:ch73-44m9.2-001 
3.59213 ptgs2b prostaglandin-endoperoxide synthase 2b 
3.549981 IMPG2 interphotoreceptor matrix proteoglycan  
3.5278482 zgc:162239  acyl-CoA synthetase long-chain family member 1 
3.5260308 FETUB fetuin B 
3.5236447 zgc:122979 DnaJ (Hsp40) homolog, subfamily B, member 5  
3.3546922 FUT9 (3 of 16) fucosyltransferase 9 
3.3368623 N/A Multiple HITS 
3.291373 N/A BLAST SEARCH GAVE NO HITS 
3.2243793 N/A BLAST SEARCH GAVE NO HITS 
3.197398 pogza pogo transposable element with ZNF domain  
3.0550892 GJA4 gap junction protein, alpha 4 
3.0521128 MATE 1 Multidrug and toxin extrusion protein 1  
3.0221562 nudix nucleoside diphosphate linked moiety X 




FCAbsolute GeneSymbol GeneName 
2.909844 N/A BLAST SEARCH GAVE NO HITS 
2.8619947 cdadc1 cytidine and dCMP deaminase domain containing 1 
2.8518662 cyp8b1 cytochrome P450, family 8 
2.8446841 SMU1 smu-1 suppressor of mec-8 and unc-52 homolog 
2.8259096 N/A BLAST SEARCH GAVE NO HITS 
2.8096638 N/A BLAST SEARCH GAVE NO HITS 
2.7729554 yipf5 Yip1 domain family, member 5 
2.7522666 ubtd1 ubiquitin domain containing 1 
2.720866 ACY1 Aminoacylase-1 61% homology to human gene 
2.7193558 N/A Probe not specific 
2.7091837 rgs2 regulator of G-protein signaling 2 
2.686784 pex14 peroxisomal biogenesis factor 14   
2.6860514 HSP3 Hermansky-Pudlak syndrome 3 
2.6850827 taar65 trace amine associated receptor 65 
2.6711266 N/A Multiple HITS 
2.64639 N/A Multiple HITS 
2.583023 N/A BLAST SEARCH GAVE NO HITS 
2.5543456 rh50 Rh50-like protein 
2.5355914 NUDT16 nucleoside diphosphate linked moiety X 
2.5262425  ENPP7 ectonucleotide pyrophosphatase/phosphodiesterase 7  
2.4969575 N/A BLAST SEARCH GAVE NO HITS 
2.4912636 SH3BGRL3 SH3 domain binding glutamic acid-rich protein like 3 
2.471074 N/A BLAST SEARCH GAVE NO HITS 
2.465009 N/A BLAST SEARCH GAVE NO HITS 
2.4475963 SH3BGRL3 SH3 domain binding glutamic acid-rich protein like 3  
2.4423368 ACE angiotensin I converting enzyme 
2.4230134 ATPBD4 ATP binding domain 4  
2.4093752 ubr3 ubiquitin protein ligase E3 component n-recognin 3 
2.4026387 bokb BCL2-related ovarian killer b 
2.3753383 zmat2 zinc finger, matrin type 2 
2.3702154 rh50 Rh50-like protein 
2.3591704 N/A BLAST SEARCH GAVE NO HITS 
2.3576367 polr1b polymerase (RNA) I polypeptide B 
2.3572855 rhcg Rhesus blood group, C glycoprotein 
2.3397517 RAB35 RAB35, member RAS oncogene family 
2.3275254 SLC16A8 similar to monocarboxylate transporter 3  
2.3168197 st14b suppression of tumorigenicity 14 (colon carcinoma) b  
2.2862763 vti1a vesicle transport through interaction with t-SNAREs  
2.2692866 mylipb myosin regulatory light chain interacting protein b 
2.258262 N/A BLAST SEARCH GAVE NO HITS 
2.2536519 CAMKK1(2 of 2) calcium/calmodulin-dependent protein kinase kinase 1 
2.243251  slco2b1 solute carrier organic anion transporter family 
2.240908 ntf3 neurotrophin 3 
2.2320147 bhlhb3l basic helix-loop-helix domain containing, class B 
2.2305305 N/A BLAST SEARCH GAVE NO HITS 
2.2201831 nt5c3 5'-nucleotidase, cytosolic III  
2.2149444 ZNF362 zinc finger protein 362  
2.2083664 dapp1 dual adaptor of phosphotyrosine and 3-phosphoinositides 
2.2026093 rgs2 regulator of G-protein signalling 2 
2.1944575 SUSD3 (3 of 3) sushi domain containing 3 




FCAbsolute GeneSymbol GeneName 
2.143542 zgc:66298 polymerase (RNA) I polypeptide B 
2.1408815 TTF1 (6 of 6) transcription termination factor, RNA polymerase I   
2.1399355 N/A BLAST SEARCH GAVE NO HITS 
2.136245 cdk5 cyclin-dependent protein kinase 5 
2.1317372 dcps mRNA de-capping enzyme  
2.1275663 guca1c guanylate cyclase activator 1C 
2.1216083 ubtd1 ubiquitin domain containing 1 
2.115108 fam151a family with sequence similarity 151, member A 
2.0885773 rbm28 RNA binding motif protein 28  
2.0721066 slc23a1 solute carrier family 23 (nucleobase transporters) 
2.0627465 N/A 3 hits but all in the wrong direction 
2.062203 N/A BLAST SEARCH GAVE NO HITS 
2.054885 si:ch211-9d9.1 Novel protein si:ch211-9d9. 
2.04587 fbxl22 F-box and leucine-rich repeat protein 22 
2.0447233 cx28.9 connexin 28.9 
2.0266476 LOC796252 chemokine CXL-C24a  
2.022967 LOC100001286 similar to C6orf106  
2.0225506 bcl2l bcl2-like 50% homology to human gene 
2.0224402 rnf207 ring finger protein 207 
2.0055213 otud7b OTU domain containing 7B  
Table 5.Up-regulated transcripts in pink1 -/- microarray. All genes highlighted in green were altered 
during re annotation. 
 
FCAbsolute GeneSymbol Description 
337.62494 A2LD1 AIG2-like domain 1  
294.653 si:dkeyp-73d8.6 Homology to ATP-binding cassette, sub-family A  
208.23721 N/A BLAST SEARCH GAVE NO HITS 
156.19023 lmbr1l Danio rerio limb region 1 like  
48.701042 im:7148382  IMAP family member 4 and GTPase 
32.852505 BLOC1S2 biogenesis of lysosomal organelles complex-1, s2 
31.081526 gltpd1- glycolipid transfer protein domain containing 1 
26.637669 polr2b polymerase (RNA) II (DNA directed) polypeptide B  
26.173359 BLOC1S2 biogenesis of lysosomal organelles complex-1, s2 
25.223787 N/A BLAST SEARCH GAVE NO HITS 
24.581673 SLC17A3  solute carrier family 17 (sodium phosphate) 
23.082857 A2LD1 AIG2-like domain 1 
21.294308 N/A BLAST SEARCH GAVE NO HITS 
21.037832 N/A Multiple HITS 
20.258842 dhrs11a dehydrogenase/reductase (SDR family) member 11a  
20.244846 N/A BLAST SEARCH GAVE NO HITS 
20.155668 kmo kynurenine 3-monooxygenas 
16.645021 N/A BLAST SEARCH GAVE NO HITS 
14.625197 gpib  glucose phosphate isomerase b 
14.02044 A2LD1 AIG2-like domain 1 
14.008943 TSEN15 tRNA splicing endonuclease 15 homolog  
12.349935 wnt9a Danio rerio wingless-type MMTV integration site  
11.57964 RAP1GAP RAP1 GTPase activating protein 
11.193585 N/A BLAST SEARCH GAVE NO HITS 




FCAbsolute GeneSymbol Description 
10.151755 gpib glucose phosphate isomerase b 
10.0883045 A2LD1 AIG2-like domain 1 
9.349176 N/A BLAST SEARCH GAVE NO HITS 
8.381044 psmg1  proteasome  assembly chaperone  
7.8119206 N/A BLAST SEARCH GAVE NO HITS 
7.7133327 TSG101 tumor susceptibility gene 101 
7.341222 dnmt4  DNA (cytosine-5-)-methyltransferase 4  
6.614778 si:ch211 si:ch211-260o22.1 no human orthologue 
6.3371925 N/A BLAST SEARCH GAVE NO HITS 
6.1110654 N/A BLAST SEARCH GAVE NO HITS 
5.987409 N/A BLAST SEARCH GAVE NO HITS 
5.91139 N/A BLAST SEARCH GAVE NO HITS 
5.4998446 N/A BLAST SEARCH GAVE NO HITS 
5.3801837 olfml3a olfactomedin-like 3a  
5.192232 RAP1GAP RAP1 GTPase activating protein 
4.8446903 STARD8 StAR-related lipid transfer domain containing 8  
4.7878747 N/A BLAST SEARCH GAVE NO HITS 
4.76362 hsf1  heat shock transcription factor 1  
4.749809 UNC13C unc-13 homolog C  
4.7147145 N/A BLAST SEARCH GAVE NO HITS 
4.6948247 si:dkey-217f16.3 Processed transcript 
4.5762057 UNC13C unc-13 homolog C  
4.4179616 N/A BLAST SEARCH GAVE NO HITS 
4.415685 N/A BLAST SEARCH GAVE NO HITS 
4.3336716 N/A BLAST SEARCH GAVE NO HITS 
4.331479 parp6a  poly (ADP-ribose) polymerase family, member 6a  
4.285228 cyp24a1l cytochrome P450, family 24, subfamily A, p1 
4.225144 N/A Multiple HITS 
4.015451 N/A BLAST SEARCH GAVE NO HITS 
3.994224 N/A BLAST SEARCH GAVE NO HITS 
3.9867797 dnmt8  DNA (cytosine-5-)-methyltransferase 8 
3.908932 N/A BLAST SEARCH GAVE NO HITS 
3.8250778 N/A BLAST SEARCH GAVE NO HITS 
3.822486 N/A BLAST SEARCH GAVE NO HITS 
3.801205 nedd1 neural cell expressed, down-regulated 1  
3.798918 N/A BLAST SEARCH GAVE NO HITS 
3.7675848 pnrc2  proline-rich nuclear receptor co-activator 2  
3.7333267 slc35c2  solute carrier family 35, member C2  
3.7078235 N/A BLAST SEARCH GAVE NO HITS 
3.6977255 cyp24a1l  cytochrome P450, family 24, subfamily A 
3.6936898 adh8a Danio rerio alcohol dehydrogenase 8a 
3.691377 N/A BLAST SEARCH GAVE NO HITS 
3.656716 N/A BLAST SEARCH GAVE NO HITS 
3.4622538 or115-15  odorant receptor, family F, subfamily 115, member 15  
3.4027152 zgc:77778 Novel gene zgc:77778 
3.3788104 N/A BLAST SEARCH GAVE NO HITS 
3.3629289 PAK6 p21 protein (Cdc42/Rac)-activated kinase 6 
3.2621887 myt1 myelin transcription factor 1 
3.238024 N/A BLAST SEARCH GAVE NO HITS 
3.1932921 N/A BLAST SEARCH GAVE NO HITS 




FCAbsolute GeneSymbol Description 
3.1504362 N/A Multiple HITS 
3.1422331 minal MYC induced nuclear antigen-like  
3.1365201 N/A BLAST SEARCH GAVE NO HITS 
3.11931 A2LD1 AIG2-like domain 1  
3.1175594 N/A BLAST SEARCH GAVE NO HITS 
3.108831 minal  MYC induced nuclear antigen-like  
3.105338 nek8 NIMA (never in mitosis gene a)-related kinase 8  
3.0960152 GST? Possible orthologue of glutathione S-transferase t2  
3.0869365 tcf21  transcription factor 21  
3.0493743 N/A BLAST SEARCH GAVE NO HITS 
3.0321693 znf511 zinc finger protein 511 
3.0255601 ITLN1 Orthologue of Human Interlectin 1 and 2 
3.0156412 N/A BLAST SEARCH GAVE NO HITS 
2.9421065 usp19 ubiquitin specific peptidase 19 
2.8969617 N/A BLAST SEARCH GAVE NO HITS 
2.8825202 zgc:162431 coiled-coil domain containing 50 
2.8793223 N/A BLAST SEARCH GAVE NO HITS 
2.7616208 ndrg1l  N-myc downstream regulated gene 1 
2.7057443 ALPP alkaline phosphatase, placental 
2.7017643 rxfp2 relaxin/insulin-like family peptide receptor 2  
2.6924372 PDRG1  p53 and DNA-damage regulated 1 
2.6574495 sema3bl sema domain, immunoglobulin domain  
2.6233196 trpc4apb transient receptor potential cation channel 
2.6145089 GPR22 (2 of 2)  G protein-coupled receptor 22  
2.612301 ttyh2  tweety homolog 2 (Drosophila) 
2.603541 N/A BLAST SEARCH GAVE NO HITS 
2.594108 atp6v1e1  ATPase, H+ transporting, lysosomal 
2.592997 trpc4apb  transient receptor potential cation channel 
2.563882 CASP7 caspase 7, apoptosis-related cysteine peptidase 
2.4672425 N/A BLAST SEARCH GAVE NO HITS 
2.4536474 N/A BLAST SEARCH GAVE NO HITS 
2.4451828 pdlim5 PDZ and LIM domain 5  
2.4280818 h3f3d H3 histone, family 3D 
2.4169915 N/A BLAST SEARCH GAVE NO HITS 
2.4159079 zgc:162431 coiled-coil domain containing 50 
2.406655 N/A Multiple HITS 
2.4065533 ormdl2 ORM1-like 2  
2.4046388 ifnphi3 interferon phi 3 
2.40159 irgf1 immunity-related GTPase family, f1 
2.3965645 COX19 COX19 cytochrome c oxidase assembly  
2.393588 N/A BLAST SEARCH GAVE NO HITS 
2.3926997 N/A BLAST SEARCH GAVE NO HITS 
2.325134 FIG4 (2 of 2)  SAC1 lipid phosphatase domain containing  
2.324486 scinlb scinderin like b 
2.31802 sfswap splicing factor, suppressor of white-apricot homolog  
2.313321 or106-8 odorant receptor, family G, subfamily 106, member 8 
2.3082094 zgc:77778 Novel gene zgc:77778 
2.3035688 plp1a  proteolipid protein 1a 
2.2929733 d2hgdh D-2-hydroxyglutarate dehydrogenase 
2.282499 ugt5g1 UDP glucuronosyltransferase 5 family 




FCAbsolute GeneSymbol Description 
2.2714615 mapk1  mitogen-activated protein kinase 1  
2.264065 h1fx H1 histone family, member X  
2.2367263 h1fx H1 histone family, member X  
2.196375 zbtb8os  zinc finger and BTB domain 8 opposite strand 
2.1856678 N/A BLAST SEARCH GAVE NO HITS 
2.1851153 N/A BLAST SEARCH GAVE NO HITS 
2.1839597 aggf1 angiogenic factor with G patch and FHA domains 1 
2.1829376 c1galt1a glycoprotein-N-acetylgalactosamine,3-beta 
2.1532488 N/A BLAST SEARCH GAVE NO HITS 
2.1515162 CCDC50 coiled-coil domain containing 50 
2.1179307 pcmt l-isoaspartyl protein carboxyl methyltransferase  
2.1156254 cry2a cryptochrome 2a  
2.1147645 ncam1b neural cell adhesion molecule 1b  
2.1113217 zgc:165603 Possible orthologue of CUGBP, Elav-like  
2.100326 N/A BLAST SEARCH GAVE NO HITS 
2.100112 LOC100000522 caspase 7, apoptosis-related cysteine peptidase 
2.090073 si:ch1073  similar to nicotinamide nucleotide transhydrogenase 
2.0878496 N/A BLAST SEARCH GAVE NO HITS 
2.0687912 zp3  zona pellucida glycoprotein 3  
2.0626397 cyp26a1  cytochrome P450, subfamily XXVIA, polypeptide 1  
2.0602734 CAMKV  similar to CaM kinase-like vesicle-associated protein  
2.0586677 arrdc3  arrestin domain containing 3 
2.0586 tmx3  thioredoxin-related transmembrane protein 3  
2.0477684 sqstm1 sequestosome 1 
2.0187578 arhgap4a Rho GTPase activating protein 4a 
2.0176172 N/A BLAST SEARCH GAVE NO HITS 
2.0170264 rxfp2 relaxin/insulin-like family peptide receptor 2  
2.0129385 cyp26a1  cytochrome P450, subfamily XXVIA, polypeptide 1  
2.0070715 N/A BLAST SEARCH GAVE NO HITS 
2.0065784 FBXL17 F-box and leucine-rich repeat protein 17 
Table 6. The down-regulated transcripts in pink1 -/- microarray. All genes highlighted in green were 
altered during re annotation. 
Of the 276 probes that had different expression between pink1 -/- and WT, 211 probes 
(76%) required re annotation.  73 probes (26%) did not match homology to any known 
zebrafish cDNA or cross reacted to a variety of transcripts equally.  Of specific interest, 
the reference gene rpl13a appeared as upregulated in the pink1 -/-, a gene previously 
utilised for normalisation in qPCR studies. The majority of gene expression changes 
that were up regulated did not appear to be related and there were only three 
mitochondrial genes. The gene ontogeny terms of the remaining changed probes were 
diverse and included autophagy, mRNA processing, calcium binding, onco-proteins 
and endocytosis. In the down regulated probes, many could not be matched to a 
specific cDNA in the zebrafish genome. Of note, 5 down-regulated probes matched to 




of isodipeptide L-gamma-glutamyl-L-epsilon-lysine to 5-oxo-L-proline and free 
alkylamine.289 
3.2 pink1 -/- Th neuron reduction is rescued by tigarb knockdown 
3.2.1 pink1 -/- gene expression changes at 5dpf 
From the microarray, several upregulated genes of interest were chosen for further 
investigation. These transcripts were coded for by the following genes, tigarb, a 
glycolytic inhibitor (up 14 fold), hdac9b a histone deacetylase (up 16 fold) and apex1 a 
DNA repair enzyme (up 5 fold).  In order to carry out functional studies with gene-
gene interactions, these changes required confirmation. Each transcript was analysed 
by qPCR to investigate the specific gene expression changes. However, no changes in 
gene expression were found between pink1 -/- and WT controls at 5dpf, for either 
hdac9b or apex1 (Figure 16). Of note, tigarb expression in pink1 -/- was found to be 
increased nearly 3 fold compared to WT controls (P<0.001 unpaired T test), and hence 





Figure 16. Gene expression analysis between pink1 -/- and WT. To confirm the upregulation of particular 
gene transcripts suggested in the pink1 -/ -microarray experiments,  qPCR was undertaken to confirm or 
refute changes in the expression of tigarb (A), hdac9b (B) and apex1 (C) in pink1 -/- 5dpf and compared to 
their WT. The only expression changes from the microarray that could be confirmed were for tigarb with 
pink1 -/- larvae having nearly a 3 fold increase (P<0.001 unpaired T test) in tigarb expression compared to 








3.2.2 tigarb is chronically upregulated during development in pink1 -/- 
larvae 
tigarb expression in WT embryos was detected as early as 4hpf by RT-PCR (Figure 17) 
and ubiquitously expressed throughout development. To establish whether tigarb 
upregulation may be mediating Th neuron reduction during embryogenesis in pink1 -
/-, expression had to be confirmed in the brain. An in situ hybridisation probe was 
constructed specifically for tigarb and utilised to stain for expression in pink1 -/- and 
their WT controls from 1-5 days post fertilisation. Expression was present through all 
age groups and was not spatially restricted.  WISH confirmed tigarb upregulation in 
pink1 -/-, development, including increased expression in the pink1 -/- brains (Figure 
18).  
 
Figure 17. tigarb expression through development. tigarb transcript levels were measured throughout 
development from 4-120hpf by RT-PCR. tigarb expression was also confirmed in adult brain material. ef1a 









Figure 18. tigarb WISH through development in pink1 -/-. Widespread tigarb expression was evident in all 
organs, with marked expression in the head and chronically increased in the pink1 -/- throughout 
development. 
3.2.3 tigarb Morpholino optimisation 
Upregulation of tigarb could either be due to it being an activated survival mechanism 
or reflect involvement of tigarb in the mechanisms leading to the observed DA cell loss. 
To further investigate this, splice Morpholinos were designed to specifically KD tigarb 
in zebrafish embryos. Exons 2, 3 and 6 were chosen for targeting as their coding region 
was of functional importance for enzyme activity. For example, exons 2 and 3 code for 
the second and third residues that form the catalytic triad required for the 
bisphosphatase activity (Figure 19).228  
 
Figure 19. Schematic demonstrating Morpholino targets against tigarb exons. Morpholinos denoted by 
an arrow, were designed against the splicing boundaries of e2i2, i2e3 and i5e6. 
 
Initial toxicity tests were performed by inspection of embryos at 1, 2, and 3 days post 
fertilisation, following injection of 0.25mM, 0.5mM and 0.9mM Morpholino at the 1 cell 






   
   








toxic, with only slight deformity seen in approximately 10% of subjects by 3dpf. In 
contrast, the Morpholino against exon 6 was found to be very toxic, the exon 6 
Morpholino induced severe developmental delay of approximately 6 hours at the 24 
hpf time point, and gross deformity, even at the lowest concentration.  This 
Morpholino was therefore not used due to clear off target effects.  As the effects of 
morpholinos generally wear off by 3dpf, to measure efficacy, RNA was extracted from 
morphants injected with all concentrations at 3dpf, reverse transcribed to generate 
cDNA and then amplified by PCR. Each sample was electrophoresed on a 2% agarose 
gel and compared to WT to investigate Morpholino effects on splicing.  
For the Morpholino targeting exon 2 of tigarb (referred to as TBMO2), more than 90% 
aberrant splicing was achieved at 0.9mM (Figure 20). Exon 2 partly codes for the 
catalytic triad region of tigarb, and TBMO2 caused a complete skip of exon 2, confirmed 
by direct sequencing) that partly codes for tigarb’s catalytic triad. The exon deletion 
also resulted in a frame shift. Lower concentrations lead to lower levels of exon 
skipping.  
Using a Morpholino targeting exon 3 of tigarb (TBMO3), did not have an effect on 
splicing even at 0.9mM and was therefore not chosen for further experiments either 





Figure 20. tigarb Morpholino 2 optimisation. A Morpholino designed to target exon 2 (e2i2) of tigarb was 
injected at several concentrations to ascertain toxicity and efficacy.  Efficacy was measure by RT-PCR at 
3dpf. Lane 1, uninjected controls, lane 2, 0.9mM, lane 3 0.5mM and lane 5, 0.25mM. The Morpholino was 
non- toxic at any concentration. With increasing concentration of the Morpholino, greater exon skip of 

















Figure 21. TBMO3 optimisation. A Morpholino designed to target exon 3 (i2e3) of tigarb was injected at 
several concentrations to ascertain toxicity and efficacy.  Efficacy was measure by RT-PCR at 3dpf. Lane 1, 
uninjected controls, lane 2, 0.9mM, lane 3 0.5mM and lane 5, 0.25mM. The Morpholino was non- toxic at 
any concentration. However the Morpholino did not lead to any obvious splicing defects at any 
concentration. 
3.2.4 tigara expression in pink1 -/- larvae 
The zebrafish genome contains many orthologues of human genes, however, due to a 
duplication event, many of these have two copies in zebrafish. Tigar is no exception, 
with the zebrafish genome containing two orthologues with approximately 50% 
protein homology, tigarb and tigara. Only tigarb was demonstrated to be upregulated in 
the pink1 -/- microarray. As both orthologues may be functionally redundant, gene 
expression analysis of tigara was investigated by qPCR and WISH, in the pink1 -/- 
larvae and their WT controls.  qPCR demonstrated approximately a twofold 
upregulation of tigara in the pink1 -/-; a similar trend to that of tigarb. However, this 
upregulation was very variable and not statistically significant (P=0.178 unpaired T 
test) (Figure 22). As these results were inconclusive, an in situ probe was constructed to 
stain tigara expression. Consequently WISH experiments using this probe were 
undertaken throughout development between WT controls and pink1 -/- larvae.  tigara 
expression was similar to tigarb, ubiquitous and not spatially restricted.  No staining 
was detected with the sense probe (Figure 23). Although tigara expression was 
demonstrated to be upregulated at certain time points, this was not found to be a 
robust phenotype on subsequent replicates or at all-time points. Consequently, 












Considering tigara may be functionally redundant to tigarb, it is plausible that tigarb KD 
may result in an increase in tigara expression levels to compensate. However, gene 
expression analysis of tigara by qPCR in TBMO2 morphants demonstrated that tigarb 
KD did not change tigara expression levels (Figure 22). 
 
Figure 22. tigara expression levels quantified by qPCR. Figure 22A comparing tigara expression between 
pink1 -/- 5dpf larvae and their WT. pink1 -/-showing a trend for increased tigara expression compared to 
WT, however this was not statistically significant. Figure 22B comparing tigara expression levels in 
uninjected WT controls at 3dpf and WT TBMO2 injected larvae. No change in tigara expression levels 
between the two groups was detected; implying tigarb KD does not increase tigara expression due to 






Figure 23. WISH of tigara in WT larvae during early development. Staining was ubiquitous and not 
spatially restricted in a similar manner to tigarb expression. No staining was detected with the sense probe, 
demonstrating antisense staining to be specific for tigara. 
3.2.5 Knockdown of tigarb rescues Th neuron reduction in pink1 -/- larvae 
With the Morpholino optimised, TBMO2 was utilised to inactivate tigarb in pink1 -/- 
and their WT controls, and investigate whether this would lead to either a rescue or a 
worsening of their phenotype in general and the effect on the number of DA neurons 
in particular. Morphants were morphologically normal in both genotypes and full KD 
was achieved in spite of tigarb upregulation in pink1 -/- larvae (Figure 24) 
 




	  	  	  
	  	  	  












Figure 24.  tigarb KD in pink1 -/- and WT larvae. tigarb KD in pink1 -/- larvae and their WT controls 
resulted in >90% KD determined by RT-PCR at 3dpf. Lane 1 WT uninjected, lane 2 WT TBMO2, lane 3 
pink1 -/- uninjected and lane 4 pink1 -/- TBMO2. Morphants were morphologically normal regardless of 
genotype. 
Analysis of TH-positive neurons at 3dpf demonstrated a 20% reduction in pink1 -/- 
uninjected larvae (P<0.05) compared to WT uninjected larvae, similar to that seen at 
5dpf. KD of tigarb in WT controls led to a small increase in TH neurons of 5% although 
this was not statistically significant. KD of tigarb in pink1 -/- larvae resulted in a 
complete normalisation of the TH  positive neuron level to that of WT controls (Figure 
25). This suggests that tigarb upregulation in the pink1 -/- is responsible for the Th 
neuron reduction. 











Figure 25.  Knockdown of tigarb rescues Th neuron reduction in pink1-/- larvae. KD of tigarb in WT 
larvae had a small effect on TH level, raising it by 5% although this did not reach significance.  The pink1-
/- un-injected larvae at 3dpf exhibited a 20% decrease in TH neuron count compared to WT as seen at 5dpf 
(P<0.05, two way anova). KD of tigarb in pink1-/- led to a complete normalisation of the TH neuron count, 
with an average TH neuron count of approximately 100% compared to the uninjected WT. WT  uninjected 
TH neuron counts normalised to 100%, experimental groups expressed as a percentage of this. See 
materials and methods for more detail. 
3.2.6 pink1 Morpholino design and optimisation 
To further confirm the functional relevance of tigarb KD as a rescue mechanism in pink1 
deficiency, the author tested its effect in a different model of pink1 deficiency with MO 
mediated pink1 KD.  tigarb KD, leading to a rescue of pink1 -/- phenotypes, needed to be 
confirmed in a second model of pink1 deficiency. However, as all published 
Morpholinos did not phenocopy the stable Y421* mutant, a new pink1 Morpholino had 
to be designed and optimised. 
Morpholino sites in pink1 were chosen by analysing each exon and evaluating it for 
ease of assay, and whether exon skip/intron inclusion would lead to a subsequent 
frame shift. See Figure 26 for a schematic, illustrating choice of exon/intron boundaries 





Figure 26. A schematic outlining pink1 Morpholino design. pink1 exons were labelled to denote locations 
of published pink1 Morpholinos ( diamond shape), novel designed gene tools Morpholino sites (triangle 
shape) and SNP sites (star shape). Consequently, exons were manufactured targeting exon 4 (i3e4 and 
e4i4) and exon 5 (e5i5). 
The company Gene Tools were able to design morpholinos to the intron-exon 
boundaries and exon-intron boundaries of exons 4 and 5, as well as the exon-intron 
boundaries of exons 6 and 7. Each Morpholino binding site was sequenced beforehand, 
to confirm that the genomic sequences on ENSEMBL that would be utilised for 
Morpholino design were correct. Any putative Morpholino target sites which 
contained SNPs were rejected, as these would prevent Morpholino binding. This left 
morpholinos targeting two sites in exon 4 and the exon-intron site of exon 5.  All 3 
morpholinos were ordered and toxicity and efficacy established in a manner similar to 
that of TBMO2 optimisation. 
Morpholino i3e4 was found to be non-toxic at all concentration levels injected, however 
lacked efficacy, causing as little as 30% aberrant splicing at 24hpf and 72hpf. This 
particular Morpholino appeared to cause an exon skip of exon 4 and activation of 
cryptic splices sites simultaneously (Figure 27). 
Morpholino e4i4 was found to be toxic at the 0.9mM injection, with morphants 
exhibiting a large delay in development and gross deformity. Injections at 0.5mM and 
0.25mM had morphants with deformities responding in a dose dependant manner, 
consequently the Morpholino was deemed too toxic for further use. The action of the 
Morpholino appeared to be that of an intron inclusion that was not possible to assay, 
due to its large size >1000bp with the polymerases commonly utilised for this type of 
RT-PCR (Figure 28).  
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Figure 27. pink1 Morpholino PINK4 (i3e4) optimisation. RT- PCR evaluating PINK4 (i3e4) efficacy. Lane 
1 and 2, uninjected controls at 1 and 3 dpf respectively. Lanes 3 and 4, 0.9mM injected at 1 and 3 dpf. Lanes 
5 and 6, 0.5mM injected  at 1 and 3 dpf.  The Morpholino was non toxic even at the highest dose. PINK4 
(i3e4) causes likely activation of cryptic splice sites and an exon skip of exon 4. Even at highest dose  and at 
the earliest time point, KD  efficacy is still very low, with approximately 30% of the transcript being 
abnormally spliced. 
 
Figure 28. pink1 Morpholino  e4i4 optimisation. RT-PCR demonstrating efficacy of pink1 Morpholino 
e4i4. Lanes 1 and 2, uninjected control at 1 and 3 dpf. Injections of 0.9mM of pink1 morpholino e4i4 was 
toxic leading to excessive deformity and delays in development. Lanes 3 and 4 are injections of 0.5 mM at 1 
and 3 dpf. Lanes 5 and 6 are injections of 0.25mM at 1 and 3 dpf. pink1 Morpholino e4i4 appears to cause 
an intron inclusion  which is not possible to assay with the current polymerases, due to its large size 
(2000bp). pink1 Morpholino e4i4  is efficient, with over 90% abnormal splicing  at 0.5mM. 
Both Morpholinos were also co-injected to investigate synergistic splicing effects. The 
concentrations utilised for Morpholino e4i4, although toxic on their own, showed 
decreased toxicity when co-injected with Morpholino i3e4 for unknown reasons. More 
than 90% KD was achieved with the co-injection leading to an exon skip of exon 4 of 










pink1 (Figure 29). Unfortunately co-injection of both of the pink1 Morpholinos with 
TBMO2 was very toxic due to the large quantities of Morpholino injected (3 times what 
the author considers to be the potential highest dose).  
The pink1 Morpholino targeting the exon intron boundary of exon 5 (PINK5) was 
found to be non-toxic at all doses and led to more than >90% aberrant splicing at the 
highest dose. PINK5 led to an intron inclusion of intron 5 (77bp, confirmed by direct 
sequencing) and a small quantity (approximately 5%) of exon skip of exon 5 (Figure 
30). A dose of 0.9mM PINK5 was chosen for co injection experiments. Co-injection of 





Figure 29. pink1 MO4  co-knockdown optimisation. RT-PCR demonstrating efficacy of co-injection of 
both PINK4 Morpholino’s. Lane 1, uninjected control at 3dpf. Lane 2 and 3 is co-injection of 0.45mM   
pink1 i3e4+ pink1 e4i4  at 1 and 3 dpf. Lanes 4 and 5 is 0.25mM at 1 and 3 dpf. Co-injection of both 
Morpholinos targeting exons 4 results in a 90% exon skip of exon 4 at highest dose, the effects not wearing 
off even at 3dpf. Injections of 0.25mM result in a similar KD efficacy although it had worn off by 3dpf.  
 
Figure 30. pink1 MO5 optimisation.  RT-PCR demonstrating efficacy of pink1 Morpholino e5i5 (PINK5).  
Lane 1 uninjected control, lanes 2,3 and 4 representing injections of 0.9mM, 0.5 mM and 0.25mM 
respectively. All at 3dpf. PINK5 led to an intron inclusion of intron 5, confirmed by direct sequencing, and 
gave  approximately 90% abnormal splicing and was non toxic at 0.9mM. 
 









Figure 31. RT-PCR demonstrating PINK5 KD in co-injection experiments. Lanes 1-3 RT-PCR with 
PINK5 primers. Lanes 4-6 RT-PCR using TBMO2 primers. Lane 1 and 4 using uninjected control, lanes 2 
and 5 PINK5 KD, lanes 3 and 6 CO injection with PINK5 and TBMO2.  90% KD was achieved in PINK5 
injected larvae, and 100% KD in TBMO2 injected larvae. Co-injected larvae had more deformity than 
PINK5 injected, however heads appeared to be intact. 
KD of pink1 with PINK5 alone caused a 20% decrease in TH neurons at 3dpf seen in 
previous experiments in the stable mutant line (P<0.05) compared to uninjected and 
control Morpholino injected. Co-injection of PINK5 and TBMO2 led to the complete 
normalisation of the TH neuron count compared to uninjected and control Morpholino 











Figure 32. Co-knockdown of pink1 and tigarb rescues Th neuron reduction. A pink1 Morpholino (PINK5) 
was utilised to confirm tigarb KD rescues Th neuron reduction in a second model of pink1 deficiency.  pink1 
KD in Zebrafish leads to a 20% decrease in TH neurons at 3dpf (P<0.05). Co-injection with tigarb 
Morpholino prevents this neural cell loss. 
3.2.7 Knockdown of tigarb rescues mitochondrial dysfunction 
Once it had been confirmed that tigarb KD rescues Th neuron reduction in pink1 -/- 
larvae, its method of action had to be addressed.  tigarb expression was again rescued 
by Morpholino KD in the pink1 -/- larvae and WT controls to investigate whether TH 
rescue was due to normalisation of mitochondrial dysfunction. At 3dpf uninjected 
larvae were found to have a decrease in mitochondrial Complex activities of 
Complexes I and III in a manner similar to pink1 -/- at 5dpf.  In contrast, KD of tigarb in 
pink1 -/- larvae completely rescued the activity of Complex I and Complex III (Figure 
33).  The mitochondrial Complex assay experiments were jointly undertaken between 
the author and Dr Heather Mortiboys. Morpholino injections were performed by the 





Figure 33. Mitochondrial Complex activities in tigarb morphants. To ascertain the rescue effect of tigarb 
KD in pink1 -/-, Mitochondrial Complex activity was measured in response to the KD of tigarb with 
TBMO2 at 3dpf. At this time point pink1 -/- larvae have a large reduction in Complex I and III which is 
completely rescued by the KD of tigarb. In each graph, first white bar represents WT uninjected, second 
white bar represents WT TBMO2 inject, the black bar represents pink1 -/- uninjected and the grey bar 
represents pink1 -/- TBMO2 injected. 
3.2.8 tigarb KD does not rescue MPP+ mediated Th neuron reduction 
 As KD of tigarb rescues the Th neuron reduction seen in a genetic model that also 
exhibits Complex I inhibition (pink1 -/-), it was hypothesised that tigarb KD may also 
rescue Th neuron reduction induced by a chemical form of Complex I inhibition; in this 
case the classical PD toxin, MPP+. 
Wildtype zebrafish larvae injected with TBMO2 and uninjected controls were treated at 
48hpf with either 3mM MPP+ or standard E3 media for 24 hours. TBMO2 injection and 
MPP+ exposure did not affect morphology. When analysing the TH neuron counts of 
MPP+ treated larvae, uninjected control larvae had a 25% decrease in TH neuron count 




larvae treated with E3 had an increase of 15% TH neurons compared to WT although 
this was not statistically significant. However tigarb KD in MPP+ treated larvae did not 
lead to normalisation of Th neuron reduction, with larvae having a 25% decrease 
compared to E3 uninjected larvae (P<0.05) (Figure 33). 
 
Figure 34. TB KD does not rescues TH loss in response to MPP+. KD of tigarb in E3 media treated larvae 
resulted in a 15% increase in TH neurons compared to E3 uninjected however this was not statistically 
significant.  Treated larvae with 3mM MPP+ uninjected and TBMO2 injected resulted in a 25% reduction 
in TH neurons (P<0.05). This demonstrates tigarb KD does not rescue TH neurons after MPP+ treatment. 
3.2.9 Knockdown of vhl rescues Th neuron reduction in pink1 -/- larvae 
Mutations in VHL lead to activation of HIF1a and the hypoxic response, causing 
certain cancers in humans. vhl -/- zebrafish larvae have been shown to have an 
increased glycolytic flux.242 Consequently vhl was chosen as a subject for gene-gene 
interaction studies in the pink1 -/- larvae. It was hypothesised homozygocity for both 
pink1 and vhl may lead to a normalisation of glycolysis and therefore a possible rescue 
of phenotype seen in either mutant. Initially vhl Morpholinos were utilised to KD vhl in 
pink1 -/- larvae. Efficacy was determined by using phd3 GFP reporter zebrafish as the 
control group. These transgenic fish possess GFP fused to the phd3 promoter; 
consequently expression of phd3 will also cause expression of GFP. vhl -/- show a very 
large upregulation of phd3, and so as a result of vhl deficiency in these reporter larvae, 
they fluoresce green. Zebrafish have such low basal expression of phd3, that uninjected 




KD of vhl in phd3 reporter zebrafish led to a large green fluorescence signal, indicating 
vhl deficiency, and no reduction of TH neurons was seen compared to phd3 uninjected. 
Uninjected pink1 -/- larvae had the standard 25% decrease in TH neurons (P<0.05) 
compared to phd3 uninjected controls. vhl KD in pink1 -/- larvae did not cause any 
morphological changes, and led to a complete rescue of Th neuron reduction (Figure 
35).  
 
Figure 35. vhl KD rescues pink1 -/- Th neuron reduction.  pink1 -/- larvae have an upregulation of tigarb, 
implying a state of inhibited glycolysis. vhl -/- larvae are in a chronic state of increased glycolytic flux.  KD 
of vhl in WT had no effect on the TH neuron count.  The pink1 -/- uninjected larvae had a 25% decrease 
compared to WT. KD of vhl in pink1 -/- larvae led to complete normalisation of TH neuron levels. 
vhl deficiency activates hypoxic signalling, that also leads to a robust upregulation of 
TH expression.290 The author subsequently wanted to confirm the rescue effect of vhl 
deficiency on TH neurons in pink1 -/- larvae by crossing the pink1 -/+ with a stable vhl 
deficient line (vhl -/+). In addition, the author wanted to confirm with the apparent 
rescue of DA neurons with a second marker of DA neurons other than TH. This is due 
to the nature of vhl deficiency, as it leads to activation of Hif1a and its downstream 
targets. Tyrosine hydroxylase is known to be a direct target of Hif1 . Consequently, in 
case the rescue seen in vhl KD was actually an increase of TH expression (caused by 
Hif1  activation) as opposed to an increase in DA neurons, DAT was chosen as a 
confirmatory marker. DAT had previously been utilised by Dr Laura Flinn to confirm 
Th neuron reduction in the pink1 -/- at 5dpf with a loss of approximately 25%, similar 
to TH.201 Consequently the pink1 Y431* line was crossed to a previously characterised 
vhl loss of function line previously characterised, to generate pink1 -/+; vhl -/+. As vhl -




incrossed to generate pink1 -/-; vhl -/+ adults from which all embryo work was to be 
conducted. Consequently, for each experiment, all larvae would have to be genotyped 
for vhl status.  This cross to generate pink1 -/-; vhl -/+ also demonstrated that pink1 -/- 
cannot rescue the lethality seen in vhl  -/-, as no pink1 -/-; vhl -/- were found in the adult 
genotyping. 
From incrossed experiments, pink 1 -/-; vhl -/- larvae were deemed to be 
indistinguishable from pink1 +/+; vhl  -/- larvae, demonstrating that the presence of 
the pink1 -/- could not rescue the morphological phenotypes exhibited by vhl -/- 
during development. When the DAT neurons were analysed at 5dpf, pink1 -/-; vhl +/+ 
showed a 20% decrease (P<0.05 two way anova) in DAT neurons compared to WT, in a 
similar manner documented by Flinn et al 2013. Upon analysis, pink1 +/+; vhl -/- 
demonstrated an even greater decrease in DAT neurons of approximately 30% (P<0.01 
two way anova).  This decrease was not rescued by pink1 -/-; vhl -/-, and in fact they 
showed a similar decrease in DAT neurons (Figure 36). 
 
Figure 36. vhl -/- has a large decrease in DAT neurons at 5dpf compared to WT. pink1 -/- at 5dpf has a 
20% decrease in DAT neurons at 5dpf similar to TH (P<0.05).  vhl -/- have an even greater decrease in DAT 
neurons  at 5dpf of 30% (P<0.001), unaffected by pink1 genotype, seen in pink1 -/-; vhl -/- also have a large 
decrease in DAT neurons of 30%. Pilot data n=1  
3.3 pink1 results summary 
The presented work contributed to the first characterisation of a stable mutant PD 
zebrafish line (part of the publication by Flinn et al 2013., see appendix). This zebrafish 




deficiency, as pink1 -/- have a reduction of TH neurons by 3dpf.  Gene expression 
analysis by WISH for neuronal developmental markers has suggested the neuronal loss 
being due to a developmental defect is unlikely after 24hpf, although may be causative 
before 24hpf. Gene expression studies also identified the upregulation of tigarb in pink1 
-/- larvae which was further confirmed by WISH and qPCR. KD of tigarb was found to 
completely rescue Th neuron reduction and mitochondrial dysfunction in pink1-/- 
larvae. However tigarb KD could not rescue Th neuron reduction in MPP+ treated 
larvae. vhl was also found to be a modifier of pink1 deficiency as KD of vhl in pink1 -/- 
larvae also rescued Th neuron reduction. The latter finding still requires further 
validation. 
Overall, the study revealed that zebrafish are indeed a valid model for pink1 deficiency 
and has revealed a potential new drug target, opening the potential for the pink1 Y431* 











4.1 Introduction and gba1 expression profile 
4.1.1 Introduction 
Homozygous mutations in GBA1 present as GD, whilst GBA1 mutations remain the 
most common genetic risk factor for development of PD.93 At the commencement of 
this study the only vertebrate models of GBA1 deficiency were mouse KO/conditional 
KO’s, which either died shortly after birth, or did not faithfully model GD or PD. The 
zebrafish has been shown to be a useful model for studying neurodegeneration, so it 
was hypothesised that zebrafish could be a useful model for GD and GBA1-linked PD. 
At the time of study only KD approaches were available, so these were utilised to 
initially generate a loss of function zebrafish model. However, as stable mutant alleles 
had become available, due to the SANGER-led zebrafish mutation project, and with the 
advent of TALEN technology, a stable loss of function mutant was also generated and 
both mutant lines were characterised. The specific objectives of this part of the thesis 
were to validate a zebrafish model of gba1 deficiency in its homozygous and 
heterozygous state, and to identify suitable phenotypes, amenable to high throughput 
zebrafish drug screens. 
4.1.2 Zebrafish gba1 orthologue identification and expression. 
To identify a zebrafish orthologue of GBA1, the human protein sequence 
(ENSP00000314508) was aligned against the zebrafish proteome using the BLAST 
online tool, identifying a single hit, of approximately 50% homology to the human 
protein, ENSDARP00000098103 annotated as gba1 in the zebrafish genome. To validate 
the hit, the putative protein orthologue sequence was then searched for in the human 
proteome, the top hit identified as ENSP00000314508, the human GBA1 protein. To 
confirm these BLAST results the human GBA1 cDNA, ENST00000368373, was searched 
for against the zebrafish genome, identifying ENSDART00000113093, the annotated 
zebrafish gba1 transcript, as the top hit, with 50% homology to the human cDNA.  Both 
genes have a similar genetic structure, with similar numbers of exons (human 11, 
zebrafish 10), transcript length and protein size. From ENSEMBL, the zebrafish gba1 
codes for a single major isoform, 518 amino acids in length, zebrafish Gba1 sharing 
57% identity to human GBA1. The human gene can be alternatively spliced into 5 
different protein coding combinations, ranging in size from 423 to 536 amino acids in 




confirm that the identified orthologue was indeed the zebrafish orthologue of GBA1, 
the human and zebrafish genomic loci were compared to determine whether gene 
synteny was also conserved.  No genes could be located up to 500kb upstream of 
GBA1/gba1 that are present in both organisms. Up to 500kb downstream of GBA1/gba1, 
3 genes were identified that were present in both organisms, namely DAP3/dap3, 
RUSC1/rusc1 and FDPS/fdps, demonstrating partial conserved gene synteny between 




Figure 37. The Genomic loci of human and zebrafish GBA1/gba1.  Cartoon comparing loci of GBA1/gba1 
orthologues.  
To assess whether gba1 is expressed during development, PCR was utilised to amplify 
a region of gba1 cDNA from 1 to 5 days post fertilisation (dpf) and a selection of adult 
tissues. Expression was detected at a constant, and low level from days 1-5 of 
embryogenesis, with similar expression in fin, liver and brain from adult organs ( 38). 
To assess if expression was spatially restricted during development, a WISH probe was 
constructed to specifically stain for gba1 expression. WISH at days 1, 2, 3 dpf revealed 
gba1 expression was widespread with marked expression in the head. No staining was 
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Figure 38. gba1 expression in early development and adult tissues. gba1 expression was monitored 
through early development and in a selection of key tissues by RT-PCR. Expression was low and constant 
at all-time points and tissues. gba1 expression was additionally confirmed in the fin, liver and brain. Ef1a 
was utilised as a loading control. 
 
Figure 39. gba1 expression through early development by WISH. gba1 expression was monitored 
spatially by WISH. gba1 Expression at days 1, 2, 3 of development in Figure 39 A, B and C demonstrated 
gba1 expression to be ubiquitous and not spatially restricted. No staining could be detected with the 
control sense probe at 3dpf, Figure 39 D.  
4.2 gba1 Morpholino optimisation and knockdown 
4.2.1 gba1 Morpholino optimisation 
To prevent gba1 expression, a Morpholino strategy was employed to KD the transcript 
during zebrafish embryonic development. Of the 300 mutations characterised in the 11 
exons of the GBA1 human gene, 100 occur in exons 8 and 9. This also includes the most 




the site of many complex alleles, due to recombination events with GBA1 and GBA1 
pseudogene, the latter containing a 55bp deletion in its 9th exon. Consequently, these 
sites were originally chosen for Morpholino KD. Exon junctions were sequenced for 
both genes to confirm the genomic sequence in ENSEMBL. Using the confirmed 
sequences, Gene tools were able to design Morpholinos binding to the i6e7 (MO7), e8i8 
(MO8) and i8e9 (MO9) junctions. See  
Figure 40 for a graphical representation of Morpholino binding sites. 
 
Figure 40. gba1 Morpholino binding sites. A schematic illustrating Morpholino binding sites to gba1. 
Morpholinos were designed against i6e7 (MO7), e8i8 (MO8) and i8e9 (MO9).  
Morpholinos were tested for efficacy and toxicity by injecting 1nl of 0.25mM, 0.5mM 
and 0.9mM into 1 cell stage WT embryos. MO7 was toxic at the highest doses (0.9mM 
and 0.5mM) and displayed low efficacy, see Figure 41. MO8 injected embryos showed 
no deformity or increased death compared to uninjected controls, at any dose and RT-
PCR demonstrated the largest KD of the WT mRNA, leading to a simultaneous exon 
skip and intron inclusion (Figure 42). MO9 was toxic at 0.9mM and had low efficacy 
(Figure 42).  









Figure 41. gba1 MO7 optimisation.  gba1 MO7 was injected at a variety of concentrations to assess toxicity 
and efficacy. gba1 MO7 was toxic at the highest doses (0.9mM and 0.5mM) and had low efficacy. Lane 1, 
uninjected, lane 2, 0.9mM injected, lane 3, 0.5mM injected. At the highest dose of 0.9mM, gba1 MO7 caused 
less than 10% exon skip. No obvious effect on splicing could be detected.  
 
Figure 42. gba1 MO8 and MO9 optimisation. RT-PCR demonstrating gba1 MO8/MO9 optimisation. gba1 
MO8 was injected at a range of different concentrations to determine toxicity and efficacy. Lane 1 
uninjected, lane 2, 0.9mM injected, lane 3, 0.5mM injected, lane 4, 0.25mM injected. gba1 MO8 was non-
toxic at all concentrations and achieved greatest KD at 0.9mM. gba1 MO9 had low efficacy even when 
injected at the highest dose (0.9mM, lane 6), compared to uninjected, lane 5. 
Due to its efficacy (~90% KD) and low toxicity, MO8 was selected as the optimal 
Morpholino for further gba1 KD experiments in WT zebrafish embryos. To confirm 












MO8 were sub-cloned into a Topo-ta vector and sequenced to confirm the effects of the 
Morpholino. The sequenced products were identified to be intron inclusions of intron 8 
(581 base pairs) and a complete exon skip of exon 8 (164 base pairs). 
4.2.2 TH neuron count of Complex I inhibited gba1 knockdown larvae 
Initially, TH neurons were counted in WT uninjected and gba1 MO8-injected zebrafish.  
Despite reliable KD of gba1 with MO8, no decrease of TH neurons was observed (data 
not shown). Consequently, it was investigated whether gba1 KD may sensitise WT 
zebrafish larvae to mitochondrial Complex I inhibition. WT uninjected and gba1 MO8-
injected zebrafish were then exposed to 3mM MPP+ (a robust Complex I inhibitor) for 
24 hours. gba1 KD with MO8-treated with control E3 media led no decrease of TH 
neurons compared to uninjected WT zebrafish, that was statistically significant, 
reproducing the results previously seen in unexposed zebrafish. Uninjected WT larvae 
treated with 3mM MPP+ had a 50% reduction of TH neurons compared to those 
uninjected WT controls treated with control E3 media. gba1 MO8-injected larvae also 
treated with MPP+  had a 60% reduction of TH neurons compared to WT uninjected 
controls treated with E3 media, however this loss was not statistically significant to the 
MPP+ treatment alone, see  
Figure 43. To confirm this lack of a synergistic effect of gba1 KD, in conjunction with 
Complex I inhibition, gba1 MO8 was utilised to KD gba1 in pink1 -/- larvae that exhibit a 
reduction in Complex I activity and a 20% reduction in TH neurons at 3dpf. The gba1 
MO8-injected WT zebrafish showed a no reduction of TH neurons that was statistically 
significant, consistent with previous findings. pink1 -/- uninjected larvae had a 20% 
reduction of TH neurons (P<0.05, two way ANOVA) compared to uninjected WT 
zebrafish. gba1 KD in pink1 -/- larvae did not exacerbate loss of TH neurons beyond the 
initial 20% reduction (observed in the pink1 -/- uninjected zebrafish. This confirms gba1 
KD in WT larvae does not sensitise TH neurons to mitochondrial Complex I inhibition 








Figure 43. TH neuron count after gba1 knockdown at 3dpf and with 3mM MPP+. gba1 KD treated with 
control E3 media developed a no decrease in TH neurons compared to uninjected (P>0.05). Uninjected 
controls treated with 3mM MPP+ had a TH neuron decrease of 50% compared to uninjected E3 treated 
control (P<0.001 two way ANOVA). TH neuron count in gba1 KD MPP+ treated larvae decreased by 60% 
compared to uninjected E3 treated control (P<0.001 two way ANOVA), although not statically significant 
decrease compared to uninjected larvae treated with 3mM MPP+ (P>0.05 two way ANOVA). 
 
 
Figure 44. gba1 knockdown in pink1 -/- larvae at 3dpf. gba1 KD in WT larvae led to no decrease in TH 
cells, compared to WT uninjected controls. pink1 -/- uninjected larvae exhibited the standard 20-25% 
decrease in TH neurons compared to WT uninjected (P<0.01, two way ANOVA). KD of gba1 in pink1  -/- 
did not increase the Th neuron reduction in pink1 -/- uninjected, demonstrating gba1 deficiency does not 




4.3 gba1 sa1621, zebrafish mutation project line 
4.3.1 gba1 sa1621characterisation 
KD strategies, although somewhat effective, are transient in nature, with KD lasting 
only up to 3-5 days in WT zebrafish larvae. Studies examining cell death in Morpholino 
KD based studies are also difficult to interpret as un-validated Morpholinos may be 
producing nonspecific phenotypes due to off target p53-mediated effects. 
Consequently, stable mutant lines are preferable for reverse genetic studies, as they 
avoid these variables and additionally allow for the analysis of loss of function 
phenotypes from development to adulthood. Previously, stable mutant lines were 
generated from large scale ENU mutagenesis screens that are costly and time-
consuming. A novel technique for targeted genome editing using TALENs has been 
developed for zebrafish embryos, as a robust method for producing insertions and 
deletions (indels) in a targeted fashion. Additionally, the zebrafish mutation project, a 
very large-scale ENU mutagenesis screen is being undertaken by the WELLCOME 
TRUST SANGER centre with the aim of identifying loss of function mutations in all 
zebrafish genes (http://www.sanger.ac.uk/resources/zebrafish/zmp/).  
The zebrafish mutation project had already identified a point mutation (sa1621) 
affecting an essential splice site in exon 4 of the gba1 transcript. The base affected was a 
G>A at the exon 4 intron 4 junction. A complete intron inclusion of intron 4 (2,718bp) 
would lead to a premature stop codon appearing at c.573, producing a truncated 
protein of 191 amino acids , as opposed to the WT 518 amino acids in length. See Figure 





Figure 45 The Genomic sequence illustrating the sa1621 allele point mutation. gba1 introns 3 and 4 are 
lower case and light and dark blue script respectively, exon 4 in upper case and purple script. The altered 
position in the sa1621 allele, generated from the zebrafish mutation project, is a G<A mutation of an 
essential splice site, at the exon 4 intron 4 boundary, highlighted in yellow. 
Pilot data from a gba1 sa1621/+ incross at 5dpf demonstrated no TH neuronal cell loss at 5 
dpf, suggesting the small decrease of the TH neuronal count seen in gba1 KD larvae is 
likely to be an off target effect of the Morpholino , see Figure 46. When the sa1621 gba1 
-/+ incross was grown to adulthood and reached 12 wpf, it was noted that a significant 
proportion of the individuals were emaciated, exhibited movement difficulties and 
were lying on the bottom of the tank. Many had to be culled immediately in line with 
animal welfare protocol.  The culled and live fish were all genotyped. All culled fish 
were all gba1 sa1621/ sa1621, the remaining gba1 sa1621/ sa1621were moved to a separate tank 
and behaviour analysed by visual inspection. The adults moved abnormally and 
would spontaneously exhibit violent, corkscrew-like, motions. See Video 1 in the 
supplementary data for an example of 12 wpf WT zebrafish locomotion and Video 2 
for an example of gba1 sa1621/ sa1621 motion. The remaining fish also were then culled. 
Each fish was measured and weighed at the point of culling.  The gba1 sa1621/ sa1621 had a 
50% decrease in mass compared to WT (P<0.01), and a decrease in length of 10% 
(P<0.01), see  
Figure 47. Although all gba1 sa1621/ sa1621 had to be culled at 12 wpf, homozygosity did not 
appear to significantly affect viability before this time point, with the alleles 
segregating in a Mendelian fashion at genotyping  with 21 WT (24.4%), 45 gba1 sa1621/ + 
(52.3%) and 20 gba1 sa1621/ sa1621 (23.3%). Attempts were made to investigate fertility in 
the gba1 sa1621/ sa1621adults, however all successive breeding attempts failed to produce 

















Figure 46. TH neuron count of 5dpf larvae in all sa1621 gba1 genotypes . 5dpf larvae from a gba1 sa1621/ + 
incross were stained for TH by WISH, neurons were counted and then larvae were genotyped. There was 
no significant difference in TH neuron count between all gba1 genotypes, WT:12, gba1 sa1621/ + :18 and 










Figure 47. The length and mass of sa1621 gba1 -/- and WT controls at 12 wpf. A, sa1621 gba1 -/- have a 
50% decrease in mass compared to WT controls at 12 wpf (P<0.05, unpaired T test). B, sa1621 gba1 -/- 
show a small, statistically significant decrease in length of 20% compared to WT (P<0.05, unpaired T test). 
N =10 for both measurements. 
4.4 gba1 TALEN mutagenesis 
4.4.1 gba1 TALEN construction 
In parallel to the sa1621 characterisation, a second loss of function gba1-mutant was 
constructed using the TALEN system of gene editing. TALEN mutagenesis requires 
pairs of TALENs to be constructed with a spacer region of approximately 20bp. By 






TALEN efficacy can be determined, as any small indels created will mutate the 
restriction site and prevent digestion. Exon 7 was chosen for targeting due to the 
presence of suitable TALEN sites flanking a MwoI restriction site. See Figure 48 for the 
position of TALENs within the gba1 gene.  
Figure 48. TALEN binding site. The Genomic sequence of the gba1 TALEN binding site showing introns 6 
and 7 are in lower case and light blue script. Exon 7 of gba1 is highlighted in red and uppercase. TALEN 
binding sites are highlighted in yellow. The MwoI site in the spacer region is underlined and in black. 
TALEN mRNA was injected into 1 cell stage WT embryos and genomic DNA (gDNA) 
extracted for restriction digest at 24 hpf. Exon 7 was amplified and digested with MwoI.  
PCR products from uninjected single embryos gDNA extraction were completely 
digested by MwoI. Digested PCR products from TALEN injected samples showed 
incomplete digestion with the presence of uncut products showing the TALEN 
possessed high efficacy. See Figure 49 for the restriction digest agarose gel image.  





   





   





















Figure 49. TALEN analytical restrictions digest. To test efficacy of gba1 TALEN, PCR products of the 
target site from gDNA from single embryos 24 hours post injection, were subjected to digestion by MwoI. 
The uncut PCR product of approximately 250 base pairs is shown in lanes 1-4. Uninjected controls cut with 
MwoI gave complete digestion, leaving two products of similar sizes at 125bp mark (Lanes 6-9). TALEN-
injected embryos (Lanes 10-15) resulted in incomplete digestion in all embryos examined, implying MwoI 
site had been mutated by the TALEN in a highly efficacious way. 
To confirm TALEN efficacy, PCR products of the target site using gDNA, pooled from 
8 TALEN injected embryos, were sub-cloned into a Topo-ta vector, transformed into 
competent cells and plated then incubated overnight. Seventy-three colonies were 
picked for colony PCR and sequenced. Out of 73 colonies, 64% were WT, 23% 
contained deletions, and 13% contained a combination of insertions and deletions. No 
clones could be identified that contained insertions exclusively.  The TALENs had a 
mutation generation rate of 33% in the pooled F0 mosaic embryos. The gba1 TALEN 
produced a wide variety of different mutations; the largest alteration being a 77bp 
deletion. For a summary of the different gba1 mutations caused by the TALEN and 















	  	   TOTAL	   %	   Description	  
WT	   47	   64	   N/A	  
DELETION	   17	   23	   3,6,7,10,17,29,68,77bp	  del	  
INSERTION	   0	   0	   N/A	  
DEL	  +	  INS	   9	   13	  
22bp	  del	  +	  46bp	  ins,	  22bp	  del	  +	  4bp	  ins,	  8bp	  del	  +	  5bp	  ins,	  
	  5bp	  del	  +	  8bp	  ins,	  3bp	  del	  +31bp	  ins,	  51bp	  del	  +	  7bp	  ins,	  	  
39bp	  del+8bp	  ins,	  5bp	  del	  +	  8bp	  ins	  
Table 7. TALEN mutation type summary. The total incidence of each mutation type (WT, deletion, 
insertion, deletion & insertion) for all sequenced clones, and their percentage incidence. 
4.4.2 gba1 TALEN founder identification 
Once TALEN efficacy had been established and confirmed, 50 TALEN injected 
embryos (F0) were raised to breeding age. In order to determine whether TALEN 
mutations were transmitted to the germ line, F0 mosaic adults were crossed with WT 
adult zebrafish and 8 embryos from each cross was analysed by restriction digest. Each 
digest was compared to an undigested product. See  
Figure 50 for representative digests of founder identification. 
Eleven initial F0 TALEN-injected adults were crossed with WT zebrafish. Restriction 
digest identified 9 founders, the transmission rate being 81%. Some of the digests 
showed the presence of multiple products, implying the founder transmitted an allele 
to the germ line containing a large deletion (see  
Figure 50). Although a deletion or insertion of 1bp is only required for a frameshift 
mutation that can produce a premature stop codon, a large deletion or insertion would 
allow the resulting allele to be genotyped by analysing of product sizes of the PCR 
product, without the need for restriction digests (that can be effected by SNPs in the 
restriction site) or direct sequencing. Being able to genotype by PCR would be 
considerably cost and time effective. Consequently, the founder strategy was altered, 
to simply amplify the TALEN region and identity F0 individuals whose outcrossed 
progeny produced 2 PCR products of different sizes (indicating a large insertion or 
deletion). A total of 26 F0 individuals were outcrossed and the embryos were analysed 
by PCR. Eleven were definite founders confirmed by digest, 3 were non-transmitting 
F0 individuals, and 12 were potential founders unconfirmed by digest. A further 9 
individuals were outcrossed however did not produce offspring. Three founders were 







Figure 50. Founder identification restriction digests. Representation gels of founder identification using 
primers situated around the TALEN-targeted MwoI site of gba1. TALEN injected adult (F0) were 
outcrossed to WT individuals and the resultant progeny (F1) utilised for gDNA isolation and subsequent 
PCR of the TALEN region for restriction enzyme analysis. Gel A, An example of a PCR of F1 gDNA of 3 
individual embryos from a non-transmitting F0 TALEN injected individual, alternating between 
undigested  (Lane 1, 3 5) and MwoI-digested PCR product (5µl) (Lane 2, 4, 6). WT PCR product gives 
complete digestion of the PCR product indicating no indels are present in the restriction site. Gel B,  an 
example of a PCR of F1 gDNA from 7 individual embryos from a transmitting F0 TALEN-injected fish 
crossed with WT fish, alternating between undigested (Odd lanes, 1, 3, 5 etc.) and digested (even lanes, 2, 
4, 6 etc.) with MwoI. Note lanes 2 and 4 contains residual undigested PCR product indicating the presence 
of an indel within the restriction site, identifying the F0 injected fish as a mutation founder. Gel C, PCR of 
F1 embryos, F0 TALEN-injected fish crossed with WT fish, alternating between undigested (Odd lanes, 1, 
3, 5 etc.) and digested (even lanes, 2, 4, 6 etc.) with MwoI. Note lanes 2, 4 and 8 not only contains residual 
undigested PCR product (indicating the presence of an indel within the restriction site), identifying the F0 
injected fish as a mutation founder. But also contains a second PCR product, indicating the allele is a large 






4.4.3  gba1 TALEN allele selection 
Three separate alleles were identified in the F1 generations; a 7, 8 and 23bp deletion 
(del), see 
 
Figure 51 for the sequence alterations.  The 23bp del had the additional advantage of 
being so large that it could be genotyped by PCR without further downstream 
techniques such as restriction digest or direct sequencing. The 7bp del alleles were 
present in both sexes in the F1 outcross so were subsequently incrossed to generate 
homozygous mutants and to investigate if the allele phenocopied the sa1621 allele.  
Embryos were monitored daily to check for potential deformity and mortality. All 
individuals in 7bp del incross developed normally. At 4 wpf, 20% of the incross looked 
comparatively small and underweight. A 7bp del outcross tank was used for a 
comparison.  From the preliminary incross, a total of 32 individuals were raised to 
8wpf and genotyped. 10 were WT (31%), 17 were 7bp del gba1 -/+ (53%) and 5 were 
























exhibited abnormal corkscrew like motions seen in the sa1621 gba1 -/-. Eventually all 
7bp del gba1 -/- had to be culled at 12 wpf.  
Due to an extremely skewed sex distribution, only females possessing the 23bp del 
allele could be identified in the F1 outcross, so a further outcross to F2 with WT had to 
be performed before a successive incross could be made. Only a single individual 
contained the 8bp del allele, so this was also outcrossed to generate the F2 generation. 
Once the F2 23bp del gba1 -/+ had grown to adulthood, they were incrossed to see if the 
23bp del gba1 -/- produced a similar phenotype to the 7bp del gba1 -/- and sa1621 gba1 -
/-. A total of 46 individuals were grown to 8 wpf and genotyped.  Of these, 20% of the 
incross appeared underweight and smaller compared to a control outcross tank. Once 
genotyped, 14 were WT (31%), 21 were 23bp del gba1 -/+ (45%) and 11 were 23bp del 
gba1 -/- (23%). All 23bp del gba1 -/- developed cork screw like motions that became 
uncontrollable so had to be culled, in an identical manner to 7bp del gba1 -/- and sa1621 
gba1 -/- . The eldest 23bp del gba1 -/- was culled at 14wpf. See Videos 3 and 4 for 
examples of 23bp del gba1 -/- impaired mobility. 
Both the 7bp del gba1 -/- and 23bp del gba1 -/- phenocopied the sa1621 gba1 -/- alleles. It 
was decided to use the 23bp del allele for subsequent studies, as genotyping could be 
performed by PCR alone without the need for restriction enzyme digestion, see Figure 
10, and the phenotype matched the phenotype observed in the other gba1 mutant 
genotypes.  To genotype the 7bp del and 8bp del required a MwoI digest and sa1621 
genotyping required direct sequencing.  Although all the different gba1 -/- mutant 
strains survive to adulthood, they all had to be culled at approximately 3 months of 
age and were seemingly unable to produce embryos. Consequently, all studies had to 
be performed from a 23bp del gba1 -/+ incross, with each subsequent embryo requiring 
genotyping, as opposed to using 23bp del gba1 -/- adults to generate 23bp del gba1 -/- 
embryos.  The 23bp allele was outcrossed to WT again to produce the F3 23bp del gba1 
-/+. All subsequent experiments were performed on the F3 incross. No further 
experiment utilised the gba1 sa1621 line, as all embryos that would be genotyped 





Figure 51. F1 TALEN-induced gba1 mutants. The genomic gba1 exon 7 sequence illustrating TALEN 
deletions that transmitted to the F1 generation.  Outcrossing F0 injected to WT in order to generate the F1 
generation led to 3 different alleles being identified for further study, namely 8, 7 and 23bp deletion, all 
within exon 7. The MwoI site is highlighted in green and deleted bases in red script. 
4.5 gba1 TALEN characterisation  
4.5.1 gba1 qPCR in gba1 -/- and WT brain tissue 
The 23bp deletion leads to a frameshift and appearance of a premature stop codon 
66bp downstream within exon 7 at c.1342, truncating the protein at position p.379 (WT 
is 518 amino acids in length). qPCR was utilised to demonstrate the stop codon led to 
nonsense mediated decay of the transcript. As it was unknown how the deletion may 
affect splicing, two pairs of primers were optimised. The first pair amplifying a region 
upstream of the deletion, the primers binding to exon 4, and the second pair binding to 
exons 8, 9 and 10, downstream of the deletion. RNA was extracted from 12 wpf brain 
























pair showed a decrease in gba1 transcript levels of 50% (P<0.05) in the gba1 -/- brain 
tissue compared to WT, indicating that the gba1 mRNA transcript is unstable due to the 
appearance of a premature stop codon, suggestive of loss of function. See Figure 52. 
 
Figure 52.  qPCR of gba1 transcript in WT and gba1 -/- brains. qPCR was utilised to investigate the 23bp 
del allele effect on stability of the gba1 mRNA transcript. Primer pairs amplifying cDNA downstream of 
the deletion (Figure 52A) and upstream the deletion (Figure 52B) were utilised to quantify gba1 transcript 
levels in WT and gba1 -/- adult brains. Both primer pairs demonstrated a decrease of 50% (P<0.05 unpaired 
t test) of the gba1 transcript in gba1 -/- compared to WT, thus demonstrating that the mutation leads to 
mRNA instability and NMD, supporting the assumption that this 23 bp deletion results at least in partial 
loss of function. Data normalised to reference gene ef1alpha 
4.5.2 Gba activity assay optimisation 
Brain homogenates were utilised to assay Gba enzyme activity to quantify the loss of 
Gba1 activity due to the 23bp deletion, the assay itself had only previously been 
optimised for mammals; therefore, temperature and inhibitors required for the assay 




determined by subtracting GBA2 inhibited activity from total GBA activity, using the 
specific GBA2 inhibiter N-Butyldeoxynojirimycin (DNJ). As this can be low, activated 
GBA1 activity is calculated by measuring total GBA activity in the presence of sodium 
taurocholate (NaT), an inhibitor that simultaneously inhibits GBA2 whilst activating 
GBA1. This can allow large improvements in signal to noise ratio.  
Firstly, the assay temperature was assessed at 37°C (mammalian body temperature) 
and 28°C (zebrafish body temperature). Total Gba activity in zebrafish at 37ºC was 
approximately 37 nmol/h/mg, whilst DNJ inhibited Gba activity was extremely low, 
even for basal Gba1 activity, at 5 nmol/h/mg. Upon inhibition with NaT, Gba1 activity 
was unchanged to basal Gba1 activity, when theoretically there should have been a 
marked Gba1 activity increase. Total Gba activity at 28°C was 55% lower than activity 
at 37ºC, with similar decreases in activity in DNJ inhibited at 28°C compared to 37ºC. 
Conversely, NaT activated Gba1 had 50% more activity at 28ºC (10.25 nmol/h/mg) 
compared to NaT activated at 37°C. Although total Gba activity was lower at 28°C, this 
temperate was chosen for future experiments as it is more physiologically relevant to 
study activity in zebrafish, and NaT appeared to be more in zebrafish at 28ºC, see 





Figure 53.Gba activity assay temperature optimisation. Temperature optimisation for the GBA activity 
assay. Total (T) Gba activity at 37°C is much higher than at 28ºC (the optimum zebrafish body 
temperature). Basal Gba1 activity (DNJ inhibited) is unexpectedly low compared to total Gba activity, only 
10% of total Gba activity. NaT simultaneously inhibits GBA2 activity and activates GBA1 activity in 
mammals. Gba1 activated at 37°C does not raise Gba1 activity; conversely, the NaT treatment at 28 degrees 
raises it to 75% of total Gba activity. 
The DNJ dose was revaluated over a range of increasing concentrations, to investigate 
whether there may be any residual Gba2 activity. The standard dose of 50uM was 







Figure 54. DNJ optimisation. The standard DNJ dose of 50µM is currently utilised in mammalian GBA 
assays. The dose was increased to investigate if further inhibition was required to prevent any residual 
Gba2 activity. 50µM DNJ reduced Gba activity to 33% of total uninhibited Gba activity. Increasing the 
concentration of the inhibitor to doses of 100, 150 and 200µM of DNJ had minimal further effects at 
decreasing Gba activity demonstrating 50uM is sufficient to inhibit all Gba2 activity. 
Subsequent studies found NaT to be highly variable at modulating Gba activity, 
occasionally giving activity readings as low, or even lower than DNJ treatment groups 
(data not shown). To further optimise NaT-activated Gba1 activity, Triton X- 100 was 
tested. Triton X has been utilised in previous studies to further increase the action of 
NaT on Gba1 activity.291 The addition of Triton X-100 to the NaT treatment led to a 
decrease of Gba activity compared to using NaT alone. Therefore, presence of Triton X-
100 clearly does not give robust Gba1 activity enhancement when utilised in 





Figure 55. Triton X-100 effect on Gba1 activity. To further increase activated Gba1 activity, a combination 
of NaT and Triton X-100was applied to zebrafish brain homogenates. DNJ reduced Gba1 activity to 6% of 
the total, whilst NaT raised the activity to 38% of the total. In contrast, a combination of NAT and TRITON 
X only raised the activity to 26% of total activity. Triton X-100, therefore, does not enhance the ability of 
NaT to activate Gba in zebrafish. 
The concentration of NaT was also re-evaluated, as more concentrated doses may be 
required to fully inhibit Gba2 and activate Gba1 in zebrafish. Increasing concentrations 
of NaT, up to 120mg/ml (from 40mg/ml) only decreased Gba activity to nearly 
background levels, in a similar manner to DNJ inhibited activity, see Figure 56. 
 
Figure 56. NaT re-optimisation. To further enhance Gba1 activity whilst inhibiting Gba2 in zebrafish, 
increasing concentrations of NaT were assayed with zebrafish brain homogenates. Increasing the 
concentration from 40mg/ml up to 160mg/ml meant that Gba activity decreased with increasing NaT 
concentrations, to levels barely above background, in a similar manner to DNJ inhibited activity. 
As both inhibitors at standard concentrations showed Gba1 basal activity is very low, 




the standard concentrations for the Gba activity assays on mutant brain tissue.  Total 
Gba activity was substantially reduced in DNJ and NaT treatment groups compared to 
uninhibited total Gba activity. Within treatment condition activity was unchanged 
between each genotype. These data imply the 23bp del does not lead to a loss of 
function of Gba1, in contrast to the qPCR data. However, the Gba activity assay may 
provide false negative data due to the assumption that both inhibitors function in a 
similar manner in zebrafish as they do in mammals. This has yet to be validated.  
 
Figure 57. DNJ and NaT sensitive Gba activity in gba 23bp del genotypes. Using DNJ and Nat to inhibit 
Gba2 activity, no change in Gba1 activity could be detected in any of the gba 23bp del genotypes. 
Consequently, the Gba1 activity assay was performed again, utilising different 
inhibitors that may behave in a similar manner in zebrafish as they do in mammals. 
CBE, an specific inhibitor of GBA1 in humans was employed to deduce the Gba1 
sensitive fraction of each homogenised brain and thus deduce Gba1 activity. This 
experiment was jointly undertaken between the author and Dr Matthew Gegg. The 
author performed the brain extractions, genotyping and processing. Dr Matthew Gegg 
performed and analysed the assay. CBE sensitive Gba activity was reduced by 50% 
compared to WT in both 23bp del gba -/+ and 23bp del gba -/- (P<0.05 one way anova), 





Figure 58.  CBE sensitive, Gba activity in 23bp del gba genotypes. CBE sensitive Gba activity, 
representative of Gba1 activity in other species was reduced 50% in both 23bp del gba -/+ and 23bp del gba 
-/- (P<0.05 one way anova) compared to WT, demonstrating the deletion leads to a loss of function. 





4.5.3 gba1 23bp del gba -/- TH count at 5dpf 
Incross of gba1 23bp del gba1 -/+ (and all other TALEN alleles) develop normally 
through embryogenesis. No embryos showed signs of developmental delay or 
deformity. TH neuron count at 5dpf in gba1 23bp del gba1 -/- showed no decrease 
compared to WT or gba1 -/+. To confirm this data, gba1 8bp del genotypes also had 
their TH neurons analysed that also showed no decrease in gba1 -/-, compared to WT or 
gba1 -/+, see Figure 59. 
 
Figure 59. TH neuron counts in TALEN alleles at 5dpf. Figure 59A, 23bp del genotypes shows no 
decrease in TH neuron count in gba1 -/- and gba1  -/+ compared to WT. Figure 59B, 8bp del genotypes 






4.5.4 TH neuron count at 12 wpf in gba1 genotypes 
In order to assess TH neuron count at older ages, TH-positive neuronal cells were 
stained by IHC and analysed by confocal microscopy at 12 wpf. TH positive neurons 
were counted by Sallinen’s definition.120  The experiment was jointly performed by the 
author and Dr Yu-Chia Chen. The author performed the genotyping, brain extraction 
and fixation. Dr Yu-Chia Chen performed the IHC. The caudal zone of the 
periventricular hypothalamus was also analysed for TH neuron count in WT (n=10), 
gba1 -/+ (n=12) and gba1 -/- (n=13). WT and gba1 -/+ showed no difference in the 
number of TH positive cells counted in this region. gba1 -/- show a marked decrease in 
TH1-positive neurons compared to WT, with a decrease of 50% (P<0.01, one way 
ANOVA) (Figure 60A). TH1 positive neuronal cells were counted in the posterior 
tuberculum in all genotypes. gba1 -/- showed a 25% decrease in TH neurons compared 
to WT (p<0.01, one way ANOVA, n= 12 and 10 respectively). gba1 -/+ showed no  





Figure 60. TH neuron counts in 12 wpf gba1 genotypes. TH1 positive cells were counted in the brains of 
12 wpf gba1 -/-,gba1 -/+ and WT in the caudal hypothalamus (A) and the posterior tuberculum (B). In both 
regions gba1 -/- exhibited a decrease of 40-50% compared to WT (P<0.01), whilst gba1 -/+ showed no 
decrease compared to WT in the caudal hypothalamus and a slight, non-significant increase of 10% in the 
posterior tuberculum. gba1 genotype n numbers for caudal hypothalamus counts for WT, gba1 -/+ and gba1 
-/- were 9, 12 and 13 respectively. gba1 genotype n numbers for posterior tuberculum counts for WT, gba1 -
/+ and gba1 -/- were 10, 13 and 12 respectively.   
4.5.5 Microglial shape in gba1 -/- larvae 
To assess if Gaucher like cells appear during embryological stages in gba1 -/- larvae, 
gba1 -/+ were crossed with the Tg(mpeg1:EGFPcaax) transgenic reporter line that 
simultaneously labels microglia and macrophages with GFP. This experiment was 
jointly performed by the author and Dr Felix Ellett. Imaging and analysis was 






Tg(mpeg1:EGFPcaax) were incrossed and microglial/macrophage morphology was 
assessed at 4dpf by confocal microscopy in all gba1 genotypes. Three separate fields of 
view were analysed for each embryo, specifically the tail, the trunk and the head. 
Macrophages/microglia were analysed for a different morphological markers, 
including shape and volume. No differences were found between WT and gba1 -/- for 
cell shape or volume in either the tail or trunk. However, in the head, these GFP 
positive cells, most likely microglial, had normal volume in all gba1 genotypes, 
however gba1 -/+ and gba1 -/- both had a decrease in their spherical shape compared to 
WT (P<0.05 and P<0.01 respectively, one way ANOVA), see Figure 61. 
 
Figure 61. Shape factor of GFP positive cells in the head of each gba1 genotype. gba1 -/+ and gba1 -/- 
exhibited a decrease in shape factor compared to WT when analysed in the head of 4dpf larvae.  WT 
microglia had an average shape factor of 0.2417 (47 GFP positive cells from 6 individuals), with gba1 -/+ 
(140 GFP positive cells from 14 individuals) and gba1 -/- (91 GFP positive cells from 10 individuals) having 
a smaller shape factor of 0.2087 (P<0.05) and 0.1997 (P<0.01). This demonstrates that gba1 -/+ and gba1 -/- 
GFP positive cells have a less spherical shape when compared to WT. 
4.5.6 Mass measurements of 23bp del gba1 genotypes 
Pilot data from 7bp del and sa1621 incross showed the gba1 -/- developing a decrease in 
mass compared to WT. Mass measurement of the gba1 23bp del genotypes was 
undertaken at 9 and 12 wpf. The 23bp del gba1 -/- (from here on referred to as gba1 -/-) 
showed a decrease in mass at 9 wpf (30% decrease P<0.05) see  
Figure 63. The incross was genotyped at 10wpf and all animals were segregated by 
genotype in separate tanks.  The mass of the gba1 -/- was normalised to WT fish by 12 
wpf, after segregation of genotypes into separate tanks. This demonstrates the decrease 




they were out competed for the limited food supply by their gba1 -/+ and WT. 
Additionally, it was noted that food fed during the afternoon was not completely eaten 
by the next morning in the gba1 -/- tank, whereas it was in the WT and gba1 -/+ tank. By 
12 wpf, all gba1 -/- developed a curve in their spine, similar to the gibbus seen in 
conditional Gba1 KO mice see Figure 62.264 
 
Figure 62. Photographs of 12 wpf WT and gba1 -/-. WT individuals (Figure 62A) did not display any 
gross morphological deformities at 12 wpf.  By 12 wpf many gba1 -/- exhibited a visible curve to their 
spine (Figure 62B), with a small minority even having an asymmetrical body axis. The spinal curvature is 





Figure 63. Mass of 23bp del gba1 allele at 9 and 12 wpf. The mass of each genotype at 9 wpf (A) and 12 
wpf (B).  gba1 -/- show a significant decrease in mass compared to WT at 9 wpf (P<0.05, one way 
ANOVA, WT:16, gba1 -/+:10, gba1 -/-:26). The gba1 -/- mass normalises by 12 wpf, once they had been 
genotyped and put into genotype specific tanks. WT:27, gba1 -/+:25, gba1 -/-:24. 
4.5.7 Movement analysis in gba1 genotypes 
Total displacement for each gba1 genotype was assayed via video tracking software at 
12 wpf. Each fish was filmed for ten minutes, with ten minutes tank habituation. gba1 -
/- showed a striking 60% decrease in total displacement compared to WT (P<0.0001). 
gba1 -/+ fish demonstrated an intermediate phenotype with a small and non-significant 
decrease of 25% compared to WT (Figure 64A). Subsequently, activity phases were 
combined into large, small and inactive movements. WT fish spent a large proportion 






opposite trend for inactive phases (P<0.0001), gba1 -/+ fish had an intermediate 
phenotype in both movements compared to WT and gba1 -/-. All genotypes spent 





Figure 64. Total displacement of gba1 genotypes. Total displacement and activity levels during 
spontaneous movement of gba1 genotypes at 12 wpf.  A, gba1 -/- exhibit a large decrease of total 
displacement of approximately 60% compared to WT (P<0.0001, one-way ANOVA), gba1 -/+ fish 
demonstrating a smaller, non-significant decrease of 25%.  When average speeds where combined into 3 
phases of activity (B), inactive, small and large movements, the large decrease in the gba1 -/- total 
displacement was revealed to be due to more time in the inactive phase (P<0.0001) and fewer large 
movements (P<0.0001) compared to the WT. 
4.5.8 Hematoxylin and Eosin (H&E) sections of gba1 23bp del genotypes 
To further understand the severe phenotypes exhibited by the gba1 -/-, H&E staining 
was conducted on sections taken from samples at 4, 9 and 12 wpf. No obvious 






4wpf individuals. This was jointly undertaken between the author and Dr Aswin 
Menke. The author genotyped and processed the fish, Dr Aswin Menke performed the 
staining and analysis.  
By 9 wpf (when the abnormal motor phenotype with cork screw motions first became 
apparent) gba1 -/- develop aggregates of swollen cells with some resemblance of 
Gaucher’s cells, the engorged macrophages seen in GD. These Gaucher-like cells form 
clusters in specific organs in the zebrafish body. This is most apparent in the brain, 
where these swollen cells accumulate specifically in the tectal ventricle (n=7). No 
Gaucher like cells could be detected in either gba1 -/+ or WT individuals (n=5). 
Gaucher-like cells were also detected most notably in the thymus of gba1 -/- 9 wpf fish, 
with some individuals (although not all) exhibiting these accumulations in the liver, 
spleen, pancreas and gonads. No Gaucher-like cells could be detected in either gba1 -/+ 
or WT 9 wpf fish (n=5). See Figure 65 for a representative example of Gaucher like cells 






Figure 65. Gaucher like cells in 9 wpf gba1 -/- brain. H&E staining  brain of 9 wpf gba1 -/- demonstrating 
the presence of Gaucher like cells (white arrows) in the tectal ventricle. Staining and analysis was 
performed by Dr Aswin Menke, genotyping and fixation by the author. 
At 12 wpf, the pathology in the gba1 -/- individuals had worsened, with lesions 
appearing in the brain (see Figure 66). Gaucher-like cells were aggregated in the 
thymus and liver of all individuals (n=5), whilst more (although not all) individuals 
presented with aggregates in the spleen, pancreas and gonads, n=3, 4 and 4 
respectively (see Figure 67).  Periodic acid–Schiff (PAS) staining showed a build-up of 
glycolipids within the aggregated cells, presumably of the undigested 
glucocerebroside. At 12 wpf, the gba1 -/+ fish showed minor cellular swelling in the 












Figure 66. H&E sagittal brain sections of 12 wpf gba1 -/+ genotypes.  At 12 wpf, Gaucher-like cells and 
lesions accumulating in the tectal ventricle in gba1 -/- (white arrows), gba1 -/+.exhibit minor cellular 
















Figure 67. Gaucher like cells in 12 wpf gba1 -/- visceral organs. H&E staining of liver, thymus and 
kidneys of 12 wpf gba1 -/- demonstrating the presence of Gaucher like cells (black arrows). Staining and 
analysis was performed by Dr Aswin Menke, genotyping and fixation by the author. 
4.6 Biochemical phenotypes of gba1 23bp del genotypes 
4.6.1  Enzyme activities of classical GD biomarkers 
In Gaucher’s disease patients, chitotriosidase activity and total β-hexosaminidase 
activity are utilised as biomarkers to assess the effects of enzyme replacement therapy. 



























these enzymes, with decreases throughout the course of treatment. The activities of 
both were analysed in the brain tissue of 12 wpf gba1 -/-, gba1 -/+ and WT controls.  
Both classical GD biomarkers were markedly upregulated in the gba1 -/- brains, 
compared to WT, see  
Figure 68. Chitotriosidase had, on average, a ten-fold increase in activity in the gba1 -/- 
compared to WT and gba1 -/+ (P<0.00001). Total β-hexosaminidase was also markedly 
elevated in the gba1 -/-, by 4 fold compared to WT (p<0.00001. β-galactosidase was 
additionally assayed in all gba1 genotypes as a control enzyme, no significant increase 
or decrease in activity could be identified compared to WT (n=8 per genotype), see 
Figure 69. 
Both biomarker assays for chitotriosidase and β-hexosaminidase are ideal read outs for 
high-throughput screening, due to their low cost, low technical difficulty and minimal 
material requirements. As the gba1 -/- exhibited such a marked increases in enzyme 
activity, it was hypothesised this may be the case in 5dpf larvae. This would be a fast 
simple and effective readout for zebrafish chemical screens, potentially able to identify 
new chemical treatments for treatment of GD. Single larvae from a gba1 -/+ incross 
were assayed for total β-hexosaminidase activity at 5dpf, the homogenate was then 
utilised to genotype all individuals. In contrast to the 12 wpf, gba1 -/- brains, enzyme 






Figure 68. Total chitotriosidase and β-hexosaminidase activity in gba1 genotypes. gba1 -/- brain tissues 
show marked elevation of traditional Gaucher’s disease biomarkers at 12 wpf. A, total chitotriosidase 
activity is elevated by 10 fold compared to WT in gba1 -/- brains (P<0.00001) with no significant difference 
in activity between WT and gba1 -/+. B, total β-hexosaminidase activity is elevated 3.5 fold in gba1 -/- 
brains compared to WT (P<0.00001). β-hexosaminidase and chitotriosidase activity was assayed in all gba1 







Figure 69. β-Galactosidase activity in gba1 genotypes. β-Galactosidase activity was assayed in all gba1 
genotypes (n=8). Activity in gba1 -/- exhibited a small, non-significant increase of 20% in activity compared 
to WT. In contrast, activity in gba1  -/+ exhibited a slight non-significant decrease in activity compared to 
WT of approximately 10%. 
Figure 70. Total β-hexosaminidase activity in 5dpf larvae. β-hexosaminidase activity was measured in all 
gba1 genotypes at 5dpf. No significant difference in activity was detected between WT, gba1 -/+ and gba1 -/-
, n= 7, 8 and 7 respectively.  
4.6.2 Classical GD biomarkers are unchanged in pink1 -/- 
Chitotriosidase activity is upregulated in activated macrophages and microglia. pink1 -




Chitotriosidase activity was measured in pink1 -/- homogenates of 20 larvae at 5dpf 
compared to WT. pink1 -/- homogenates had no significant changes in activity 
compared WT. See Figure 5. Clearly Chitotriosidase activity is not a suitable read of for 
phenotypic drug screens in pink1 -/-. 
Total β Hexosaminidase activity, another GD biomarker was assayed for in the pink1 -
/- 5dpf homogenates as a possible drug screen read out. Total β Hexosaminidase has 
previously been shown to decrease in cerebrospinal fluid in sporadic PD patients. 11 
The assay is preferable as a drug screen read out due to its requirement for very small 
tissue samples (5µl homogenate of 2mg/ml protein) and the speed of assay (10 
minutes). Total β Hexosaminidase activity was unchanged between pink1 -/- and WT, 





Figure 71. Chitotriosidase and beta hexosaminidase activities in pink1 -/- and WT. Figure 71A, pink1 -/- 
show no significant change in activity compared to WT. Figure 71B, total β-hexosaminidase activity is 
unchanged between pink1 -/- and WT. 
4.6.3 Mass spectrometry analysis of sphingolipid metabolites in gba1 alleles 
Sphingolipid metabolites were analysed by mass spectrometry in 12 wpf gba1 -/-, gba1 -
/+ and WT brains to further elucidate the biochemical consequences of gba1 deficiency. 
This was jointly undertaken between the author and Dr Hai Bui, the author genotyped 
extracted and processed the brain samples, Dr Hai Bui performed the mass 
spectrometry and subsequent analysis. gba1 -/- showed large dysregulation of most 
analysed metabolites compared to WT and gba1 -/+ with highly elevated levels of 






lactosyceramide and gangliosides compared to WT (P<0.00001). Low molecular weight 
dihydroceramides (C14:0 to C18:0), ceramides (C14:0 to C20:0) and galactosylceramide 
(C16 and C18) also show a high accumulation in gba1 -/- brains compared to WT. 
However, high molecular weight dihydroceramides (C22:0 to C24:0), ceramides (C22:0 
to C24:0) and galactosylceramide (C20 and C24), are all decreased in the gba1 -/-, 
showing a reduced levels compared to WT. All changes were statistically significant, 
with the exception of the decrease in in dihydroceramides (C22:0 to C24:0), ceramides 
C20 (increase), C23 and C24:1 (decrease). gba1 -/+ brains showed few differences 
compared to WT, with the exception of galactosylceramide C20 and C22 that were 





Metabolite gba1 -/- % change Significance gba1-/+ % change Significance 
Sph 101.8257993 **** 7.616997247 ns 
Sa 32.12020523 ** -4.598635528 ns 
HexSph 2734.134563 *** 0 ns 
S1P -12.79776202 * 6.388802447 ns 
DHCer (C16:0) 78.44923164 ** -15.21157476 ns 
DHCer (C18:0) 74.38079648 * -20.52226775 ns 
DHCer (C22:0) -39.17801471 ns 30.96156414 ns 
DHCer (C24:1) -19.22123153 ns 9.932727669 ns 
DHCer (C24:0) -38.92186153 ns -10.83898132 ns 
Cer (C14:0) 135.044829 **** 21.67382643 ns 
Cer (C16:0) 102.6808401 **** -2.431257609 ns 
Cer (C18:0) 41.85715181 **** -4.648751669 ns 
Cer (C18:1) 115.8841224 **** 16.62848969 ns 
Cer (C20:0) 20.30314387 ns -5.203168812 ns 
Cer (C22:0) -44.29546135 ** 15.39658039 ns 
Cer (C23:0) -25.30982469 ns 8.456590168 ns 
Cer (C24:1) -4.024969258 ns 9.362985403 ns 
Cer (C24:0) -31.4830211 * 6.93120657 ns 
HexCer (C14:0) 1382.157511 **** 11.41672443 ns 
HexCer (C16:0) 3466.013156 **** 2.801254756 ns 
HexCer (C18:0) 7957.318434 **** 20.38332697 ns 
HexCer (C20:0) 549.0958593 **** 15.68309227 ns 
HexCer (C22:0) 27.33122019 *** 7.07047193 ns 
HexCer (C23:0) 9.431597549 ns 10.71208532 ns 
HexCer (C24:1) 42.95955413 **** 9.658944035 ns 
HexCer (C24:0) -22.35357736 * 6.195719944 ns 
GlucosylCer (C14:0) 210.373226 **** 4.391630775 ns 
GlucosylCer (C16:0) 9882.521703 **** 21.61574145 ns 
GlucosylCer (C18:0) 14514.04145 **** -7.169052539 ns 
GlucosylCer (C20:0) 2885.8451 **** 14.79933588 ns 
GlucosylCer (C22:0) 529.5906243 **** 15.11069321 ns 
GlucosylCer (C23:0) 348.5546373 **** 13.87395725 ns 
GlucosylCer (C24:1) 421.7412698 **** 18.88677559 ns 
GlucosylCer (C24:0) 112.0538577 **** 9.617032105 ns 
GalactosylCer (C16:0) 46.97169221 * 5.671671856 ns 
GalactosylCer (C18:0) 112.6041678 **** 6.572369034 ns 
GalactosylCer (C20:0) -39.80263245 **** 18.063784 * 




Metabolite gba1 -/- % change Significance gba1-/+ % change Significance 
GalactosylCer (C23:0) -48.38752436 **** 15.8204541 ns 
GalactosylCer (C24:1) -45.28273411 *** 20.61044589 ns 
GalactosylCer (C24:0) -55.09351962 **** 9.281332468 ns 
LacCer (C16:0) 989.8202929 **** 19.43392737 ns 
LacCer (C18:0) 2092.221844 **** 4.76117511 ns 
LacCer (C20:0) 1481.346375 **** 10.68494713 ns 
LacCer (C22:0) 601.1440845 **** 14.79503812 ns 
LacCer (C23:0) 295.3751503 **** 0.579652139 ns 
LacCer (C24:1) 292.0227223 **** 15.53764801 ns 
LacCer (C24:0) 340.8251407 **** 25.00821108 ns 
GM3 (C16:0) 226.7453547 **** -8.165992634 ns 
GM3 (C18:0) 230.2296156 **** 9.119074479 ns 
GM3 (C22:0) 458.1100752 **** -22.58397659 ns 
GM3 (C24:1) 351.4096211 **** 25.46355691 ns 
GM3 (C24:0) 263.9855849 **** -6.904832976 ns 
 
4.6.4 Mitochondrial Complex activities in gba1 genotypes 
Mitochondrial dysfunction has been demonstrated in familial forms of PD as well as 
GD mouse models.284, 285 The activity of each Complex of the mitochondrial electron 
transport chain was analysed in each gba1 23bp deletion genotype. This was jointly 
undertaken between the author and Dr Marc DaCosta. The author genotyped, 
extracted and processed the samples, Dr Marc DaCosta performed the mitochondrial 
Complex assays and subsequent analysis. Activities of mitochondrial Complex I and II 
were unchanged between WT, gba1 -/+ and gba1 -/- 12 wpf brains (Figure 72 A and B). 
In contrast, there was a specific decrease of 40% compared to WT of the activity in 
Table 8. Sphingolipid metabolite changes in gba1 -/- and gba1 -
/+ brains. Brains of 12 wpf gba1 -/-,gba1 -/+ and WT were analysed 
by mass spectrometry for changes in sphingolipid metabolites 
(n=10 for all genotypes).  The gba1 -/- brains showed marked 
dysregulation of metabolites, with a large accumulation of Gba1 
substrate compared to WT. The gba1 -/+ group showed a trend 
toward some changes compared to WT however these were not 
statistically significant. There were exceptions to this including a 
80% decrease in GalactosylCer (C20:0) and GalactosylCer (C22:0) 
compared to WT, P<0.05.  Abbreviatios, Sph: Sphingosine, Sa: 
Sphinganine, Hexsph: Phycosine, S1P, Sphingosine 1 Phosphate, 
DHcer: Dihydroceramide, Cer: Ceramide, HexCer: 
Heoxsylceramide, Glucosyl: Glucosylceramide, Galaccer: 


















mitochondrial Complexes III and IV (P<0.05). gba1 -/+ brains showed no significant 
differences compared to WT. See Figure 72 C and D.  
 
Figure 72. Mitochondrial Complex activities I-IV in gba1 genotypes. Activity of mitochondrial Complex 
I, II, III and IV were analysed in 12 wpf gba1 -/-, gba1 -/+ and WT brains. No statistical differences were 
found between genotypes in Complex I and II activity (A and B). gba1 -/- showed a large decrease of 50% 
in both Complex III and IV compared to WT (P<0.05 one way ANOVA) (C,D). gba1 -/+ showed no 
significant decreased compared to WT.  
4.7 gba1 results summary 
This study represents the first characterisation of a gba1 loss of function model using 
teleost fish.  All previous loss of function in vivo models had either utilised Drosophila 
or mice. Zebrafish were found to possess a single gba1 orthologue, with conserved gene 
synteny, whose expression was low, but consistent and not spatially restricted, at least 
during early development. gba1 KD was found to not lead to substantial Th neuron 
reduction or synergistically increase Th neuron reduction seen in Complex I inhibited 






resultant allele produced juvenile fish with a marked movement phenotype and early 
lethality. H&E staining revealed many Gaucher like cells appearing in key GD organs 
as well as the brain. Mass spectrometry of sphingolipids showed accumulation of 
many metabolites in the sphingolipid pathway including gba1 substrates within the 
brains of 12 wpf gba1 -/-. This was accompanied by large increases in GD biomarkers. 
TH neuron count revealed a large decrease in the brain of gba1 -/-, which may be a 












The aims of this research project were to establish the zebrafish as a new model for 
pink1 and gba1 deficiency; identify phenotypes of the resulting mutants; investigate 
potential new genetic interactions; and establish assays for phenotypic drug discovery. 
Both projects were successful in establishing loss of function models for the relevant 
gene, and mutants were characterised to investigate how useful they are as models of 
their respective neurological disorders. The tigarb/vhl interaction study, part of the 
pink1 project, has produced potential novel drug targets to treat PD. The gba1 project 
was successful in characterising the first teleost model of gba1 deficiency, exhibiting 
phenotypes in a manner similar to the GD state of type 2 patients.  Although new 
phenotypes were discovered in both mutant lines, none are currently suitable for 
phenotypic drug discovery. 
5.2 pink1 -/- characterisation 
The zebrafish pink1 -/- line was, until very recently, the only model of pink1 deficiency 
which exhibited spontaneous and progressive DA neuron loss. Recent studies of rats 
exhibiting PINK1 loss of function have now been reported, which progressively lose 
DA neurons and display motor dysfunction in a progressive manner. Gait dysfunction 
appears as early as 4 months of age, in the PINK1 -/- rats, while TH neuron counts 
showed a decrease of 25% at 6 months of age, increasing to 50% at 8 months of age, 
compared to WT. TH neuron count reduction was also found to occur in the absence of 
SNCA pathology.292 
The demonstration of a late onset motor phenotype in aged (3 year old) pink1 -/- 
zebrafish may imply that a more marked decrease in TH neurons has occurred 
(compared to 18 months), which is in keeping with the progressive loss of TH neurons 
in PD patients. However, similar phenotypes have also been recorded in other 
vertebrate models of pink1 deficiency which lack Th neuron reduction.188, 199 Although 
Th neuron reduction increases between embryonic and adult (18 month old) time 
points from 20 to 50%, whether this decreases further during aging still needs to be 
addressed, by counting the TH neurons at the 3 year old time point. If Th neuron 
reduction was not large enough to cause PD like symptoms, the late onset defect in 
movement seen in pink1 models that lack Th neuron reduction, could suggest a role of 




The pink1 -/- microarray that first identified tigarb upregulation in pink1 -/- during 
development was one of the first whole transcriptome studies comparing the effect of 
pink1 loss of function to WT in an unbiased approach. Previously, a single pink1 loss of 
function microarray had been published in zebrafish. Although, this relied on the use 
of a Morpholino strategy which can cause off target effects.156 The study by 
Priyadarshini et al., identified many gene expression changes in their pink1 morphants 
involved in hypoxic signalling. This included a large decrease in hifa expression. 
Although this change would functionally agree with the vhl KD rescue described in 
this thesis, no single gene expression changes were similar between those described by 
Priyadarshini et al., and those described by Flinn et al., even after the re-annotation of 
the microarray in this thesis. These discrepancies may at least partially be due to the 
different time points utilised for each microarray study, 2 and 5dpf respectively, and 
the two different methods of model generation, Priyadarshini et al., utilised a transient 
KD approach, were as Flinn et al., utilised a kinase dead mutant. The latter may not 
even be producing Pink1 protein due to nonsense-mediated decay.175, 192 The re-
annotation of the microarray was successful in identifying many of the transcripts’ 
human orthologues, but did not highlight any particular pathways previously implied 
in the pathogenesis of PD, such as dysregulation of mitophagy pathways or 
intracellular calcium homeostasis. This could be because gene expression changes 
leading to Th neuron reduction may be more specific to neuronal cells and the 
microarray was conducted with RNA extracted from whole larvae as opposed to cells 
of a DA neuron origin. Future gene expression studies in the pink1 -/- line, especially 
those which investigate the gene expression changes at different time points including 
adult pink1 brains should focus purely on brain tissue. Isolating brain tissue from 
larvae is technically challenging, however one method to achieve this would be to use 
fluorescence activated cell sorting of labelled cells of interest.  
To address whether the Th neuron reduction observed at 5dpf in the pink1 -/- was due 
to cell death or a developmental defect, the expression of key neuronal developmental 
genes was analysed in both genotypes. Spatial expression of all genes was identical in 
both genotypes suggesting Th neuron reduction was not developmental in origin, at 
least at the time points analysed. This is unsurprising as PD is a neurodegenerative 
disease and no evidence has shown it to be developmental in origin. This study 
highlights the advantages of using the zebrafish as a model due to its ex vivo 




vertebrate models such as mice. Furthermore, data from the microarray suggested that 
neuronal developmental defects were unlikely. This, in conjunction with 
developmental gene expression patterns examined by WISH, lead the author to 
conclude that the TH defects seen in pink1 -/- were not caused by developmental 
dysregulation, but by neurodegeneration. But a developmental phenotype could still 
be causative for the reduction, as all time points analysed were 24hpf or later. 
5.3 tigarb upregulation 
The identification of up regulated tigarb in pink1 -/- larvae through early developmental 
stages has not previously been reported in any pink1 deficient model systems. The 
finding that tigarb KD ameliorates mitochondrial dysfunction and Th neuron reduction 
seen in the pink1 -/- is also counter intuitive as all previous research implies PINK1 
linked Th neuron reduction to be due to oxidative stress. TIGAR is an oxidative stress 
response protein in humans; it’s up-regulation reduces oxidative stress and apoptosis 
in other model systems including mice. Consequently an upregulation of tigarb in pink1 
-/- could be seen as a protective mechanism, as opposed to causing Th neuron 
reduction. KD of tigarb preventing cell loss in the pink1 -/- larvae is in contrast to 
previous data where KD of TIGAR led to an increase in apoptosis.228 This also 
contradicts models of stroke, where Tigar upregulation is neuroprotective.293 Of note, 
pink1 KO Drosophila develop a marked phenotype, (motor defects, TH neuron cell loss, 
male sterility) without possessing a TIGAR orthologue. This would suggest that Tigar 
over expression is not driving pathology in the pink1 -/- zebrafish, rather, the metabolic 
changes induced by tigarb KD are neuroprotective.130 
Initial characterisation of tigarb in WT and pink1 -/- demonstrated expression is 
constant and not spatially restricted, although there was a more concentrated 
expression in the head. This is in keeping with previously described expression data 
described in numerous cancer cell lines and mouse tissue.228, 231 At basal levels, TIGAR 
is constantly expressed under the control of an sp1 promoter, in a p53 independent 
mechanism.228, 294 tigarb is highly expressed in zebrafish brain, in keeping with 
expression data recorded for mice. This was to be expected due to the effects on tigarb 
levels on TH neurons.293, 295 tigara, the tigarb paralogue,  is also expressed in a 
ubiquitous fashion, however, its upregulation in pink1 -/- larvae remains inconclusive 




expression was unchanged in the pink1 microarray. Western blotting could be utilised 
further evaluate the status of tigara expression in pink1  -/-, however this would require 
a functional antibody that is selective for tigara alone. No antibodies of this specificity 
are commercially available. A change in tigara expression may also be of no functional 
consequence as although tigarb has confirmed bisphosphatase activity, tigara does not. 
Of the catalytic triad required for the bisphosphatase activity, tigarb has 2 out of 3 
residues conserved, whereas tigara only has 1 out of 3 conserved. However, this 
assumes Tigarb’s catalytic activity is responsible for pink1 -/- Th neuron reduction.296 
Ultimately if the gene expression changes seen in the pink1 -/- larvae are different 
between the two tigar paralogues, this may be due to them evolving different 
functions. 
5.4 tigarb Morpholino optimisation 
Morpholino optimisation for tigarB was successful and led to the identification of a 
Morpholino capable of producing 100% KD without toxic off-target effects or 
deformity. The complete KD by TBMO2 also illustrates that tigarb is unlikely to be 
maternally expressed, or only maternally expressed at very low levels.  The mechanism 
of TBMO2, an exon skip of exon 2 leads to a deletion of a part of the catalytic triad and 
also causes a frame shift. This suggests to total loss of function. To fully demonstrate 
the loss of function caused by TBMO2, bisphosphatase assays could be utilised. 
However, these are impractical, since they require the prior cloning, expression and 
purification of the truncated Tigarb protein resulting from the deletion of exon 2 and 
WT protein. 
5.5 Inhibition of glycolysis as a pathogenic PD mechanism 
Glycolysis is a complicated biochemical pathway which provides both energy in form 
of ATP and other metabolites such as NADH for the cell. Its flux is highly tissue and 
age specific, global inhibition of glycolysis may have far reaching consequences for 
many cell types. Its activity in the brain is poorly understood compared to other organs 
such as the liver. The majority of the brain’s energy requirements is believed to be 
covered by oxidative phosphorylation. Although this is widely accepted, glycolytic 
flux still generates a sizable proportion of ATP for the brain of approximately 10% 




negative effects on neuronal health. Glycolytic inhibition may be more relevant at the 
time point analysed in pink1 -/- model, as these were at early developmental stages 
since the brain of pre-term infants has been found to consume 90% of the body’s 
glucose levels.298 In the adult brain, glycolytic rates vary dramatically within different 
cell types and regions of the brain.299 It is conceivable that, due to the brain’s larger 
glucose requirement in development, glycolytic inhibition would lead to a decrease in 
ATP levels that could lead to Th neuron reduction during gestation. Consequently at 
birth, PINK1 linked PD patients may have a reduced number of DA neurons compared 
to healthy individuals, so therefore are closer to the threshold required for developing 
motor symptoms, hence the early onset of PINK1 linked PD.  
A more plausible argument is that general glycolytic inhibition is pathogenic towards 
DA neurons regardless of developmental stage. Current literature is conflicting 
regarding the effect on glycolysis modulation on neuronal health, however this is likely 
to be dependent on which model is utilised. In contrast to other cell types, neurons 
preferentially metabolise glucose via the pentose phosphate pathway over glycolysis. 
Reducing the level of glycolysis even further might reduce levels of ATP to an extent 
neurons can no longer tolerate.300 A study on sporadic patients’ fibroblasts detected no 
change in glycolytic flux. Models of pink1 deficiency have even shown an increase in 
glycolytic flux in pink1 -/- compared to WT, which is in direct contrast to the zebrafish 
data described in this study.301-303 However, the former studies were all conducted in 
cell culture systems whose metabolic rates may be altered to that in vivo. More 
importantly, the pink1 studies utilised Pink1 KO mouse tissue that does not recapitulate 
early onset Parkinson’s and most importantly does not exhibit TH cell loss. This may 
explain the discrepancies in glycolytic rates. 301-303 
Recent data in flies and worms has demonstrated a neuroprotective effect for Glucose 
Phosphate Isomerase (GPI), a glycolytic enzyme that converts glucose-6-phosphate into 
fructose 6-phosphate in a reversible fashion. Glucose-6-phosphate has the capacity to 
be fed into the glycolytic system if converted into fructose-6-phosphate, or can enter 
the pentose phosphate pathway. Data by Knight et al., has shown GPI inhibition to 
exacerbate phenotypes of DA neuron loss, exhibited by flies and worms both 
overexpressing SNCA. Overexpression of GPI was also found to be neuroprotective in 
both these in vivo models of PD, whilst its inhibition was found to exacerbate 
neurodegeneration.304 Its mechanism of action was found to be producing glycolytic 




glycolysis by 2-deoxyglucose led to neurodegeneration whilst addition of glucose 
ameliorated phenotypes exhibited by the fly PD models. Even though flies lack a 
TIGAR orthologue, glycolytic inhibition may still be key to their pathogenesis.304 
The fly data discussed above is in keeping with the zebrafish pink1 microarray data 
that revealed a downregulation the zebrafish orthologue of GPI, glucose phosphate 
isomerase b (gpib) whilst its paralogue, glucose phosphate isomerase a (gpia) remains 
unchanged. This is significant, as unlike GPI, Gpia and Gpib have preferences as to 
which direction metabolism proceeds. It has been demonstrated that Gpib 
preferentially catalyses glucose-6-phosphate to fructose-6-phosphate, whilst the 
reverse occurs in Gpia (Figure 73). Consequently, as upregulation of tigarb would 
results in a net accumulation of fructose-6-phosphate, the main metabolic product of 
Gpib. Downregulation of Gpib may be an attempt to normalise fructose-6-phosphate 
levels, further aiding the action of Tigarb. This further suggests inhibition of glycolysis 
in the pink1 -/- and a move of metabolism towards the PPP.305  
 
Figure 73. The zebrafish gpi paralogues in relation to the glycolytic pathway. Zebrafish paralogues and 
their preferred mechanism glycolytic flux are shown within the glycolytic pathway. The red arrow is 
showing preferred flux of Gpib, converting Glucose-6-phosphate to Fructose-6-phosphate, and the blue is 
arrow showing preferred flux of Gpia, which is opposite to its paralogue Gpib. Adapted with permission 
from Lee et al.230 
The upregulation of tigarb and its inhibition of glycolysis may in fact be exerting its 
pathogenic effect through the inhibition of autophagy. PINK1 is required for the 










hindered in PINK1 KO models.199, 205, 218 Upregulation of tigarb will in theory, lower 
oxidative stress, a key cellular signal for autophagy induction. TIGAR activity has been 
shown to modulate autophagy in a p53 independent manner.232 TIGAR’s modulation 
of autophagy can also modulate mitophagy independently of the PINK1/PARKIN 
pathway as TIGAR inhibition can activate mitophagy through the BNIP3 pathway.238 
Consequently, the upregulation of tigarb in the pink1 -/- zebrafish may be indirectly 
leading to inhibition of Pink1 independent mitophagy pathways in an effort to reduce 
oxidative stress. Consequently, KD of tigarb in the pink1 -/-, although it may result in an 
initial increase of oxidative stress, will increase the flux through mitophagy in a 
pink1/parkin independent manner, therefore indirectly decreasing oxidative stress by 
the removal of damaged mitochondria. 
The lack of a rescue effect of tigarb KD when exposing larvae to MPP+ is inconsistent 
with the pink1 data. However, this may be due to the dosing procedure. Although both 
pink1 deficiency and MPP+ exposure both lead to mitochondrial Complex I inhibition 
and 20% reduction in TH neurons at 72hpf, the Complex I inhibition in pink1 -/-is 
chronic in nature. In contrast, the MPP+ exposure protocol is acute, with larvae 
receiving a single dose of the toxin at 48hpf until 72hpf. The administration of MPP+ in 
a single dose, and at a late time point, may overwhelm the neuroprotective power of 
tigarb KD. Consequently administering a less concentrated dose of MPP+ in a chronic 
fashion (such as administering daily and from fertilisation) may lead to a more chronic 
inhibition of Complex I inhibition and gradual decrease in TH neuron count, which 
could then possibly also be rescued by tigarb inactivation. 
5.6 Future work for pink1 -/- 
Although a developmental cause of TH neuronal cell loss in the pink1 -/- larvae has 
been largely excluded, the cause of cell loss (such as apoptosis) still requires 
explanation. 
tigarb KD, as a rescue mechanisms in pink1 -/- still needs to be further explained. But, 
this has become more complicated as the role of Tigarb as a glycolytic inhibitor has 
recently been challenged. Its catalytic affinity for fructose-2,6-bisphosphate (originally 
described as Bensaad et al.) is several orders of magnitude lower than that for 23BPG, 
consequently, 23BPG may be the main physiological substrate of TIGAR in vivo,   




interpret, as cellular levels of 23BPG have never been recorded due to contamination 
from red blood cells which contain very high quantities of the metabolite. The function 
of 23BPG is still unknown (apart from in red blood cells where it has a role of 
regulating affinity of haemoglobin for oxygen). However, this still does not prevent 
TIGAR inhibiting glycolysis through its originally discovered function as it still has 
significant affinity for fructose-2,6-bisphosphate in vivo. The pink1 microarray data also 
suggests pathogenic mechanisms may be due to the inhibition of glycolysis. This is not 
only due to tigarb upregulation but also due to downregulation of the gpib that has a 
high affinity towards Glucose-6-phosphate catabolism, a glycolytic intermediate.305 
To fully understand tigarb’s recue mechanism in pink1 -/-, confirmation of decreased 
glycolytic rate needs to be demonstrated biochemically, for example by measuring 
glycolytic metabolites. If there proves to be no dysregulation, it would add strength to 
the argument against Tigar being involved in inhibition of glycolysis, and would point 
to other novel functions, most likely involving its capacity to re-localise to the 
mitochondria and bind HK2 under cellular stress.234 If tigarb rescue is due to increased 
mitophagic flux, specific markers of autophagy could be analysed for any potential 
changes.  
To firmly establish TIGAR as a potential therapeutic target for PINK1 disease/PD, 
stable tigarb mutants need to be generated to cross with the stable pink1 mutant line to 
evaluate rescue effects in later life. This would allow evaluation of whether chronic loss 
of function of both proteins has negative consequences in aged fish. This is especially 
important, as the studies described in this thesis only examine a single time point 
(3dpf). Tigar inhibition studies should also be carried out in mammalian PINK1 loss of 
function models to demonstrate this rescue is not exclusively a teleost phenomenon. 
Tigar KD in other models of PD should also be investigated to ascertain potential 
therapeutic rescue in other forms of the disease, for example in LRRK2 or SNCA linked 
PD. 
To achieve this, TIGAR could be inhibited by KD in patient fibroblasts that have 
previously been characterised, and look for a rescue in phenotypes. For example, 
inhibiting TIGAR in LRRK2 patient fibroblasts and evaluating its effect on ATP levels 
and mitochondrial membrane potential. It would be prudent to investigate TIGAR 




linked) is being driven by TIGAR upregulation. This could be achieved by analysing 
sporadic patient microarray data. 
5.7 vhl knockdown rescues pink1 -/- Th neuron reduction 
The rescue of Th neuron reduction by vhl KD is intriguing, but could not be confirmed 
using stable mutant lines and with a second marker of DA neurons. As the principle 
read out from the vhl KD experiments was TH positive cells stained by in situ, this may 
produce a false positive result as KD may only be increasing TH expression in the 
mutants as opposed to rescuing TH cell loss. This is especially important as TH is 
known to be a direct target of Hifa which accumulates in response to vhl deficiecny.290 
Consequently, staining for DAT would be a more suitable marker to confirm the TH 
cell rescue.  
Increased expression of TH is unlikely to be a cause of the apparent TH cell rescue in 
the pink1 -/-, since there is no effect of vhl deficiency in WT control zebrafish, with an 
identical TH neuron count in WT with vhl KD and WT uninjected zebrafish larvae. 
The confirmation of TH neuron rescue by vhl KD in a second model system is critical to 
be certain of its true significance and to be sure the TH cell rescue was not a non-
specific consequence of the Morpholino injection (however unlikely it may be). Stable 
mutants were the most obvious choice and were available. Unfortunately, staining for 
DAT at 5dpf proved not to support the working hypothesis, as vhl -/- had an even 
larger cell loss (30%) than pink1 -/- (20%). This is likely due to developmental defects 
and general retardation as opposed to neurodegeneration itself. Complete loss of 
function of vhl is not compatible with life as both vhl -/- mice and zebrafish are not 
viable. pink1 -/- loss of function is mild in comparison as pink1 status does not affect 
lifespan in zebrafish. Consequently, potential rescue of pink1 -/-, by vhl loss of function 
should analysed earlier in development where Th neuron reduction is present in pink1 
although not in vhl, such as 3dpf. 
How vhl KD could rescue pink1 -/- phenotypes requires further investigation. The 
original hypothesis was a normalisation of glycolytic flux as both loss of function 
mutations have opposing rates of glycolysis. This is plausible, but as previously 
discussed TIGARs status as an glycolytic inhibitor has recently been questioned.231 




vhl KD. This has been shown to rescue defects seen in other PD models. Moreover, DJ1 
has been found to be a direct negative regulator of vhl/hif1a interaction.228  
5.8 gba1 orthologue identification, expression and knockdown 
This study was the first reverse genetic study of gba1 in teleosts, and other than mouse 
models, represents the only other loss of function vertebrate model. Identification of a 
single orthologue of GBA1 is in keeping with ENSEMBL data listing a single 
orthologue of GBA1 in every other vertebrate with a sequenced genome. Although 
zebrafish possess many duplicated genes in their genome due to a genome duplication 
event, only a single GBA1 orthologue could be identified in the zebrafish genome. 
Unlike humans, zebrafish lack a GBA1 pseudo gene as this is only present in apes.244 
 Gene synteny was demonstrated to be partially conserved with high homology at not 
only at the DNA, but also at the protein level. Both the synteny and homology data 
clearly shows ENSDARG00000076058 to be the true zebrafish gba1 and not gba2. 
Expression analysis of WT tissue confirmed gba1 expression occurs at consistent, 
although low levels throughout development, with earliest expression detected at 
1dpf. Expression in adult zebrafish was confirmed in both liver and brain; key tissues 
for pathology seen in KO mouse studies and GD linked pathology. Expression was 
additionally monitored through development by WISH. The staining for expression 
was specific as no staining could be detected in the sense control probe. Expression 
was found to be in all organs and concentrated in the head. A similar study in murine 
developmental stages, also found gba1 expression in all organs, through all 
development stages, in keeping with the observed expression pattern in zebrafish.264, 
306, 307 
Morpholino optimisation was successful in producing a Morpholino with high 
efficacy. Optimisation of the Morpholino targeting exon 8, led to high levels of 
abnormal splicing in the WT transcript, producing exon skips and intron inclusions. It 
was noted that 100% KD could not be achieved, even by injecting this Morpholino at 
toxic doses, suggesting that gba1 may be maternally expressed. 
 KO mice die shortly after birth due to skin defects that lead to a loss of water. It was 
therefore unexpected that gba1 KD did not grossly affect morphology or development, 




TH neurons seen in gba1 KD (10-15%) was not statistically significant and likely to be 
due to a non-specific off target effect of the Morpholino as TH neuron count in 23bp 
del gba1 -/- was unchanged compared to WT, and in all other stable mutants analysed 
in this thesis. The lack of phenotype may also be due to the residual WT transcript in 
the morphant group and the early time point analysed. If gba1 deficiency phenotypes 
are indeed due to substrate accumulation, this may take time, especially if not all of the 
WT transcript has been mis-spliced as some mouse models have shown to have a large 
reduction in Gba1 activity with little or no phenotype. The latter is likely due to a 
higher activity level of Gba1 in the brains of some loss of function mouse models. It 
appears that if the residual GBA1 activity is more than 20% in the brain, neurological 
decline is prevented in mice.263  
The apparent lack of synergistic decrease in TH neuron count in Complex I 
compromised larvae after MPP+ treatment, subjected to gba1 KD is also unexpected, 
although it may be due to the early time point (3dpf). This is not the first study to 
investigate an interaction between GBA1 and Complex I deficiency. In a study by Gegg 
et al., KD of PINK1 in SH-SY5Y cell line already led to a 30% decrease in GBA1 activity 
and expression. It is therefore plausible that pink1 -/- larvae already have a decrease in 
gba1 activity, prior to gba1 KD. Although this does not rule out a genetic interaction 
between the two, it is likely that it may take longer to modulate phenotypes, especially 
as stable mutants show minor phenotypes until 2 months of age, as opposed to 2-3 
days. Gegg et al., also utilised a similar approach of evaluating gba1 activity in response 
to Complex I inhibition by using chemical insults, in this case rotenone. However, this 
showed no decrease in activity. Most likely to the long half-life of GBA1 in vivo (72 
hours) and the short treatment period of the Complex I inhibitor (48 hours).268 
5.9 gba1 stable mutant line generation 
The generation of a stable mutant gba1 line using the TALEN system highlights its 
importance as a highly efficient genome editing technology. All previous targeted 
genome editing technology applicable for zebrafish were either not cost effective 
(Sigma Zinc Fingers) or limited by context dependence (Zinc fingers designed by the 
context dependant assembly method). For example, initial bioinformatics analysis of 
the gba1 genomic sequence identified only 3 sites (2 overlapping) that could be utilised 




identified over 50. Further advantages of TALENs over zinc finger nucleases are that 
the construction is technically simple and very rapid. The resulting TALEN pair 
mutated gba1 exon 7 in a targeted and highly efficient fashion. The initial screen on 
single embryos showed more than 50% mutation rate in some individuals. Sub cloning 
of undigested TALEN injected PCR products allowed direct sequencing of the 
mutations induced by the TALEN in the F0 mosaics individuals. Sequencing identified 
a mutation rate of 40%, producing deletions and indels of a similar magnitude as 
reported in the literature. The only exception was a complete lack of insertions.308 As 
expected, the mutations were present in the germ line, with 80% of the F0 injected 
individuals identified as founders. Outcrossing two F0 founders to generate the F1 
generation, and subsequent genotyping by digest identified the 7, 8 and 23bp del 
alleles. The 23bp del allele was preferred due to the capacity to genotype by PCR alone, 
which eventually proved to be extremely cost and time effective. The time taken from 
construction to having heterozygous adults that could be utilised for incross 
experiments was 6 months but would then obviously only represent F1 individuals. All 
F1 adults would require direct sequencing to ascertain their mutation, as F0 founders 
can still produce F1 individuals with different mutations if their germ line is a mosaic 
harbouring multiple mutations. Caution must also be taken when outcrossing each 
allele to remove background mutations. ENU screens for example, as they are not 
targeted, produce many mutations within a genome, and consequently, mutant alleles 
generated by this method have traditionally been outcrossed to WT individuals until 
the F5 generation is reached. At this point, any confounding mutations are deemed to 
have been removed from the line, and therefore the adults can be utilised for 
experiments. In contrast, TALENs produce targeted mutations, but may still induce 
off-target mutations. How often this occurs and how much they vary between TALEN 
pairs is still being evaluated, appropriate guidelines have not been developed yet.309 
The technical simplicity of TALEN construction, and the availability of loss of function 
mutations from the SANGER zebrafish mutation project, makes the zebrafish a highly 
amenable model organism for future reverse genetic work which allows the 
confirmation of mutant phenotypes in a further zebrafish stable mutant line in which 




5.10 23bp del gba1 -/- loss of function 
Mutants were generated to investigate loss of function of gba1 in zebrafish, to 
determine whether zebrafish are a suitable model for GD or GBA1 linked PD. 
Analysing the mutations at a structural level, the gba1 sa1621 mutant most likely leads 
to abnormal splicing due to the alteration of an essential splice site. If leading to 
complete insertion of the following intron, this would generate a premature stop codon 
downstream of the point mutation, and the deletion of the latter two thirds of the 
coding sequence at protein translation. All TALEN deletions in the F1 generation, lead 
to a similar scenario due to the creation of frame shifts. All alleles leading to a 
premature stop codon appear within exon 7, deleting the last third of the amino acid 
sequence at protein translation.  
The 3D structure of zebrafish Gba1 has not been elucidated, but the 3D structure of 
human GBA1 is well characterized. The domains are not linear in their organisation, 
and the N and C terminal parts of the amino acid sequence bind to each other at 
several points within domains I and II. Disease causing mutations appear in all exons 
in the human gene, and it is plausible that any kind of deletion similar to those seen the 
stable mutant zebrafish would prevent proper folding of the enzyme, causing complete 





Figure 74. GBA1 cartoon structure. A cartoon illustrating the structure of GBA1.  Triangles represent 
numbered β strands, whilst circles represent numbered α helices. Amino acids denoted in pink are 
associated with domain I, amino acids denoted in green are associated with domain II, whilst amino acids 
denoted in blue are associated with domain III. Certain amino acid residues are numbered in certain 
positions within the connecting groups for clarity. Note that the N and C terminals bind to each other at 
several locations to form domains II and III. Clearly a large deletion would lead to improper folding and 
loss of function. Reproduced from Dvir et al.310 
To establish whether the 23bp del gba1 -/- represented a true loss of function, qPCR was 
utilised to investigate potential activation of the nonsense mediated decay pathway. 
qPCR demonstrated a 50% reduction of the gba1 transcript in the brains of gba1 -/- to 
that of WT levels, implying the mutant transcript is unstable and being degraded by 
RNA surveillance pathways.311 This suggests that the deletion does indeed lead to loss 
of function. 
The GBA1 activity assay has previously been utilised as a robust tool for measuring the 
activity of GBA1 in homogenates of mammalian tissue, distinguishing it from GBA2 by 
the use of specific GBA2 inhibitors. To improve signal to noise ratios, NaT can be 
utilised, this simultaneously inhibits GBA2 whilst activating GBA1. The assay found no 
difference in activity between any Gba1 23bp del alleles suggesting the mutation has 
no effect on Gba1 function. This does not explain how several different mutations, that 
all produce premature termination codons, lead to such marked robust phenotypes 




del allele, also includes organ invasion by Gaucher like cells seen in loss of function 
mouse models, and also activation of classical GD biomarkers such as Chitotriosidase 
and β hexosaminidase but also accumulation of GBA1 substrates within the brain, 
confirmed by mass spectrometry and PAS staining. Mass spectrometry revealed 
especially large increases in the level of Gba1 substrates in the 23bp del gba1 -/- 
compared to WT. These increases in the different glucocerebrosides ranged from a 5 
fold increase compared to WT, to nearly a 100 fold increase, depending on the fatty 
acid side chain analysed. These results are similar to loss of function mouse models 
that accumulate similar levels of glucocerebroside in their brain, spleen and liver. 
Human patient tissue also exhibits similar changes to those seen in the zebrafish brain 
mass spectrometry data. Patient GD fibroblasts from Type I and II patients both exhibit 
large accumulations of ceramides and glucocerebrosides. GD patient plasma has also 
found to have large increases in levels of ceramides and glucocerebrosides. When 
analysing GD patients spleens, (an organ key in GD pathology), these changes were 
also present, but also contained a large accumulation of GM3.312, 313 Studies of these 
small metabolites in patient brain tissue of type II and III GD also show large 
accumulations of in glucocerebrosides, ceramides, GM3 gangliosides. Of note these 
were found to be especially high in the cerebellum, a site of Gaucher like cell 
accumulation, within the gba1 -/- zebrafish brains. Human GD brains also have a large 
accumulation of the metabolite hexosyl-sphingosine (psychosine), which is never 
present in normal healthy brain tissue. Hexosyl-sphingosine was also undetected in the 
WT and gba1 -/+ brains, but was detected in large quantities in the gba1 -/- zebrafish 
brains. These data combined suggest the zebrafish is a valid model for neuropathic 
GD.128, 262, 314 
Although the Gba1 activity assay itself showed no difference in Gba1 activity between 
WT and gba1 -/- brain tissue this may be due to the specificity of the inhibitors utilised 
to differentiate Gba1 activity from Gba2 activity. DNJ inhibits Gba2, leaving residual 
Gba1 activity with basal readings at 5 nm/h/mg in zebrafish brain tissue. These 
readings are comparatively low compared to mammalian brain tissue, which gives 
much higher readings of approximately 12 nm/h/mg (both at 37°C). This may be a real 
physiological reflection of lower total Gba activities in zebrafish brain homogenates, 
with levels at 35 nm/h/mg compared to mouse brains with GBA1 enzymatic activity 
close to 100nm/h/mg (both at 37ºC). Determining Gba1 activity merely from basal 




signals compared to total activity.315 The majority of studies examining Gba1 activity 
use NaT that simultaneously inhibits Gba2 and activates Gba1. The optimisation 
experiments carried out by the author revealed that NaT, although inhibiting Gba2 
quite successfully, did not lead to the activation of Gba1, even in the presence of Triton 
X-100. This suggests that either Gba1 activity is very low in zebrafish brain and is 
unchanged in mutant compared to WT, or NaT is inhibiting both Gba1 and Gba2. 
These inhibitors have never been tested before in zebrafish and had not been validated. 
A final possibility is that the Gba activity left in NaT and DNJ gba1 -/- groups is not in 
fact Gba1 but a different Glucocerebrosidase, such as the klotho protein.315, 316 
However, the morphological and behavioural phenotypes, the RNA instability, and the 
marked substrate accumulation in the brain of gba1 -/-, all reminiscent to patients and 
KO mouse models, suggest that the gba1 23bp del is indeed a loss of function allele. 
Based on the gba1 structure, it is plausible to hypothesise that any of the alleles 
discussed in this thesis would lead to improper folding and subsequent null enzyme 
activity. When alternative inhibitors were used, specifically CBE, a specific irreversible 
inhibiter of Gba1 to assess the activity of the two enzymes, 23bp del gba -/- were found 
to have a 50% decrease in Gba activity in the CBE sensitive Gba activity. However, 
these experiments were again complicated by low Gba activity levels. Consequently, 
the Gba1 activity data generated by the NaT and DNJ inhibitors is likely to be false 
negative data, as the functional activity of these inhibitors has yet to be validated in 
zebrafish.  
Alternatively, these stable mutants may confer a toxic gain of function. Indeed, 
arguments for toxic gain of function have been put forward to explain the link between 
partial GBA1 deficiency and PD.269 However, this is unlikely for the 23bp del gba1 -/-, 
as toxic gain of function mutations tend to be due to microsatellite repeat expansions 
(for example the CAG expansion in Huntington’s) or missense mutations (such as 
LRRK2 linked PD) but only rarely as deletions or splice site alternations.74, 91 In 
addition, the probability that three separate mutant alleles, essentially created at 
random (only exon 7 was defined as a target, not the nature and size of the actual 
mutation), in two separate regions of the gene, and different two different types of 
mutations, would all phenocopy each other due to toxic gain of function, is highly 
unlikely. Additionally, if the mutation were indeed loss of function, more of a 




5.11 gba1 -/- characterisation 
The decrease in mass exhibited by the gba1 23bp del -/-, gba1 7bp del -/- and gba1 
sa1621 -/- would appear similar to that previously described in murine models of Gba1 
deficiency, however the reduction in mass of the mutant zebrafish is likely to be due to 
their inability to compete with their WT controls for limited food supplies due to their 
movement defect. This decreased mass was normalised back to WT levels upon re-
housing in a genotype specific tank, suggesting that the decreased mass is not as a 
result of “failure to thrive”.261, 262   
As zebrafish develop ex utero and gba1 -/- survive until 12 wpf, they are far easier to 
study than Gba1 KO mice, which die shortly after birth.128, 261 The stereotyped “barrel 
rolling/corkscrew like motions” exhibited by the gba1 -/- zebrafish that generally 
occurred upon loss of balance are unlikely to be due to ear defects, as no detectable 
pathology could be found upon H&E staining in the ear. However, this does not 
exclude balance defects due to degeneration of the lateral line. The violent motions are 
reminiscent of seizures exhibited by the neuropathic conditional mouse KOs described 
by Enquist et al., as the cork screw motions seen could be due to the combination of 
muscle spasms and the curvature of the body axis, however this requires further 
investigation.128 
The gibbus formation and body axis defects seen at the 12 wpf in gba1 -/- is very similar 
to those exhibited by the conditional Gba1 mouse KO that lack GBA1 activity in only in 
hematopoietic and mesenchymal stem cell lineages. These mice are viable and do not 
display neurological defects, however, show large substrate accumulation and organ 
invasion by Gaucher cells.251, 264 These conditional KO mouse also develop severe bone 
complications including focal osteonecrosis and osteopenia, mimicking the bone 
phenotype typically seen in type I GD. Bone phenotypes were not evaluated in the 
adult stages of the 23bp del gba1 -/- zebrafish, but should be investigated in the future 
Gaucher cell infiltration may be present in bone marrow of gba1 -/- at 12 wpf similar to 
the Gaucher cell infiltration observed in the bone marrow of conditional KO mice 





5.12 23bp del gba1 -/- TH neuron loss 
The TH neuron loss in gba1 -/- is progressive in nature, reaching a 50% decrease by 12 
wpf. The lack of a decrease at 5dpf in the gba1 -/- is most likely due to the requirement 
for Gba1 substrate to build up in the brain tissue.274 Although there appears to be a 
change in microglial morphology at 4dpf in the gba1 -/+ and gba1 -/-, this requires 
further investigation to assess the functional consequences of these cells being less 
spherical. The lack of an upregulation of GD biomarkers at 5dpf in the gba1 -/- further 
implies that pathology in the embryological stages is limited or very subtle in nature, 
and takes time to manifest. The large TH neuron loss seen at 12 wpf, is in keeping with 
conditional KO mice described by Enquist et al.  Although they did not quantify TH 
neuron count specifically, they noted conditional KO mice had smaller brains and a 
reduction of cellular density in the thalamus, cortex, cerebellum, pons and medulla. 
There was a large increase in apoptotic cells (measured by TUNEL and anti-caspase 3 
staining). Additional markers of further neuronal populations should be investigated 
in the gba1 -/- 12 wpf zebrafish to determine whether TH neuron loss is specific or a 
consequence of global neurodegeneration.128 No TH neuron loss could be detected in 
the gba1 -/+ 12 wpf zebrafish compared to WT. This is likely due residual enzyme 
activity in the gba1 -/+ individuals. As GBA1 linked PD manifests as a late onset disease 
(at least when compared to PINK1 linked PD) it could be expected that TH neuron loss 
is unlikely to be detected at this early time point of 12 wpf. This is especially true as 
although there was the appearance of minor cellular swelling within the tectal 
ventricle, there was no robust accumulation or deficiency of any metabolites in the 
sphingolipid pathway. It should also be noted that although GBA1 mutations are the 
most common risk factor for PD, the vast majority of GBA1 mutation carriers do not 
develop the disease. 
5.13 23bp del gba1 -/- Gaucher cell invasion 
H&E staining revealed the presence of Gaucher like cells invading organs in the 23bp 
del gba1 -/-which are also affected in GD and in GD mouse models. The Gaucher like 
cells were first detected at 9 wpf, with pathology worsening by 12 wpf, specifically in 
the thymus, liver, spleen, and pancreas; all these organs are affected in GD. However, 
unlike in mouse models of GBA1 deficiency, there was a distinct lack of Gaucher cell 




et al.  These mice, although exhibiting hepatosplenomegaly, are viable and live to old 
age, bone invasion may therefore be a phenomenon that requires further time to 
appear in zebrafish. Unfortunately the 23bp del gba1 -/- do not survive long enough to 
investigate this possible phenomenon.264 The accumulation of Gaucher like cells in the 
brains of the 23bp del gba1 -/-, has previously been documented in mouse models and 
human patients.317, 318 The main accumulation site is within and adjacent to the tectal 
ventricle, a structure analogous to the cerebral aqueduct in humans. Over time this has 
evolved to be much smaller in the human brain than in zebrafish. In zebrafish, the 
tectal ventricle is located in the optic lobes, the ventral and lateral regions of the tectum 
opticum in zebrafish play an important role in the coordination of sensory signals and 
motoric integration. These regions are involved in a wide range of responses, including 
swimming. The brain lesions and Gaucher cells in this area are therefore a likely cause 
of the abnormal swimming behaviour seen in the 23bp del gba1 -/-. In addition, it also 
serves as the main visual area of the brain, functionally analogous to the visual areas of 
the cerebral cortex in mammals. The Corpus cerebellum, analogous to the cerebellum 
in humans, is the site of considerable sphingolipid metabolite accumulation in types II 
and III GD, the observed accumulation of Gaucher-like cells in the corpus cerebellum is 
therefore in keeping with the pathological changes observed in human GD patients.314, 
318 
PAS staining confirmed the Gaucher-like cells to be filled with glycolipids, however to 
confirm their status as genuine Gaucher cells, co-staining for microglial and 
macrophage markers should be carried out in the gba1 23bp del gba1 -/-, such as mac2 
and puc.1. The appearance of minor cellular swelling the in the 23bp del gba1 -/+ at 12 
wpf, was unexpected and difficult to interpret, however it does suggest that 
heterozygous mutations for gba1 is pathogenic, even at this comparatively early time 
point. Further investigation is required to ascertain whether this is neurodegenerative 
in nature. Most likely the gba1 -/+ will have more marked phenotypes at older ages as 
TH cell loss could not be detected at this age. Major changes in sphingolipid 
composition were also not detected at this age. 
5.14 23bp del gba1  -/- mitochondrial dysfunction 
Mitochondrial dysfunction has been widely reported in models of PD, although only a 




mammalian models.199, 201, 272, 284, 285 Mitochondrial dysfunction has been shown to 
decrease the activity of GBA1, however it is still uncertain whether GBA1 deficiency 
can lead to defects in the mitochondrial electron transport chain.  In this thesis, 23bp 
del gba1  -/- were found to have a specific decrease in mitochondrial Complex activities 
of Complexes III and IV compared to WT. No specific changes in activity were 
reported in any 23bp del gba1 genotypes in Complexes I and II. The only prior study 
similar to this was by Osellame et al., who found a specific decrease in Complex I and 
III, without a decrease in Complex IV activity, in cultured mouse Gba1 KO neurons. No 
decrease in activity could be found in a chemically induced model of GBA deficiency 
by Cleeter et al., who utilised CBE to inhibit GBA1 in cultured SH-SY5Y cell lines. The 
lack of an effect in the latter suggests that the acute nature of CBE treatment may only 
partially reflect any genetically determined GBA1 enzymatic deficiencies. The 
discrepancies between Complex I activity between this thesis and the report by 
Osellame et al., could be due to the difference in species, and of the tissue used. This 
thesis utilised whole brain homogenates, whereas Osellame et al., utilised cultured 
mouse neurons specifically from isolated midbrain neurons to investigate 
mitochondrial dysfunction. However, both confirm that Gba1 loss of function can 
result in mitochondrial dysfunction.272, 285 In other mouse models of Gba1 deficiency, 
Amyloid precursor protein has been found to co localise with COX IV. This in theory 
could be a represent a direct association between both proteins, which may help to 
explain the decrease in mitochondrial Complex IV seen in gba -/- brains.319 
Models of other lysosomal storage disorders have also been recorded to exhibit 
mitochondrial dysfunction. Mouse models of GM1 glangliosidoses, have mutations in 
the gene coding for β-Galactosidase, and have a specific decrease in mitochondrial 
Complex IV activity, in a similar manner to gba1 -/- zebrafish brains. They also exhibit a 
decrease in their mitochondrial membrane potential and defects in mitochondrial 
morphology.320 Mouse models of Niemann pick disease, possess mutations in 
sphingomyelin phosphodiesterase, also show defects in mitochondrial Complex 
activity, specifically Complex V.321 Clearly, mitochondrial dysfunction is a key feature 




5.15 Future work for 23bp del gba1 -/- 
The mutant zebrafish described in this thesis has proven to be a robust model of GD, 
with a marked reproducible phenotype in juvenile zebrafish. The GD phenotype 
displayed most reminiscent of type 2 GD, due to the marked neurological impairment. 
TH neuron loss at 12 wpf is especially novel as it is the first example of Gba1 deficiency 
leading to TH neuron loss in an SCNA independent fashion, as zebrafish do not 
possess an orthologue of SCNA. Whilst this does not rule out SNCA being a major 
factor in GBA1 linked neurodegeneration it highlights SNCA independent 
neurodegenerative mechanisms. However, identifying these specific mechanisms 
requires further investigation.  
As zebrafish do not possess a SNCA orthologue, they are an ideal model to analyse 
SNCA dependent and independent effects due to Gba1 deficiency. By crossing 
transgenic over-expressing SNCA lines to the gba1 23bp del line, further evaluation 
could be undertaken. Although it is difficult to predict how human SNCA would affect 
zebrafish nerve cells, it would be useful to assess the effect of possible SNCA 
aggregation in the context of gba1 deficiency.  
Additionally, recent data has demonstrated SNCA can effect PD progression by 
moving between cells, a feature exacerbated by GBA1 deficiency. By expressing SNCA 
under specific promoters within the zebrafish larvae (such as within the  olfactory 
bulb), potential transmission can be tracked through the brain by IHC in 23bp del gba1 
genotypes.322  
 Although not implicated in GD, MAPT has been linked to PD through GWAS. Hence 
over expressing MAPT may be useful to investigate interactions between these two 
genes in the context of PD, especially as a MAPT over expressing line has previously 
been characterised. 102, 323 
Gene- gene interactions could be further elucidated by over expressing and inhibiting 
other members of the sphingolipid pathway or other Glucocerebrosidases. Of these, 
sphingomyelinase and GBA2 are key examples.  Sphingomyelinase  (SMPD1)  converts  
sphingomyelin   to   ceramide.   Homozygous   mutations   lead   to   another   lysosomal  
storage   disorder,   Niemann   Pick   disease,   whilst   heterozygous   mutations   (like  




smpd1   in   the  23bp  del  gba1   -­‐‑/+  or   -­‐‑/-­‐‑  by  Morpholinos,  may  reveal  phenotypes   that  
would  demonstrate  an  interaction  between  the  mutations.    
gba2   is  another  candidate  gene  for  investigation  in  the  23bp  del  gba1  genotypes  as  
Gba2  has   recently  been   found   to  be  a  modifier  of  Gba1  phenotypes   in   conditional  
mouse   models   of   GD.   The   deletion   of   Gba2   in   a   conditional   Gba1   KO   mice  
described  by  Mistry  et  al.,  had  a  complete  rescue  of  hepatosplenomegaly  and  bone  
defects   exhibited   by   the   conditional  Gba1      KO  mouse   previously   described.325   It  
should  be  noted  that  the  conditional  Gba1  KO  mice  utilised  by  Mistry  et  al.,  retain  
GBA1  activity  in  the  brain.  Gba2  deficient  Gba1  conditional  KO  mice,  although  they  
have   a   rescue   of   phenotypes,   also   undergo   higher   quantities   of   sphingolipid  
accumulation   compared   to   either  mutant   alone.   Consequently  Gba2   deletion   in   a  
full  Gba1   loss  of   function  model  may  be  even  more  destructive   to  neuronal   tissue  
than  Gba1  loss  of  function  on  its  own.  But  this  requires  further  investigation.  
  limp2   is   another   obvious   choice   to   inhibit   in   23bp   del   gba1   -­‐‑/-­‐‑   zebrafish   as   it  
involved  with   trafficking  Gba1   to   the   lysosome  and  has  been   implicated   in  PD  in  
meta  GWAS   studies.   But   investigations   in   zebrafish  would  be   impractical   due   to  
multiple  limp2  ortholgues.102,  325  
As  the  majority  of  human  GBA1  -­‐‑/+  carriers  do  not  develop  PD,  it  remains  crucial  to  
identify   the   factors   that   lead   to   disease   development.   One   factor   previously  
discussed  is  genetic  interactions.  The  other  is  environmental  factors.  As  Complex  I  
inhibition  has  not  be  shown  to  synergistically  increase  TH  neuron  loss  in  gba1  KD,  
it  may  be  prudent   to   explore  other   toxins   implicated   in  PD,  or   at   least   later   time  
points.   Suitable   candidates   would   be   investigating   potential   susceptibility   to  
proteosome   inhibitors   such   as   MG132,   as   these   have   extensively   been   used   to  
model  PD.170  Alternatively,  as  gba1  mutations  leads  to  lysosomal  dysfunction,  gba1  -­‐‑
/-­‐‑   and   -­‐‑/+  may   be  more   susceptible   to   inhibition   of   general   lysosomal   proteases,  
such  as  Cathepsin  D  with  pepstatin  A.  Cathepsin  D  would  be  of  particular  interest  
as   not   only   is   it   the   main   protease   required   for   SNCA   breakdown,   but   sole  




The Gaucher like cells described in this thesis, are likely to be true Gaucher cells 
judging from the areas they accumulate, although further confirmation is required. To 
achieve this, the 23bp del gba1 -/+;Tg(mpeg1:EGFPcaax) could be incrossed and grown 
to 12 wpf and a combined IHC for GFP and H&E could be conducted in order to 
investigate co-localisation as this transgenic reporter simultaneously labels microglia 
and macrophages with GFP.286  
As thus far, the majority of phenotypes exhibited by 23bp del gba1 -/- such as the 
appearance at of Gaucher like cells within the brain are first recorded during juvenile 
stages. To further understand pathology, it would be useful to identify when 
phenotypes first begin. This could be achieved by analysing the phenotypes with the 
largest read out, specifically chitotriosidase activity in a time course fashion. Although 
brain tissue would be difficult to extract from whole embryos at early stages, whole 
embryos themselves could be used for the assay, until the individuals become large 
enough for brain extraction to become practical. If pathology is being driven by 
substrate accumulation as is currently thought, measuring levels of sphingolipid 
metabolites by mass spectrometry at earlier time points is also crucial. As in the case 
with chitotriosidase activity at early time points, brain removal is impractical, 
consequently whole larvae could be utilised for analysis, but would have to be 
genotyped before flash freezing.  
Ultimately, using the 23bp del gba1 -/- larvae for drug based discovery for new 
therapeutics to treat GD and even PD would be desirable but currently two major 
difficulties remain. Firstly, suitable readout would need to be established since gba1 -/- 
larvae are phenotypically normal. The only abnormality detected so far were 
alterations to microglial shape, which is labour intensive to analyse and of uncertain 
functional significance.  Using fluorescent read outs such as those for the lysosomal 
assays are ideal, however further lysosomal enzymes require testing for phenotypes in 
the 23bp del gba1 -/- larvae to identify potential new read outs.  Alternatively, 
fluorescent dyes that label specific organelles such as lysotracker or mitotracker could 
be amenable to high throughput analysis.  
5.16 Concluding remarks 
This study highlights the zebrafish as a new model for PD and GD, proving to 




failed, or have proved to be impractical for study. Both models are prime candidates to 
identify readouts for phenotypic drug discovery to treat GD and PD, as well as models 
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